
<html lang="en"     class="pb-page"  data-request-id="1d94174e-6ef1-4a33-9d50-3ec3ececf6b4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2018.61.issue-3;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.7b01490;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors" /></meta><meta name="dc.Creator" content="Bin  Yang" /></meta><meta name="dc.Creator" content="Melissa M.  Vasbinder" /></meta><meta name="dc.Creator" content="Alexander W.  Hird" /></meta><meta name="dc.Creator" content="Qibin  Su" /></meta><meta name="dc.Creator" content="Haixia  Wang" /></meta><meta name="dc.Creator" content="Yan  Yu" /></meta><meta name="dc.Creator" content="Dorin  Toader" /></meta><meta name="dc.Creator" content="Paul D.  Lyne" /></meta><meta name="dc.Creator" content="Jon A.  Read" /></meta><meta name="dc.Creator" content="Jason  Breed" /></meta><meta name="dc.Creator" content="Stephanos  Ioannidis" /></meta><meta name="dc.Creator" content="Chun  Deng" /></meta><meta name="dc.Creator" content="Michael  Grondine" /></meta><meta name="dc.Creator" content="Nancy  DeGrace" /></meta><meta name="dc.Creator" content="David  Whitston" /></meta><meta name="dc.Creator" content="Patrick  Brassil" /></meta><meta name="dc.Creator" content="James W.  Janetka" /></meta><meta name="dc.Description" content="Checkpoint kinase 1 (CHK1) inhibitors are potential cancer therapeutics that can be utilized for enhancing the efficacy of DNA damaging agents. Multiple small molecule CHK1 inhibitors from differen..." /></meta><meta name="Description" content="Checkpoint kinase 1 (CHK1) inhibitors are potential cancer therapeutics that can be utilized for enhancing the efficacy of DNA damaging agents. Multiple small molecule CHK1 inhibitors from differen..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 19, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01490" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01490" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01490" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01490" /></link>
        
    
    

<title>Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01490" /></meta><meta property="og:title" content="Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0015.jpeg" /></meta><meta property="og:description" content="Checkpoint kinase 1 (CHK1) inhibitors are potential cancer therapeutics that can be utilized for enhancing the efficacy of DNA damaging agents. Multiple small molecule CHK1 inhibitors from different chemical scaffolds have been developed and evaluated in clinical trials in combination with chemotherapeutics and radiation treatment. Scaffold morphing of thiophene carboxamide ureas (TCUs), such as AZD7762 (1) and a related series of triazoloquinolines (TZQs), led to the identification of fused-ring bicyclic CHK1 inhibitors, 7-carboxamide thienopyridines (7-CTPs), and 7-carboxamide indoles. X-ray crystal structures reveal a key intramolecular noncovalent sulfur–oxygen interaction in aligning the hinge-binding carboxamide group to the thienopyridine core in a coplanar fashion. An intramolecular hydrogen bond to an indole NH was also effective in locking the carboxamide in the preferred bound conformation to CHK1. Optimization on the 7-CTP series resulted in the identification of lead compound 44, which displayed respectable drug-like properties and good in vitro and in vivo potency." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01490"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01490">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01490&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01490&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01490&amp;href=/doi/10.1021/acs.jmedchem.7b01490" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 3</span><span class="cit-fg-pageRange">, 1061-1073</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/3" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01468" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01536" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bin++Yang">Bin Yang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-1499-5569" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Melissa+M.++Vasbinder">Melissa M. Vasbinder</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexander+W.++Hird">Alexander W. Hird</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qibin++Su">Qibin Su</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Haixia++Wang">Haixia Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yan++Yu">Yan Yu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dorin++Toader">Dorin Toader</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+D.++Lyne">Paul D. Lyne</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jon+A.++Read">Jon A. Read</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Breed">Jason Breed</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephanos++Ioannidis">Stephanos Ioannidis</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chun++Deng">Chun Deng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Grondine">Michael Grondine</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nancy++DeGrace">Nancy DeGrace</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Whitston">David Whitston</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Patrick++Brassil">Patrick Brassil</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+W.++Janetka">James W. Janetka</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>§</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Oncology Chemistry, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Discovery Sciences, IMED Biotech Unit, AstraZeneca, Building 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.</span></div><div class="corresp-info"><strong>*</strong>Phone: +1 781-839-4135. E-mail: <a href="/cdn-cgi/l/email-protection#2d4f444303544c434a6d4c5e595f4c574843484e4c034e4240"><span class="__cf_email__" data-cfemail="482a2126663129262f08293b3c3a29322d262d2b29662b2725">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01490&amp;href=/doi/10.1021%2Facs.jmedchem.7b01490" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 3</span><span class="cit-pageRange">, 1061–1073</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 4, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 October 2017</li><li><span class="item_label"><b>Published</b> online</span>19 January 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 February 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01490" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01490</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1061%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBin%2BYang%252C%2BMelissa%2BM.%2BVasbinder%252C%2BAlexander%2BW.%2BHird%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D3%26contentID%3Dacs.jmedchem.7b01490%26title%3DAdventures%2Bin%2BScaffold%2BMorphing%253A%2BDiscovery%2Bof%2BFused%2BRing%2BHeterocyclic%2BCheckpoint%2BKinase%2B1%2B%2528CHK1%2529%2BInhibitors%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1073%26publicationDate%3DFebruary%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01490"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2706</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">10</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01490" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Bin&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Melissa&quot;,&quot;last_name&quot;:&quot;M. Vasbinder&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;W. Hird&quot;},{&quot;first_name&quot;:&quot;Qibin&quot;,&quot;last_name&quot;:&quot;Su&quot;},{&quot;first_name&quot;:&quot;Haixia&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Yan&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Dorin&quot;,&quot;last_name&quot;:&quot;Toader&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;D. Lyne&quot;},{&quot;first_name&quot;:&quot;Jon&quot;,&quot;last_name&quot;:&quot;A. Read&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Breed&quot;},{&quot;first_name&quot;:&quot;Stephanos&quot;,&quot;last_name&quot;:&quot;Ioannidis&quot;},{&quot;first_name&quot;:&quot;Chun&quot;,&quot;last_name&quot;:&quot;Deng&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Grondine&quot;},{&quot;first_name&quot;:&quot;Nancy&quot;,&quot;last_name&quot;:&quot;DeGrace&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Whitston&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;Brassil&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;W. Janetka&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;1061-1073&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01490&quot;},&quot;abstract&quot;:&quot;Checkpoint kinase 1 (CHK1) inhibitors are potential cancer therapeutics that can be utilized for enhancing the efficacy of DNA damaging agents. Multiple small molecule CHK1 inhibitors from different chemical scaffolds have been developed and evaluated in clinical trials in combination with chemotherapeutics and radiation treatment. Scaffold morphing of thiophene carboxamide ureas (TCUs), such as AZD7762 (1) and a related series of triazoloquinolines (TZQs), led to the identification of fused-ring bicyclic CHK1 inhibitors, 7-carboxamide thienopyridines (7-CTPs), and 7-carboxamide indoles. X-ray crystal structures reveal a key intramolecular noncovalent sulfur–oxygen interaction in aligning the hinge-binding carboxamide group to the thienopyridine core in a coplanar fashion. An intramolecular hydrogen bond to an indole NH was also effective in locking the carboxamide in the preferred bound conformation to CHK1. Optimization on the 7-CTP series resulted in the identification of lead compound 44, which displayed &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01490&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01490" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01490&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01490" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01490&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01490" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01490&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01490&amp;href=/doi/10.1021/acs.jmedchem.7b01490" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01490" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01490" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01490%26sid%3Dliteratum%253Aachs%26pmid%3D29301085%26genre%3Darticle%26aulast%3DYang%26date%3D2018%26atitle%3DAdventures%2Bin%2BScaffold%2BMorphing%253A%2BDiscovery%2Bof%2BFused%2BRing%2BHeterocyclic%2BCheckpoint%2BKinase%2B1%2B%2528CHK1%2529%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D3%26spage%3D1061%26epage%3D1073%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291862" title="Indoles">Indoles</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291870" title="Piperidines">Piperidines</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/3" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/jmcmar.2018.61.issue-3/20180208/jmcmar.2018.61.issue-3.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Checkpoint kinase 1 (CHK1) inhibitors are potential cancer therapeutics that can be utilized for enhancing the efficacy of DNA damaging agents. Multiple small molecule CHK1 inhibitors from different chemical scaffolds have been developed and evaluated in clinical trials in combination with chemotherapeutics and radiation treatment. Scaffold morphing of thiophene carboxamide ureas (TCUs), such as AZD7762 (<b>1</b>) and a related series of triazoloquinolines (TZQs), led to the identification of fused-ring bicyclic CHK1 inhibitors, 7-carboxamide thienopyridines (7-CTPs), and 7-carboxamide indoles. X-ray crystal structures reveal a key intramolecular noncovalent sulfur–oxygen interaction in aligning the hinge-binding carboxamide group to the thienopyridine core in a coplanar fashion. An intramolecular hydrogen bond to an indole NH was also effective in locking the carboxamide in the preferred bound conformation to CHK1. Optimization on the 7-CTP series resulted in the identification of lead compound <b>44</b>, which displayed respectable drug-like properties and good in vitro and in vivo potency.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45673" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45673" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Both normal and tumor cells employ strictly regulated DNA damage repair (DDR) pathways to survive DNA damage induced by ultraviolet rays, chemical, or replication errors, or chemotherapeutic and radiation treatments for cancer patients. It is well established that disruption of DNA repair pathways is a promising therapeutic strategy that can be used to sensitize the effects of DNA-damaging treatments.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> An attractive approach to modulating DNA repair activity and thus potentially improving the therapeutic index of DNA-damaging therapy is to interfere with cell cycle checkpoint signaling. Checkpoint kinase 1 (CHK1, CHEK1) and checkpoint kinase 2 (CHK2, CHEK2) are Ser/Thr protein kinases that mediate the cellular response to DNA damage. In response to DNA damage, CHK1 is activated by phosphorylation of residues Ser-317 and/or Ser-345 by ATR kinase, and tumor cells subsequently undergo S or G2/M phase cell-cycle arrest, primarily driven by CDK inhibition, allowing cells to repair damaged DNA.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> CHK2 is activated by phosphorylation on Thr-68 mediated by ATM kinase in response to DNA damage and causes cell cycle arrest at the G1 phase. A CHK1 inhibitor would allow a cell with damaged DNA to abrogate the cell cycle arrest and progress through the cell cycle, ultimately leading to mitotic catastrophe and/or apoptosis.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> CHK1 inhibitors have attracted substantial interest from both academia and industry as potential cancer therapeutics, and a number of diverse CHK1 inhibitors have been disclosed and evaluated in human clinical trials.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8 ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8 ref9 ref10 ref11 ref12">(5-12)</a> We previously reported two series of structurally distinct CHK1 inhibitors, thiophene carboxamide ureas (TCUs) and triazoloquinolones (TZQs) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Our past efforts identified the clinical candidate <b>1</b> (AZD7762), a small molecule agent that could be dosed intravenously in combination with standard chemo- or radiotherapies and selectively sensitize p53-negative tumors over normal cells.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13-15)</a> Herein, we report on our expanded medicinal chemistry exploration of CHK1 inhibitors and discovery of two new series of thienopyridine and indole carboxamide bicyclic CHK1 inhibitors, derived from X-ray structure-based modification or “scaffold morphing” of the TCU and TZQ chemical series. Notably we first disclosed this work in an earlier patent publication<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> which was subsequently followed by a report of similar compounds from others.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0016.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. TCU and triazoloquinolone CHK1 inhibitors and their fused ring analogs using a scaffold morphing strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70413" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70413" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We previously reported X-ray crystallography data on our CHK1 inhibitors in which we elucidated that the urea carbonyl group in the TCU and the triazolone carbonyl in the TZQ compounds form the key hinge-binding interaction with the backbone NH of Cys-87 in the ATP-binding pocket of CHK1 (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YDK">2YDK</a><a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X8E">2X8E</a><a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a>). Furthermore, the urea NH forms an H-bond to the backbone carbonyl of Glu-85, in addition to three polar interactions between the protonated piperidine nitrogen and the CHK1 residues, Asp-148, Glu-134, and Asn-135, at the edge of the ribose binding pocket (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> We made a key observation that compound <b>1</b> and its matched pair isomeric thiophene, <b>3</b>, both adopt a bound conformation having an intramolecular H-bond between the internal urea NH to the C-2 (<b>1</b>) or C-3 carbonyl (<b>3</b>) of the amide group (blue dotted line in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Thus, we envisioned that a 5,6-bicyclic ring system, such as the thienopyridine core in <b>4</b> and <b>5</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), would mimic this intramolecular hydrogen bond existing in the TCU inhibitors. Separately, disconnecting the hydrazide bond of the five-membered triazolone ring in the TZQ scaffold also generates a similar bicyclic core that the thienopyridine group resembles. Guided by the above structural insight from two distinct chemotypes, we undertook a “scaffold morphing” strategy to explore the potential for a variety of 5,6-bicyclic scaffolds as novel CHK1 inhibitors.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray crystal structure overlay of compounds <b>1</b> and <b>3</b> bound to human CHK1 kinase domain. Carbon atoms and hydrogen bonds of <b>1</b> bound to CHK1 are colored green, and carbon atoms of <b>3</b> are colored yellow (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YDJ">2YDJ</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YDK">2YDK</a>, respectively). Selected residues and inhibitors are depicted as sticks. Picture was generated in PYMOL.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Scaffold Morphing of TCU to 4-CTPs and 7-CTPs</h3><div class="NLM_p">Due to its closest similarity to the clinical candidate TCU <b>1</b>, we first pursued the synthesis and evaluation of thienopyridine <b>4</b> and the des-fluoro analog <b>12</b>. Shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, the synthesis of <b>4</b> starts with a Knoevenagel type condensation of glyoxylic acid with 2-(3-thienyl)acetonitrile to afford the unsaturated carboxylate <b>7</b>. Subsequently the acid was transformed to the acyl chloride followed by reaction with sodium azide to give acyl azide <b>8</b> in overall 82% yield. Curtius rearrangement of the acyl azide followed by electrophilic cyclization onto the thiophene ring at high temperatures yielded the fused ring thienopyridone <b>9</b>. The 2-position of the thiophene ring was selectively brominated with <i>N</i>-bromosuccinimide followed by treatment with phosphorus oxychloride to give chloropyridine intermediate <b>10</b>, which was further displaced by 1-<i>N</i>-Boc-protected (<i>S</i>)-3-aminopiperidine in the presence of potassium carbonate in NMP. The resultant bromothienopyridine <b>11</b> was coupled to <i>m</i>-fluorophenylboronic acid using a palladium-catalyzed Suzuki reaction. The desired thienopyridine carboxamide <b>4</b> was generated by partial hydrolysis of the nitrile to the carboxamide with simultaneous Boc deprotection using polyphosphoric acid. We labeled this scaffold 4-CTP since the carboxamide group is substituted on C-4 of the thienopyridine core. Compound <b>12</b> was generated in a similar fashion to <b>4</b> from <b>11</b> using phenylboronic acid.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 4-CTP <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) glyoxylic acid, K<sub>2</sub>CO<sub>3</sub>, MeOH, reflux, 3 h, 90% yield; (b) oxalyl chloride, DCM, rt, 63% yield; (c) NaN<sub>3</sub>, dioxane/water, rt, 1.5 h, 82% yield; (d) diphenyl ether, 230 °C, 0.5 h, 44% yield; (e) NBS, AcOH/DMF, 80 °C, 1 h, 96% yield; (f) POCl<sub>3</sub>, 110 °C, overnight, 82% yield; (g) (<i>S</i>)-3-amino-Boc-piperidine, K<sub>2</sub>CO<sub>3</sub>, NMP, 80 °C, quantitative yield; (h) Pd(Ph<sub>3</sub>P)<sub>4</sub>, <i>m</i>-F-PhB(OH)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, dioxane/water, 80 °C, 54% yield; (i) PPA, 110 °C, 12 h.</p></p></figure><div class="NLM_p">Surprisingly, both compounds <b>4</b> and <b>12</b> showed very weak potency (500- to 1000-fold drop vs <b>1</b>) in the CHK1 biochemical assay (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). We suspected that the steric repulsion between the carbonyl group of the C-4 carboxamide and C-3 hydrogen forced the carboxamide out of the plane of the thienopyridine bicycle, rendering the binding conformation of compounds <b>4</b> and <b>12</b> to CHK1 protein a high energy state. In <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>, the urea groups in both compounds <b>1</b> and <b>3</b> share a coplanar conformation with the thiophene ring, which likely contributes to their potent activity in CHK1 inhibition. A search of similar analogs in our internal crystal structure database revealed that in similar ligands with primary carboxamide groups substituted at C-4 of the 5,6-bicyclic heteroaryl core, the dihedral angle was measured to be 25–30°, significantly larger than we measured in both TCUs (15.1° for <b>1</b> and 15° for <b>3</b>). Despite their weaker potency, we demonstrated that 4-CTPs <b>4</b> and <b>12</b> had improved properties relative to TCU <b>1</b>, including weaker hERG inhibition (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. CHK1 Potency and hERG IC<sub>50</sub> of <b>1</b> and Its 4-CTP Analogs</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">CHK1</th><th class="colsep0 rowsep0" align="center" char=".">hERG</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">0.005</td><td class="colsep0 rowsep0" align="char" char=".">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">6.8</td><td class="colsep0 rowsep0" align="char" char=".">>31.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="char" char=".">2.6</td><td class="colsep0 rowsep0" align="char" char=".">>31.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">IC<sub>50</sub> represents activity of the compound in a CHK1 biochemical assay. IC<sub>50</sub> values are the geometric mean of at least two measurements.</p></div></div></div><div class="NLM_p">We surmised that an alternative thienopyridine analog would be a direct mimic to compound <b>3</b>, essentially flipping the sulfur in 4-CTP to the carboxamide side of the thienopyridine core to give compound <b>5</b>. In this 7-carboxamide thienopyridine (7-CTP) scaffold, the close proximity of the carboxamide carbonyl group and the sulfur atom in the thiophene ring would make the noncovalent oxygen–sulfur interaction possible, and we hypothesized that it would enable the 7-CTP compounds to adopt a conformation that better mimics the coplanar feature between the carboxamide group and thiophene ring in <b>1</b> and <b>3</b>. Therefore, we synthesized 7-CTP analogs using a similar route to the syntheses of compounds <b>4</b> and <b>12</b>, starting from commercially available 2-(2-thienyl)acetonitrile. CHK1 potency, aqueous solubility, and hERG inhibition of these compounds are shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. To our delight, the 7-CTP compounds indeed showed excellent activity in CHK1 inhibition. Inhibitors <b>5</b> and <b>13</b> are matched pairs of <b>12</b> and <b>4</b>, yet their IC<sub>50</sub> values are vastly improved and reach the same levels of potency as the original TCU compounds <b>1</b> and <b>3</b>. On the basis of TZQ analog <b>2</b>, two analogs containing thiophene substituents incorporated at the 2-position were also synthesized, also showing similar potency to <b>5</b>. Encouraged by these promising results, the 7-CTP inhibitors were tested in our previously described HT29 cell abrogation assay.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Compounds <b>5</b>, <b>13</b>, <b>14</b>, and <b>15</b> indeed proved to be extremely potent in abrogating the HT29 cell-cycle arrest caused by camptothecin-induced DNA damage. Further profiling of these compounds revealed they have good aqueous solubility and moderate to low activity in hERG inhibition (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). However, when tested for their in vivo pharmacokinetic properties, these compounds were found to have very high systemic clearance in the rat (exceeding rat liver blood flow), warranting a further optimization effort to increase their half-life and improve their in vivo exposure.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Potency and Properties of Close Analogs of <b>4</b> and <b>12</b> with 7-CTP Core</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0009.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">CHK1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">abrogation EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">solubility (μM)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">hERG IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">rat clearance CL (mL min<sup>–1</sup> kg<sup>–1</sup>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">0.007</td><td class="colsep0 rowsep0" align="char" char=".">0.019</td><td class="colsep0 rowsep0" align="char" char=".">>2000</td><td class="colsep0 rowsep0" align="char" char=".">>31.6</td><td class="colsep0 rowsep0" align="char" char=".">49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="char" char=".">0.007</td><td class="colsep0 rowsep0" align="char" char=".">0.026</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">19.7</td><td class="colsep0 rowsep0" align="char" char=".">>72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left"><i>m</i>-F-Ph</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="char" char=".">0.024</td><td class="colsep0 rowsep0" align="char" char=".">334</td><td class="colsep0 rowsep0" align="char" char=".">14.2</td><td class="colsep0 rowsep0" align="char" char=".">>72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="char" char=".">0.015</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">3-thienyl</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="char" char=".">980</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="char" char=".">>72</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">IC<sub>50</sub> and EC<sub>50</sub> values are the geometric mean of at least two measurements.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">EC<sub>50</sub> represents cellular activity in cells pretreated with a DNA-damaging agent, camptothecin, prior to compound treatment.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Solubility is measured using solids from evaporated DMSO solution.</p></div></div></div><div class="NLM_p">In our previous communications on TZQ CHK1 inhibitors, pyrazoles that occupy the solvent channel of CHK1 in place of the thiophene group in compound <b>2</b> were tolerated.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Using this as precedent, we grafted those more hydrophilic heterocycles to the new 7-CTP scaffold, installing them on C-2 of the 7-CTP core (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>) to reduce the lipophilicity of 7-CTPs as a strategy to address metabolic stability issues and to improve margin over hERG inhibition. Nevertheless, while we found CHK1 enzyme potency was retained with these heteroaryl substituents, pyrazoles <b>16</b> and <b>17</b> and imidazole <b>19</b> caused a drop in cell potency, likely due to reduced cell permeability, as lower cLogP (<b>16</b> and <b>19</b> compared with <b>18</b>) or an additional hydrogen bond donor (<b>16</b> compared with <b>17</b>) is associated with larger biochemical to cellular potency drop-off. Benzylpyrazole <b>18</b> maintained cellular potency but had high lipophilicity (cLogP = 4.0) due to the hydrophobic benzyl substitution. We also evaluated analogs with smaller C-2 substituents such as methyl group at C-2 (<b>20</b>) but found significantly reduced CHK1 potency, suggesting an aromatic ring or larger groups at C-2 is essential.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Heteroaryl or Alkyl Substitutions at C-2 of 7-CTP Reduced CHK1 Cellular Potency</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0010.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0011.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> and EC<sub>50</sub> values are the geometric mean of at least two measurements. *Not determined.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Modification of Thienopyridines to Indoles</h3><div class="NLM_p">Intramolecular sulfur–oxygen interactions are known to be isosteric to hydrogen-bonding interactions.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Recognizing the carbonyl oxygen and thiophene sulfur interaction in 7-CTPs was critical for the potency of the already explored bicyclic scaffolds, we were intrigued by the potential of an indole core that can offer an intramolecular hydrogen bond between the carbonyl of the carboxamide group and the indole NH (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). We surmised that a hydrogen bond can lock the 7-carboxamide of the indole compound <b>21</b> in the desired conformation for its optimal binding to CHK1.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Isosteric replacement of S–O interaction using the hydrogen bond of the indole NH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Illustrated in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> is the synthetic route to the initially designed indole analog <b>21</b>, based on 7-CTP <b>5</b>. The nitroanthranilate derivative <b>22</b> was converted to methyl ester <b>23</b> using thionyl chloride in methanol under reflux conditions. Ester <b>23</b> then underwent a novel one-pot multistep transformation using potassium <i>tert</i>-butoxide in DMSO which involved generation of an enamine by reaction with acetophenone and nucleophilic aromatic substitution ortho to the activating nitro group, followed by air oxidation to produce the indole carboxylic acid <b>24</b>. The indole intermediate <b>24</b> was converted to amide <b>25</b> upon treatment of isobutyl chloroformate and ammonia. Hydrogenation of the nitro group of <b>25</b> yielded the aniline compound <b>26</b>, which was then converted to the anticipated racemic version of the product <b>21</b> by reductive amination with Boc protected 3-oxopiperidine in good yield. Chiral separation of the racemic mixture of <b>21</b> by chrial preparative HPLC afforded the desired <i>S</i>-enantiomer <b>21</b> and its <i>R</i>-enantiomer (<i>R</i>)-<b>21</b>.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Indole Analog <b>21</b>.<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) SOCl<sub>2</sub>, MeOH, reflux, 2 days, 63% yield; (b) acetophenone, KO<i>t</i>-Bu, DMSO, −15 °C, 1 h, 90%; (c) isobutyl chloroformate, NH<sub>3</sub>, DCM, −15 °C to rt, 80% yield; (d) H<sub>2</sub>, 10% Pd/C, rt, overnight, MeOH, 80% yield; (e) 3-oxo-Boc-piperidine, Na<sub>2</sub>SO<sub>4</sub>, NaBH(OAc)<sub>3</sub>, rt, AcOH, 30% yield; (f) 4 N HCl in dioxane, MeOH, 2 h, 78% yield; (g) chiral preparative HPLC for enantiomeric separation.</p></p></figure><div class="NLM_p">In addition to <b>21</b>, three additional analogs bearing <i>m</i>-fluorophenyl, <i>p</i>-fluorophenyl, and <i>p</i>-chlorophenyl groups at C-2 of the indole core were also synthesized (<b>27</b>, <b>28</b>, and <b>29</b>, <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). As we expected, these indole analogs proved to be equal to or slightly less potent relative to their matched pairs of <b>5</b> and <b>13</b>, both in the CHK1 inhibition assay and in the cell-cycle abrogation assay. The aqueous solubility of compound <b>21</b> is still respectable at 280 μM but lower than the matched 7-CTP analog <b>5</b>. An unanticipated concern for these indole compounds, however, is their hERG inhibition liability, as shown in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. All four analogs (<b>21</b> and <b>27</b>–<b>29</b>) are more potent hERG inhibitors compared with their 7-CTP matched pairs. Compound <b>21</b>, as a representative from this subseries of CHK1 inhibitors, was taken into rat in vivo PK studies, and similar to its 7-CTP analog, (<i>S</i>)-<b>1</b> showed high clearance (CL = 160 mL min<sup>–1</sup> mg<sup>–1</sup>), high volume of distribution (V<sub>ss</sub> = 46 L/kg), and a short half-life (<i>t</i><sub>1/2</sub> = 2.6 h).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. CHK1 Potency, Solubility, and hERG Inhibition of Indole and Furopyridine Analogs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0012.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">Ar</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">CHK1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">abrogation EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">solubility (μM)</th><th class="colsep0 rowsep0" align="center">hERG IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.031</td><td class="colsep0 rowsep0" align="left">0.053</td><td class="colsep0 rowsep0" align="left">280</td><td class="colsep0 rowsep0" align="left">11.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left"><i>m</i>-F-Ph</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.009</td><td class="colsep0 rowsep0" align="left">0.030</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">7.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left"><i>p</i>-F-Ph</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.023</td><td class="colsep0 rowsep0" align="left">0.040</td><td class="colsep0 rowsep0" align="left">380</td><td class="colsep0 rowsep0" align="left">6.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left"><i>p</i>-Cl-Ph</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="left">0.070</td><td class="colsep0 rowsep0" align="left">320</td><td class="colsep0 rowsep0" align="left">4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">0.33</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">IC<sub>50</sub> and EC<sub>50</sub> values are the geometric mean of at least two measurements.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Not determined.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">For the synthesis of the furopyridine analog <b>30</b>, see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01490/suppl_file/jm7b01490_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div></div></div><div class="NLM_p">To further test the importance of the noncovalent intramolecular interaction perceived to exist both in 7-CTPs and in the indole analogs (<b>21</b> and <b>27</b>–<b>29</b>), we synthesized a furopyridine compound <b>30</b>, aiming to deprive the hydrogen bond interaction between the NH and the carboxamide carbonyl group of indole <b>21</b>. As we expected, switching indole NH in <b>21</b> to O in <b>30</b> caused a 10-fold drop in potency, confirming the critical role of the intramolecular electrical interaction for these CHK1 inhibitors, existing in 7-CTPs as an oxygen–sulfur interaction and in the indoles as a hydrogen bond. Consistent with our observations first reported in 2006<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and now a complete account herein, a series of CHK1 inhibitors published by Zhao et al. also contains additional 5,6-bicyclic aromatic cores, such as thiazolopyridine and thiazolopyridazine, which embed the sulfur atom next to the carboxamide group.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Presumably, the oxygen–sulfur interaction also strongly contributed to the potency in a similar fashion to that seen in these 7-CTP examples.</div><div class="NLM_p">Next, we obtained X-ray crystal structures for both compounds <b>13</b> and <b>21</b> bound to CHK1. Undeniably, these two molecules superimposed on each other and TCUs <b>1</b> and <b>3</b> closely, both maintaining a near coplanar conformation between the carboxamide group and the bicyclic heteroaryl core, and made analogous polar and nonpolar interactions with the CHK1 protein (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Same as in both TCUs (<b>1</b> and <b>3</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), the carboxamides of <b>13</b> and <b>21</b> make hydrogen-bonding interactions with the hinge residues Glu-85 and Cys-87. Their protonated piperidine nitrogens make three polar interactions in the ribose binding pocket, including to Asp-148, Glu-134, and Asn-135. In both structures, the C-4 NH interacts with the terminal carboxylate of Glu-91 through a water molecule. The indole or thienopyridine bicyclic core is sandwiched between the hydrophobic side chains of Val-23 and Leu-15 of the P-loop and Leu-137 of the catalytic loop (not shown in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). The indole NH of <b>21</b> makes no direct polar interactions with CHK1, unlikely to directly contribute to the binding affinity of <b>21</b> to CHK1 other than the intramolecular hydrogen-bonding to the carboxamide group. Here, we experimentally demonstrated that the indole NH was an effective isosteric replacement to the sulfur atom in 7-CTPs and good potency was achieved with the indole core. However, due to the concern on the hERG activity of these indole compounds, we shifted our focus back to the thienopyridines.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structure overlay of compounds <b>13</b> and <b>21</b> bound to human CHK1 kinase domain. Carbon atoms and hydrogen bonds of <b>13</b> bound to CHK1 are colored yellow, and carbon atoms of <b>21</b> are colored green (PDB codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FC8">6FC8</a> for <b>13</b> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FCK">6FCK</a> for <b>21</b>). <b>13</b> is modeled as a dual conformation. Selected residues and inhibitors are depicted as sticks. Picture was generated in PYMOL.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Optimization of the Aminopiperidine Group</h3><div class="NLM_p">Our previous work on TCUs explored the SAR of the solvent channel aryl groups (equivalent to the C-2 aryl on 7-CTPs) extensively, and simple phenyl or halogen substituted phenyl groups were identified to offer a better overall profile.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> As previously noted, we and others also published extensive C-2 aryl or heteroaryl SAR exploration on the thienopyridine core as CHK1 inhibitors.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> As summarized in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> and <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>, neither the variation on the C-2 aryl groups of the 7-CTP core nor switching the core from CTP to indole effectively lowered the in vivo rat clearance. Shown in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a> is the measured intrinsic clearance when compounds (<b>5</b>, <b>14</b>, <b>15</b>, and <b>21</b>) were incubated with human or rat liver microsomes. Consistent with the observed high in vivo rat clearance, these compounds showed moderate to high CL<sub>int</sub> in rat microsomal studies, although their human microsomal CL<sub>int</sub> values were more moderate. Our earlier SAR studies on the TCUs identified 3-(<i>S</i>)-aminopiperidine as a more potent group,<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> and we suspected the high rat clearance for both the thienopyridine and indole compounds at least was partially due to the metabolic liability of the aminopiperidine group. Herein, we set out to further study the SAR around the aminopiperidine group in 7-CTPs to address metabolic stability and hERG issues associated with this series of compounds.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro Metabolic Stability of 7-CTPs and Indole <b>21</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">core</th><th class="colsep0 rowsep0" align="center" char=".">Hu mics CL<sub>int</sub> (μL min<sup>–1</sup> mg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">rat mics CL<sub>int</sub> (μL min<sup>–1</sup> mg<sup>–1</sup>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">7-CTP</td><td class="colsep0 rowsep0" align="char" char=".">9.2</td><td class="colsep0 rowsep0" align="char" char=".">32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">7-CTP</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">7-CTP</td><td class="colsep0 rowsep0" align="char" char=".">29</td><td class="colsep0 rowsep0" align="char" char=".">72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">indole</td><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="char" char=".">120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">7-CTP</td><td class="colsep0 rowsep0" align="char" char=".">35</td><td class="colsep0 rowsep0" align="char" char=".">>120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">7-CTP</td><td class="colsep0 rowsep0" align="char" char="."><5</td><td class="colsep0 rowsep0" align="char" char=".">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">7-CTP</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">37</td></tr></tbody></table></div></div><div class="NLM_p">While it was not clear to us if the C-4 NH played a role in contributing to the metabolic instability of the 7-CTPs, we were also intrigued to know how significant its water-molecule-bridged polar interaction with Glu-91 was to the potency. This interaction can be disrupted by small alkyls substitutions on the C-4 nitrogen. A list of compounds that were evaluated from this effort is shown in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>. The syntheses of these analogs followed a route very similar to that of compound <b>5</b>. Analogs <b>31</b> and <b>32</b> with the C-4 oxygen and sulfur replacements for nitrogen, respectively, were synthesized when 3-(<i>S</i>)-hydroxy or 3-sulfanyl Boc piperidine was used in step g, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, but using 7-CTP as the intermediate (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01490/suppl_file/jm7b01490_si_001.pdf" class="ext-link">Supporting Information</a>). Analogs with alkyl substitutions on the C-4 nitrogen were obtained when <i>N</i>-substituted-Boc-piperidines were used.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. CHK1 Potency of Analogs after Replacement of the Thienopyridine C-4 Nitrogen</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0013.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center" char=".">CHK1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">abrogation EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">hERG IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="char" char=".">0.083</td><td class="colsep0 rowsep0" align="left">0.34</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b><a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="char" char=".">0.056</td><td class="colsep0 rowsep0" align="left">0.21</td><td class="colsep0 rowsep0" align="char" char=".">4.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">NCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.025</td><td class="colsep0 rowsep0" align="left">0.84</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">NCH<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.035</td><td class="colsep0 rowsep0" align="left">0.11</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">N(CH<sub>2</sub>)<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="char" char=".">0.079</td><td class="colsep0 rowsep0" align="left">3.70</td><td class="colsep0 rowsep0" align="char" char=".">>31.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">NCH<sub>2</sub>CH<sub>2</sub>Ph</td><td class="colsep0 rowsep0" align="char" char=".">0.66</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">2.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">IC<sub>50</sub> and EC<sub>50</sub> values are the geometric mean of at least two measurements.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Racemic version only.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Not determined.</p></div></div></div><div class="NLM_p">When tested for CHK1 activity, both <b>31</b> and <b>32</b> showed about a 10-fold drop in potency compared with <b>5</b> in the CHK1 biochemical assay, and their cellular potency decrease was similar or more significant. Small alkyl substituents at the C-4 nitrogen of 7-CTP (compounds <b>33</b> and <b>34</b>) were slightly better in maintaining biochemical activity (3- to 5-fold drop), but cellular potency also dropped significantly. More polar substitutions, such as compound <b>35</b>, which contains a terminal hydroxy group on the alkyl group, brought a similar drop in biochemical activity, but their toll on cellular activity was more profound. Large hydrophobic substitution (<b>36</b>) was detrimental to potency. Interestingly, the <i>N</i>-methyl compound (<b>33</b>) showed improved stability in both human and rat microsomal assays, but C-4 O-linker analog <b>31</b> showed significantly reduced microsomal stability (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Unfortunately, these compounds, except the hydroxyethyl analog <b>35</b>, also showed increased hERG liability, and their increased lipophilicity (cLogP of 3.87 for <b>5</b> and up to 4.60 for <b>34</b>) likely contributed to their promiscuous hERG inhibition.</div><div class="NLM_p">In order to address the metabolic stability concern of the 3-aminopiperidine group, we next focused on the structural modifications close to the piperidine nitrogen, as it is known that a basic nitrogen can be susceptible to oxidation by FMO (flavin-containing monooxygenase) enzymes in the hepatocytes.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Reducing nitrogen p<i>K</i><sub>a</sub> is a known approach in mitigating FMO induced metabolic stability, and we were also aware that the basic piperidine likely strongly contributed to the high volume of distribution of these compounds in rat PK studies.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> However, as illustrated in the binding modes of both TCUs (<b>1</b> and <b>3</b>) and compounds <b>13</b> and <b>21</b>, the basic nitrogen was important for potency in this scaffold, so we suspected significantly modulating the p<i>K</i><sub>a</sub> of the piperidine group would not be a viable strategy. We instead focused on introducing different substitutions on the piperidine ring, anticipating that these substitutions could afford more metabolically stable compounds while maintaining CHK1 potency. Shown in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a> are a series of compounds that we constructed in this study.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. CHK1 Potency and hERG Inhibition of Substituted 3-Aminopiperidine Analogs<a class="ref internalNav" href="#t7fn4" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0014.gif" alt="" id="fx6" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">CHK1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t7fn2" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">abrogation EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t7fn2" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">hERG IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">0.14</td><td class="colsep0 rowsep0" align="left">0.88</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t7fn3" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">0.006</td><td class="colsep0 rowsep0" align="left">0.008</td><td class="colsep0 rowsep0" align="left">>31.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">0.069</td><td class="colsep0 rowsep0" align="left">0.050</td><td class="colsep0 rowsep0" align="left">5.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b><a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.010</td><td class="colsep0 rowsep0" align="left">0.41</td><td class="colsep0 rowsep0" align="left">>31.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b><a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.083</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">>31.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b><a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.012</td><td class="colsep0 rowsep0" align="left">0.010</td><td class="colsep0 rowsep0" align="left">8.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b><a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.021</td><td class="colsep0 rowsep0" align="left">0.030</td><td class="colsep0 rowsep0" align="left">2.45</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn4"><div class="footnote" id="t7fn4"><sup>a</sup><p class="last">For the detailed syntheses of <b>43</b>, <b>46</b>, <b>47</b>, <b>48</b>, and <b>49</b>, see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01490/suppl_file/jm7b01490_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t7fn1"><sup>b</sup><p class="last">Racemic mixture.</p></div><div class="footnote" id="t7fn2"><sup>c</sup><p class="last">IC<sub>50</sub> and EC<sub>50</sub> values are the geometric mean of at least two measurements.</p></div><div class="footnote" id="t7fn3"><sup>d</sup><p class="last">ND: not determined.</p></div></div></div><div class="NLM_p">The key for the syntheses of the piperidine-modified compounds in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a> was to obtain the piperidine intermediates with a variety of substitutions and stereoisomers. Illustrated in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> is the route to the Cbz protected 3-amino-2-methylpiperidine intermediate for compounds <b>44</b> and <b>45</b>. Protected <span class="smallcaps smallerCapital">l</span>-ornithine <b>37</b> reacted directly with methyllithium to yield ketone <b>38</b> which underwent cyclization under hydrogenation conditions to form a mixture of four piperidine diastereomers <b>39</b>, due to racemization at the α stereocenter. The Cbz group was reinstalled to the ring nitrogen to facilitate the separation of <i>trans</i> and <i>cis</i> diastereomers, and Boc deprotection provided the Cbz protected 3-aminopiperidine intermediates, setting the stage for synthesis of the final inhibitors (cf. steps g–i in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The <i>trans</i> racemic mixture <b>41</b> led to the desired pure enantiomer <b>44</b> after chiral HPLC separation, while the c<i>is</i> racemic mixture <b>42</b> led to <b>45</b>.</div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 3-Amino-2-methylpiperidines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MeLi, THF, 0 °C to rt, 5 h, 14% yield; (b) 10% Pd/C, H<sub>2</sub>. MeOH, rt, 3 days, 100% yield; (c) CbzCl, DIPEA, DCM, rt, 1 h, 49% yield; (d) silica gel column separation, EtOH/hexane, 49% yield <i>trans</i> isomer and 35% yield for <i>cis</i> isomer; (e) 4 N HCl in dioxane, MeOH, rt, 100% yield.</p></p></figure><div class="NLM_p">Simple methyl substitution on the ring nitrogen in piperidine (<b>43</b>) caused a 20-fold potency drop from <b>5</b>, confirming the importance of the multipoint polar interaction between the piperidine (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>) and the CHK1 ribose binding pocket residues. Interestingly, one of the two diastereomers synthesized from 3-amino-2-methylpiperidine intermediates, the (2<i>R</i>,3<i>S</i>)-diastereomer (<b>44</b>), showed superior potency over the other diastereomer <b>45</b>, offering similar potency to <b>5</b>. We later obtained the X-ray crystal structure for <b>44</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). The binding mode of <b>44</b> is nearly identical to <b>3</b> and maintained all of the polar or hydrophobic interactions. As expected with <b>44</b>, the 2-methyl group <i>trans</i> to the 3-amino group on the piperidine ring adopted the equatorial conformation, directing it toward Leu-137. The presumed axial 2-methyl in <b>45</b> is less preferred. A <i>trans</i> 4-hydroxyl substituted piperidine analog (<b>46</b>) retained biochemical activity, but cellular potency dropped significantly. A more extended <i>trans</i> 2-hydroxylethyl group on the piperidine ring was not well tolerated for potency (<b>47</b>). The all <i>cis</i> trisubstituted piperidine analog <b>48</b> showed comparably good enzyme and cellular potency. The <i>cis</i>-racemic mixture of 3-amino-6-methylpiperidine analogs were also synthesized (<b>49</b>), and it remained reasonably potent. Interestingly, the diastereomeric pair <b>44</b> and <b>45</b> showed significantly different hERG activity, and to our delight, the more potent <b>44</b> demonstrated improved hERG profile with IC<sub>50</sub> values greater than 31.6 μM, the maximum tested concentration in the assay. In addition, when tested in human and rat liver microsomal stability assays, compound <b>44</b> showed a stability improvement over <b>5</b> (<5 μL min<sup>–1</sup> mg<sup>–1</sup> in human microsomes and <10 μL min<sup>–1</sup> mg<sup>–1</sup> in rat microsomes).</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray crystal structure overlay of compounds <b>44</b> and <b>3</b> bound to human CHK1 kinase domain. Carbon atoms and hydrogen bonds of <b>44</b> bound to CHK1 are colored yellow, and carbon atoms of <b>3</b> are colored green (PDB codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FCF">6FCF</a> for <b>44</b>). Selected residues and inhibitors are depicted as sticks. Pictures were generated in PYMOL.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> 7-CTPs Shows Enhanced DNA-Damaging Effects in Vitro and in Vivo</h3><div class="NLM_p">To evaluate the potentiating effect of our new lead 7-CTP CHK1 inhibitors to DNA-damaging agents, such as gemcitabine, we employed a potentiation assay that was described in detail previously.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Briefly, the concentration–response of tumor cells to proliferation inhibition by DNA-damaging agents was measured with or without the presence of CHK1 inhibitors, which was dosed in a predefined constant concentration. The ratio of the GI<sub>50</sub> from the DNA-damaging agent alone over the GI<sub>50</sub> from the combination of DNA-damaging reagent and a CHK1 inhibitor was designated as the potentiation factor (PF). Compounds <b>5</b>, <b>13</b>, and <b>44</b>, along with previously reported <b>3</b>, were evaluated in this assay, each against three cell lines (SW620, MDA-MB-231, and H460-DNp53). Their potentiating effects on gemcitabine-induced cell proliferation inhibition are shown in <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>. These four compounds all demonstrated synergistic effects when dosed in combination with gemcitabine. The potentiation factor (PF) was found to be more significant in the more gemcitabine-resistant cell line (H460-DNp53, an engineered cell line that was developed by retroviral infection of a dominant-negative p53 construct)<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and less so in the more gemcitabine-sensitive cell line (MDA-MB-231). Compound <b>3</b> exhibited higher PF among these four compounds when tested in MDA-MB-231, but in the slightly less sensitive cell line SW620, all four compounds tested showed a similar level of PF. However, compound <b>44</b> stood out with a superior enhancing effect (PF = 124) when tested in H460-DNp53 cells, lowering the gemcitabine GI<sub>50</sub> from 2.1 nM to 0.017 nM. The enhancing effect between <b>5</b> and <b>13</b> was marginal in both MDA-MB-231 and SW620 cells, but <b>13</b> exhibited a stronger effect in H460-DNp53 cells.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Proliferation Inhibition Potentiation Effect of CHK1 Inhibitors When Used in Combination with Gemcitabine<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">single agent GI<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">single agent GI<sub>25</sub> (nM)</th><th class="colsep0 rowsep0" align="center">combination GI<sub>50</sub> (nM)<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">PF<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="center">MDA-MB-231</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">596</td><td class="colsep0 rowsep0" align="left">300</td><td class="colsep0 rowsep0" align="left">0.027</td><td class="colsep0 rowsep0" align="left">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">536</td><td class="colsep0 rowsep0" align="left">270</td><td class="colsep0 rowsep0" align="left">0.052</td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">641</td><td class="colsep0 rowsep0" align="left">320</td><td class="colsep0 rowsep0" align="left">0.068</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">306</td><td class="colsep0 rowsep0" align="left">150</td><td class="colsep0 rowsep0" align="left">0.052</td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gemcitabine</td><td class="colsep0 rowsep0" align="left">0.251</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="center">SW620</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">839</td><td class="colsep0 rowsep0" align="left">420</td><td class="colsep0 rowsep0" align="left">0.077</td><td class="colsep0 rowsep0" align="left">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">970</td><td class="colsep0 rowsep0" align="left">490</td><td class="colsep0 rowsep0" align="left">0.067</td><td class="colsep0 rowsep0" align="left">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">841</td><td class="colsep0 rowsep0" align="left">420</td><td class="colsep0 rowsep0" align="left">0.091</td><td class="colsep0 rowsep0" align="left">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">725</td><td class="colsep0 rowsep0" align="left">360</td><td class="colsep0 rowsep0" align="left">0.074</td><td class="colsep0 rowsep0" align="left">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gemcitabine</td><td class="colsep0 rowsep0" align="left">0.84</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="center">H460-DNp53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">1231</td><td class="colsep0 rowsep0" align="left">620</td><td class="colsep0 rowsep0" align="left">0.031</td><td class="colsep0 rowsep0" align="left">67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">1798</td><td class="colsep0 rowsep0" align="left">900</td><td class="colsep0 rowsep0" align="left">0.075</td><td class="colsep0 rowsep0" align="left">28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">2904</td><td class="colsep0 rowsep0" align="left">1450</td><td class="colsep0 rowsep0" align="left">0.055</td><td class="colsep0 rowsep0" align="left">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">2453</td><td class="colsep0 rowsep0" align="left">1230</td><td class="colsep0 rowsep0" align="left">0.017</td><td class="colsep0 rowsep0" align="left">124</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gemcitabine</td><td class="colsep0 rowsep0" align="left">2.085</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">GI<sub>50</sub> and GI<sub>25</sub> values are the mean value of two duplicated runs.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">CHK1 inhibitors concentration used in the combination with gemcitabine was its GI<sub>25</sub> as a single agent.</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last">Potentiation factor <span class="NLM_inline-formula"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/jm-2017-014906_m001.gif" alt="" /></img></span>.</p></div></div></div><div class="NLM_p">Compounds <b>5</b>, <b>13</b>, and <b>44</b> were dosed intravenously to mouse, rat, and dog to evaluate their pharmacokinetic (PK) properties (<a class="ref internalNav" href="#tbl9" aria-label="Table 9">Table 9</a>). All three compounds were measured to have high plasma clearance in rat; however, due to their high volume of distribution, likely resulting from the presence of the basic piperidine group, these compounds still showed reasonable half-lives. Their clearance was found to be more moderate in dog. Both in terms of CL and <i>t</i><sub>1/2</sub>, compound <b>5</b> was found to be slightly inferior in comparison to <b>13</b> and <b>44</b>. Compound <b>44</b> showed a more consistent profile across mouse and rat with lower CL, longer <i>t</i><sub>1/2</sub>, and lower <i>V</i><sub>ss</sub>, and in dog its <i>t</i><sub>1/2</sub> is notably longer, likely associated with its larger <i>V</i><sub>ss</sub> in dog.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. In Vivo PK of <b>5</b>, <b>13</b>, and <b>44</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>5</b></th><th class="colsep0 rowsep0" align="center"><b>13</b></th><th class="colsep0 rowsep0" align="center"><b>44</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL min<sup>–1</sup> kg<sup>–1</sup>) mouse/rat/dog</td><td class="colsep0 rowsep0" align="left">45/295/11</td><td class="colsep0 rowsep0" align="left">28/196/10</td><td class="colsep0 rowsep0" align="left">29/105/10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i> <sub>1/2</sub> (h) mouse/rat/dog</td><td class="colsep0 rowsep0" align="left">1.5/3.1/5.4</td><td class="colsep0 rowsep0" align="left">8.5/4.4/5.1</td><td class="colsep0 rowsep0" align="left">3.4/5.1/9.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a> mouse/rat/dog</td><td class="colsep0 rowsep0" align="left">4.0/75/3.7</td><td class="colsep0 rowsep0" align="left">4.6/54.3/4.4</td><td class="colsep0 rowsep0" align="left">4.6/24/7.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">Steady-state volume of distribution after intravenous dose.</p></div></div></div><div class="NLM_p">We tested these three compounds for their in vivo effects in a mouse hollow fiber (HF) model.<a onclick="showRef(event, 'ref14 ref21'); return false;" href="javascript:void(0);" class="ref ref14 ref21">(14, 21)</a> In this model, HCT116 cells were treated with the DNA-damaging agent topotecan to induce cell cycle arrest in the G2 phase. The hollow fibers were filled with cell cycle arrest cells and subsequently were implanted subcutaneously in mice before compounds were intravenously dosed. Implanted fibers were retrieved after 30 h to determine the cell cycle profile of the enclosed cells. When dosed with CHK1 compounds, the G2 arrest was overcome causing a reduction in the number of cells in G2 and a concomitant increase in the number of cells re-entering the G1 phase. The “odds value” was then calculated as the ratio of the G2/G1 populations for topotecan alone and the CHK1 inhibitor combination. On the basis of the odds value, we calculated an odds ratio (OR) that allowed quantitative assessment of the degree of checkpoint abrogation. The greater is the OR, the higher is the level of checkpoint abrogation. Shown in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a> are the odds ratios for <b>5</b>, <b>13</b>, and <b>44</b>. All three compounds showed G2 arrest abrogation effect in the HCT116 HF assay, with <b>13</b> showing the lowest OR (2.0) among these three compounds. Compounds <b>5</b> and <b>44</b> demonstrated similar PD effects in this model at the same dose (10 mg/kg), with OR at 3.2 and 3.7, respectively.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Odds ratio of <b>5</b>, <b>13</b>, and <b>44</b> in hollow fiber mouse PD assay (iv administration, using HCT116 cells). The error bars represent the standard error of the mean odds ratio of multiple runs of the study. <span class="NLM_inline-formula"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/jm-2017-014906_m002.gif" alt="" /></img></span> and <span class="NLM_inline-formula"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/jm-2017-014906_m003.gif" alt="" /></img></span>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51541" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51541" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Using X-ray structure-based drug design, we employed a scaffold morphing strategy to successfully design several new series of potent CHK1 inhibitors featuring 5,6-bicyclic cores that mimic the productive conformation of TCU compounds bound to CHK1. We discovered a key intramolecular oxygen–sulfur interaction was critical for the potency of carboxamide thienopyridines (CTPs), as this interaction allows the carboxamide group to orient in a coplanar conformation with the bicyclic aromatic core. Replacement of the O–S interaction by an intramolecular hydrogen bond was proven to be effective in maintaining the critical coplanar conformation and hence resulted in similar CHK1 potency. Additional structural optimization of this class of thienopyridine compounds has led to the identification of advanced lead compound <b>44</b>, which contains a <i>trans</i> 3-amino-2-methylpiperidine group to occupy the ribose pocket of CHK1. Compound <b>44</b> encompasses a combination of excellent potency, reduced hERG liability, and improved in vitro metabolic stability. When used in combination with gemcitabine, it strongly enhanced the proliferation inhibition effect of gemcitabine in multiple tumor cell lines. The in vivo plasma clearance of <b>44</b> in rodents was found to be high, but in dog both the clearance and half-life were reasonable. When tested for its in vivo PD activity in combination with topotecan, compound <b>44</b> demonstrated the mode of action in abrogating HCT116 G2 cell cycle arrest induced by topotecan, which presumably would lead to eventual apoptosis of HCT116 cells. In a subsequent preclinical rat telemetry study, compound <b>44</b> was found to induce reversible hypotension and reflex tachycardia when dosed to male Han Wistar rats at 12.5 mg/kg. Given that cardiac dose-limiting toxicities occurred in patients of <b>1</b> and other CHK1 inhibitors in phase I clinical trials,<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> the decision was not to progress compound <b>44</b> or other CHK1 inhibitors from this class into additional preclinical and clinical studies. Currently there are multiple CHK1 inhibitors (prexasertib, ARRY-575, and CCT-245737) (Citeline/Trialtrove, as of October, 2016) in clinical trials, and it remains a hope that one or more of these inhibitors will eventually be approved, bringing important new treatment options to cancer patients.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31777" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31777" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Information</h3><div class="NLM_p">All solvents used were commercially available in anhydrous grade. Reagents were utilized without further purification unless otherwise stated. Evaporation of solvent was carried out using a rotary evaporator under reduced pressure at a bath temperature of up to 60 °C. Temperatures are given in degrees Celsius (°C), and operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18–30 °C. In general, the course of reactions was followed by thin layer chromatography or mass spectroscopy, and reaction times are given for illustration only; where a synthesis is described as being analogous to that described in a previous example, the amounts used are the millimolar ratio equivalents to those used in the previous example. NMR data are in the form of δ values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 or 400 MHz using deuterated solvent. Analytical mass spectra were run with an electron energy of 70 eV in the chemical ionization (CI) mode using a direct exposure probe, where indicated ionization was effected by electron impact (EI), electrospray (ESP), or atmospheric pressure chemical ionization (APCI); values for <i>m</i>/<i>z</i> are given; generally, only ions which indicate the parent mass are reported. All final compounds were purified to ≥95% purity, as assessed by analytical HPLC using an Agilent 1100 equipped with Waters columns (Atlantis T3, 2.1 mm × 50 mm, 3 μm or Atlantis dC18, 2.1 mm × 50 mm, 5 μm) eluted for >10 min with a gradient mixture of water and acetonitrile with either formic acid or ammonium acetate added as a modifier, monitored at wavelengths of 220, 254, and 280 nm.</div><div class="NLM_p last">All experimental activities involving animals were carried out in accordance with AstraZeneca animal welfare protocols, which are consistent with The American Chemical Society Publications rules and ethical guidelines.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 2-(3-Fluorophenyl)-7-[(3<i>S</i>)-piperidin-3-ylamino]thieno[2,3-<i>c</i>]pyridine-4-carboxamide (<b>4</b>)</h3><div class="NLM_p last">To a flask containing <i>tert</i>-butyl (3<i>S</i>)-3-{[4-cyano-2-(3-fluorophenyl)thieno[2,3-<i>c</i>]pyridin-7-yl]amino}piperidine-1-carboxylate was added approximately 2.00 mL of PPA. The reaction mixture was stirred at 110 °C for 12 h. The crude reaction mixture was then diluted with 10.0 mL of water and brought to a basic pH with 6 N NaOH. The mixture was then extracted with ethyl acetate (4 × 100 mL) followed by CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1/1, 4 × 100 mL), dried over MgSO<sub>4</sub>, and concentrated under reduced pressure to yield the crude product which was purified by silica gel chromatography (100% CH<sub>2</sub>Cl<sub>2</sub> to 20% MeOH/CH<sub>2</sub>Cl<sub>2</sub>/3% NH<sub>4</sub>OH) to afford the title compound. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 8.01 (s, 1H), 7.91 (s, 1H), 7.51 (s, 1H), 7.38 (m, 1H), 7.36 (m, 2H), 7.34 (br s, 1H), 6.80 (m, 1H), 4.21 (m, 1H), 3.15 (m, 2H), 2.87 (m, 2H), 1.92–1.46 (m, 4H); LCMS (ES, M + H) = 371.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 2-Phenyl-4-[(3<i>S</i>)-piperidin-3-ylamino]thieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>5</b>)</h3><div class="NLM_p last">A solution of <i>tert</i>-butyl (3<i>S</i>)-3-{[7-cyano-2-(phenyl)thieno[3,2-<i>c</i>]pyridin-4-yl]amino}piperidine-1-carboxylate (80 mg, 0.18 mmol, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01490/suppl_file/jm7b01490_si_001.pdf" class="ext-link">Supporting Information</a>) and 12 N HCl (conc, 4 mL) was stirred for 24 h. Water (10–20 mL) was added, and the pH of the solution was adjusted to 10–11 with sat. NaHCO<sub>3</sub>. The material was isolated by filtration and was washed with a small amount of cold water. The material was dried and then purified by MPLC (SiO<sub>2</sub>; NH<sub>4</sub>OH/MeOH/CH<sub>2</sub>Cl<sub>2</sub>; 2:10:88) to give the title compound (24 mg, 38%). <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 8.58 (s, 1H), 8.27 (s, 1H), 7.98 (br s, 1H), 7.79 (d, 2H), 7.55 (dd, 2H), 7.43 (dd, 1H), 7.34 (br s, 1H), 7.25 (d, 2H), 4.22 (m, 1H), 3.21 (d, 1H), 2.91 (d, 1H), 2.48 (m, 2H), 2.05 (m, 1H), 1.76 (m, 1H), 1.55 (m, 2H). LCMS (ES, M + H) = 353.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (2<i>Z</i>)-3-Cyano-3-(3-thienyl)acrylic Acid (<b>7</b>)</h3><div class="NLM_p last">To 3-thiopheneacetonitrile (<b>6</b>, 166 mmol) were added glyoxylic acid (174 mmol), methanol (332 mL) and potassium carbonate (174 mmol). The resulting mixture was heated to reflux for 3 h followed by cooling to rt. The resultant solid was filtered, rinsed with methanol, and dried in a vacuum oven to afford the desired product (<b>7</b>) (26.6 g, 90% yield). LCMS (ES, M – H) = 178.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (2<i>Z</i>)-3-Cyano-3-(3-thienyl)acryloyl Azide (<b>8</b>)</h3><div class="NLM_p last">To a solution of oxalyl chloride (27.3 mL, 313 mmol) in dichloromethane (57 mL) was added (2<i>Z</i>)-3-cyano-3-(3-thienyl)acrylic acid (<b>7</b>) (26.6 g, 149 mmol) in portions. The resulting solution was stirred at rt until LCMS indicated completion of the reaction. The reaction mixture was then filtered and rinsed with dichloromethane. The filtrate was collected, concentrated under reduced pressure, and dried under vacuum to afford the product as a yellow solid as the acyl chloride intermediate. To a solution of sodium azide (12.2 g, 187 mmol) in a 1:1 mixture of dioxane/water (23 mL) was added at 0 °C the intermediate in 33 mL of dioxane. The reaction was stirred for 15 min at 0 °C, followed by warming the reaction to rt. After approximately 1.5 h, water (100 mL) was added to the reaction and the resulting solid was filtered and dried in a vacuum oven to yield the product (<b>8</b>) (15.1 g). <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 8.24 (s, 1 H), 7.76–7.71 (m, 2 H), 7.25 (s, 1 H). LCMS (ES, M – H) = 204.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 7-Oxo-6,7-dihydrothieno[2,3-<i>c</i>]pyridine-4-carbonitrile (<b>9</b>)</h3><div class="NLM_p last">To a solution of phenyl ether (224 mL) and tributylamine (53.0 mL) at 230 °C was added dropwise (2<i>Z</i>)-3-cyano-3-(3-thienyl)acryloyl azide (<b>8</b>) in approximately 10 mL of dichloromethane. The mixture was stirred at 230 °C for 30 min, cooled to rt, followed by the addition of 500 mLof hexane, which afforded a yellowish solid. The resultant solid was washed with hexane and dried under vacuum to yield the product (<b>9</b>) (4.61 g, 44% yield). <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 12.4 (br s, 1 H), 8.26 (m, 2 H), 7.42 (d, 1 H).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 2-Bromo-7-chlorothieno[2,3-<i>c</i>]pyridine-4-carbonitrile (<b>10</b>)</h3><div class="NLM_p">To a solution of 7-oxo-6,7-dihydrothieno[2,3-<i>c</i>]pyridine-4-carbonitrile (2.30 g, 13.1 mmol) in 1/1 acetic acid/DMF (10 mL) was added <i>N</i>-bromosuccinimide (11.6 g, 65.3 mmol). The reaction mixture was heated to 80 °C for one. The solution was cooled to rt and diluted with 100 mL of water. The reaction was then neutralized with saturated sodium bicarbonate followed by filtration of the resulting solid, which was dried in a vacuum oven to afford 2-bromo-7-oxo-6,7-dihydrothieno[2,3-<i>c</i>]pyridine-4-carbonitrile (3.20 g, 96% yield). <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 12.7 (br s, 1 H), 8.41 (s, 1 H), 8.32 (d, 1 H); LCMS (ES, M + H) = 256.</div><div class="NLM_p last">To 2-bromo-7-oxo-6,7-dihydrothieno[2,3-<i>c</i>]pyridine-4-carbonitrile (3.20 g, 12.5 mmol) was added 45.0 mL of phosphorus oxychloride. The reaction was heated to reflux overnight after which LCMS indicated reaction was complete. The reaction was then cooled to rt, and the volatiles were removed under reduced pressure. To the resulting residue was added approximately 200 mL of water. The black solid was filtered and rinsed with copious amounts of water and dried under vacuum to yield the title compound (2.80 g, 82% yield). <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 8.97 (s, 1H), 8.71 (s, 1H).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>tert</i>-Butyl (3<i>S</i>)-3-[(2-Bromo-4-cyanothieno[2,3-<i>c</i>]pyridin-7-yl)amino]piperidine-1-carboxylate (<b>11</b>)</h3><div class="NLM_p last">To a solution of 2-bromo-7-chlorothieno[2,3-<i>c</i>]pyridine-4-carbonitrile (2.80 g, 10.2 mmol) in <i>N</i>-methylpyrrolidine (NMP, 10.0 mL) were added potassium carbonate (4.23 g, 30.6 mmol) and <i>tert</i>-butyl (3<i>S</i>)-3-aminopiperidine-1-carboxylate (4.92 g, 24.6 mmol). The reaction mixture was heated to 130 °C until LCMS indicated the reaction was complete. The reaction mixture was then cooled to rt, and approximately 100 mL of water was added. The resulting solid was filtered and vacuum-dried to afford the title compound. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 8.47 (s, 1H), 8.35 (s, 1H), 7.90 (br s, 1H), 4.14 (m, 1H), 3.38 (m, 1H), 3.24 (m, 1H), 2.93 (m, 2H), 1.94–1.73 (m, 4H), 1.37 (s, 9H); LCMS (ES, M + H) = 338.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>tert</i>-Butyl (3<i>S</i>)-3-{[4-Cyano-2-(3-fluorophenyl)thieno[2,3-<i>c</i>]pyridin-7-yl]amino}piperidine-1-carboxylate (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, step h)</h3><div class="NLM_p last">To <i>tert</i>-butyl (3<i>S</i>)-3-[(2-bromo-4-cyanothieno[2,3-<i>c</i>]pyridin-7-yl)amino]piperidine-1-carboxylate (<b>11</b>, 428 mgs, 0.979 mmol) were added cesium carbonate (957 mg, 2.94 mmol), 3-fluorophenylboronic acid (206 mgs, 1.47 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (113 mgs, 0.0979 mmol), and dioxane/water (4 mL/2 mL). The reaction was heated to 80 °C for 1 h whereupon the reaction was cooled to rt, filtered, and purified using silica gel chromatography (100% hexanes to 100% ethyl acetate) to afford the title compound (241 mg, 54% yield). LCMS (ES, M + H) = 453.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 2-Phenyl-7-[(3<i>S</i>)-piperidin-3-ylamino]thieno[2,3-<i>c</i>]pyridine-4-carboxamide (<b>12</b>)</h3><div class="NLM_p last">Compound <b>12</b> was prepared in a similar procedure to <b>4</b> using the phenylboronic acid. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 8.01 (s, 1H), 7.86 (s, 1H), 7.68 (m, 1H), 7.49–7.24 (m, 5H), 7.12 (br s, 1H), 4.50 (m, 1H), 3.15 (m, 2H), 2.87 (m, 2H), 2.01–1.20 (m, 4H); LCMS (ES, M + H) = 353.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 2-(3-Fluorophenyl)-4-[(3<i>S</i>)-piperidin-3-ylamino]thieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>13</b>)</h3><div class="NLM_p last">Compound <b>13</b> was prepared using a similar procedure to <b>5</b>. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 8.59 (s, 1 H), 8.34 (s, 1 H), 7.98 (s, 1 H), 7.51–7.64 (m, 3 H), 7.37 (s, 1 H), 7.21–7.30 (m, 3 H), 4.22 (s, 1 H), 3.19 (d, 1 H), 2.90 (d, 1 H), 2.38–2.53 (m, 2 H), 2.04 (m, 1 H), 1.75 (m, 1 H), 1.54 (m, 2 H); LCMS (ES M + H) = 371.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 4-[(3<i>S</i>)-Piperidin-3-ylamino]-2-(2-thienyl)thieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>14</b>)</h3><div class="NLM_p last">Compound <b>14</b> was prepared using a similar procedure to <b>5</b>. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 9.42 (s, 1H), 8.94 (s, 1H), 8.55 (s, 1H), 8.34 (s, 2H), 7.65 (d, 1H), 7.46 (d, 1H), 7.40 (m, 1H), 7.17 (m, 1H), 4.57 (m, 1H), 3.50 (m, 1H), 3.21 (m, 1H), 2.96 (m, 2H), 2.05 (m, 2H), 1.76 (m, 2H); LCMS (M + H) = 359.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 4-[(3<i>S</i>)-Piperidin-3-ylamino]-2-(3-thienyl)thieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>15</b>)</h3><div class="NLM_p last">Compound <b>15</b> was prepared using a similar procedure to <b>5.</b><sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 9.72 (s, 1H), 9.08 (s, 1H), 8.79 (s, 1H), 8.55 (s, 1H), 8.40 (s, 1H), 7.96 (s, 1H), 7.78 (t, 1H), 7.72 (s, 1H), 7.54 (d, 1H), 4.63 (m, 1H), 3.19 (m, 2H), 3.02 (m, 2H), 2.06 (m, 2H), 1.81 (m, 2H); LCMS (M + H) = 359.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 4-[(3<i>S</i>)-Piperidin-3-ylamino]-2-(1<i>H</i>-pyrazol-4-yl)thieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>16</b>)</h3><div class="NLM_p last">Compound <b>16</b> was prepared using a similar procedure to <b>5.</b><sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 1.81–1.57 (m, 2H), 2.10–1.91 (m, 2H), 2.90 (m, 2H), 3.24 (m, 1H), 3.47 (m, 1H), 4.47 (m, 1H), 7.64 (m, 1H), 7.82 (m, 1H), 8.03 (m, 3H), 8.53 (m, 1H), 8.78 (m, 2H); LCMS (M + H) = 343.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 2-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-4-[(3<i>S</i>)-piperidin-3-ylamino]thieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>17</b>)</h3><div class="NLM_p last">Compound <b>17</b> was prepared using a similar procedure to <b>5.</b><sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 9.44 (br s, 1H), 8.89 (m, 1H), 8.47 (s, 1H), 8.45–8.20 (m, 2H), 8.18 (s, 1H), 7.80 (s, 1H), 7.63 (br s, 1H), 4.54 (m, 1H), 3.89 (s, 3H), 3.47 (m, 1H), 3.20 (m, 1H), 3.10 (m, 1H), 2.99 (m, 1H), 2.05 (m, 1H), 1.97 (m, 1H), 1.78 (m, 2H); LCMS (M + H) = 459.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 2-(1-Benzyl-1<i>H</i>-pyrazol-4-yl)-4-[(3<i>S</i>)-piperidin-3-ylamino]thieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>18</b>)</h3><div class="NLM_p last">Compound <b>18</b> was prepared using a similar procedure to <b>5</b>. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 9.45 (br s, 1H), 8.90 (m, 1H), 8.48 (s, 1H), 8.41–8.14 (m, 2H), 8.33 (s, 1H), 7.85 (s, 1H), 7.61 (s, 1H), 7.39–7.27 (m, 5H), 5.38 (s, 2H), 4.54 (m, 1H), 3.47 (m, 1H), 3.18 (m, 1H), 3.08 (m, 1H), 2.97 (m, 1H), 2.05 (m, 1H), 1.97 (m, 1H), 1.77 (m, 2H); LCMS (M + H) = 433.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 2-(1<i>H</i>-Imidazol-1-yl)-4-[(3<i>S</i>)-piperidin-3-ylamino]thieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>19</b>)</h3><div class="NLM_p last">To a solution of CuI (2.7 mg, 0.014 mmol), imidazole (46 mg, 0.670 mmol), and cesium carbonate (191 mg, 0.586 mmol) under nitrogen were added <i>tert</i>-butyl (3<i>S</i>)-3-[(7-cyano-2-iodothieno[3,2-<i>c</i>]pyridin-4-yl)amino]piperidine-1-carboxylate (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01490/suppl_file/jm7b01490_si_001.pdf" class="ext-link">Supporting Information</a>) (135 mg, 0.279 mmol), <i>trans</i>-1,2-cyclohexanediamine (4.2 μL, 0.056 mmol), and anhydrous 1,4-dioxane (1.0 mL). The reaction mixture was stirred at 110 °C for 24 h at which point the reaction was cooled to rt and diluted with DCM. The mixture was filtered and solvents were removed under reduced pressure. The black residue was purified by preparatory HPLC (5–95% MeCN, H<sub>2</sub>O, 0.1% TFA) to afford the intermediate <i>tert</i>-butyl (3<i>S</i>)-3-{[7-cyano-2-(1<i>H</i>-indazol-1-yl)thieno[3,2-<i>c</i>]pyridin-4-yl]amino}piperidine-1-carboxylate. The intermediate was added to a flask containing 1.00 mL of 12 N HCl. The reaction mixture was stirred at rt. Additional 12 N HCl was added over 12 h to complete the conversion to the desired product. Upon completion, the reaction mixture was cooled to 0 °C and treated with 6 N NaOH dropwise until a pH of 12 was obtained. The mixture was extracted with EtOAc in addition to CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1/1), and organic layers were dried over magnesium sulfate, filtered, and concentrated in vacuo to yield the product. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 1.82–1.70 (m, 2H), 2.03–1.94 (m, 2H), 2.97–2.92 (m, 2H), 3.24 (m, 1H), 3.38 (m, 1H), 4.24 (m, 1H), 7.27 (m, 1H), 7.43 (m, 1H), 7.66 (s, 1H), 7.89 (s, 1H), 8.06 (br s, 1H), 8.16 (s, 1H), 8.58 (s, 1H); LCMS (ES, M + H) = 343.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 2-Methyl-4-[(3<i>S</i>)-piperidin-3-ylamino]thieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>20</b>)</h3><div class="NLM_p last">To a flask containing <i>tert</i>-butyl (3<i>S</i>)-3-[(7-cyano-2-methylthieno[3,2-<i>c</i>]pyridin-4-yl)amino]piperidine-1-carboxylate was added 5.00 mL of 12 N HCl. The reaction mixture was stirred at rt and monitored by LCMS. Additional 12 N HCl was added over 12 h to afford complete conversion to the desired product. Upon completion, the reaction mixture was diluted with water and concentrated under reduced pressure to yield product, which was purified by silica gel chromatography (100% CH<sub>2</sub>Cl<sub>2</sub> to 20% MeOH/CH<sub>2</sub>Cl<sub>2</sub>/3% NH<sub>4</sub>OH) to afford the title compound. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 8.42 (s, 1 H), 7.81 (br s, 1 H), 7.41 (s, 1 H), 7.14 (s, 1 H), 7.14 (br s, 1 H), 6.96 (d, 1 H), 4.11 (m, 1 H), 3.31 (s, 3 H), 3.14 (m, 2 H), 2.82 (m, 2 H), 1.94 (m, 1 H), 1.52 (m, 1 H), 1.36 (m, 2 H); LCMS (ES, M + H) = 291.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 2-Phenyl-4-[(3<i>S</i>)-piperidin-3-ylamino]-1<i>H</i>-indole-7-carboxamide (<b>21</b>)</h3><div class="NLM_p last">To a solution of 4-amino-2-phenyl-1<i>H</i>-indole-7-carboxamide (<b>26</b>) (0.60 g, 2.4 mmol) and <i>tert</i>-butyl 3-oxopiperidine-1-carboxylate (0.6 g, 2.8 mmol) dissolved in AcOH (15 mL) was added Na<sub>2</sub>SO<sub>4</sub>. The mixture was stirred at rt for 1 h and then slowly charged with sodium triacetoxyborohydride (1.5 g, 7.2 mmol). The reaction was stirred at rt for 1 h. The mixture was diluted with EtOAc and water, washed with sat. NaHCO<sub>3</sub>, 1 N HCl, and sat. NaCl. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica gel column to afford the intermediate <i>tert</i>-butyl 3-{[7-(aminocarbonyl)-2-phenyl-1<i>H</i>-indol-4-yl]amino}piperidine-1-carboxylate. A stirred solution of the intermediate (0.15 g, 0.35 mmol) in MeOH (10 mL) was charged with 4.0 N HCl in dioxane (10 mL). The reaction was stirred for 2 h at rt and then concentrated in vacuo to give the hydrochloride salt. The residue was diluted with 2.0 N NH<sub>3</sub> in MeOH (10 mL) and concentrated in vacuo. The residue was purified by silica gel column (10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>/1.5% NH<sub>4</sub>OH–20% MeOH/CH<sub>2</sub>Cl<sub>2</sub>/3% NH<sub>4</sub>OH) to give the racemic product as an off-white solid (90 mg, 78%). The racemic mixture was separated by chiral preparatory HPLC (column: Chiralpak OD, 250 mm × 21 mm, 10 μm) and eluted with 85% hexane and 15% 1:1 ethanol/methanol, 0.1% diethylamine at a flow rate of 20 mL/min. The second to elute was collected and concentrated to afford the title compound (<i>t</i><sub>R</sub> = 27.9 min, 97% ee) to give <b>21</b>. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 10.87 (s, 1 H), 7.69 (d, 2 H), 7.57 (d, 1 H), 7.45 (t, 2 H), 7.28 (t, 1 H), 7.20 (s, 1 H), 6.96 (br s, 1 H), 6.15 (d, 1 H), 6.02 (d, 1 H), 3.50 (d, 1 H), 3.30 (s, 2 H), 3.05–3.20 (m, 2 H), 2.84 (d, 1 H), 2.34–2.46 (m, 1 H), 1.98 (s, 1 H), 1.60–1.72 (m, 1 H), 1.43–1.58 (m, 2 H); LCMS (ES, M + H) = 335.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Methyl 2-Amino-4-nitrobenzoate (<b>23</b>)</h3><div class="NLM_p last">To a solution of 2-amino-4-nitrobenzoic acid (25 g, 0.137 mol) in MeOH (100 mL) was bubbled HCl (g) for 15–20 min. The resulting solution was refluxed for 2 days. Upon cooling, the crystalline product was isolated by filtration and drying under high vacuum (16.9 g, 63%). <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 7.90 (d, 1 H), 7.67 (d, 1 H), 7.25 (dd, 1 H), 7.13 (s, 2 H), 3.84 (s, 3 H).</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 4-Nitro-2-phenyl-1<i>H</i>-indole-7-carboxylic Acid (<b>24</b>)</h3><div class="NLM_p last">To a solution of methyl 2-amino-4-nitrobenzoate (2.2 g, 11.2 mmol) and acetophenone (2.8 g, 23.3 mmol) in DMSO (30 mL) cooled to −15 °C was added solid KO<i><sup>t</sup></i>Bu (2.7 g, 24 mmol). After stirring for 20 min, the reaction was quenched with sat. NH<sub>4</sub>Cl (200 mL) and then stirred for an additional 1 h at rt. The red precipitate was filtered, washed with water, and dried under high vacuum to give the title compound (2.85 g, 90%). <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 12.05 (s, 1 H), 7.99 (d, 1 H), 7.89 (d, 2 H), 7.65 (d, 1 H), 7.50 (t, 2 H), 7.44 (s, 1 H), 7.41 (d, 1H), 7.30 (br s, 1 H). LCMS (ES, M – H) = 281.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 4-Nitro-2-phenyl-1<i>H</i>-indole-7-carboxamide (<b>25</b>)</h3><div class="NLM_p last">To a solution of 4-nitro-2-phenyl-1<i>H</i>-indole-7-carboxylic acid (0.60 g, 2.1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) at −15 °C was added isobutyl chloroformate (0.5 mL, 3.8 mmol). After stirring for 1 h, NH<sub>3</sub> (g) was bubbled through the reaction mixture for 10–15 min and then stirred for an additional 1 h at rt. After removing the solvent, the residue was purified by silica gel column (50–100% EtOAc/hexanes) to give the product as a dark yellow solid (0.50 g, 85%). <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 11.72 (s, 1 H), 8.46 (s, 1 H), 8.11 (d, 1 H), 8.02 (d, 2 H), 7.92 (s, 1 H), 7.76 (d, 1 H), 7.50–7.57 (m, 3 H), 7.47 (d, 1 H); LCMS (ES, M + H) = 282.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 2-(3-Fluorophenyl)-4-[(3<i>S</i>)-piperidin-3-ylamino]-1<i>H</i>-indole-7-carboxamide (<b>27</b>)</h3><div class="NLM_p last">Compound <b>27</b> was prepared using a similar procedure to <b>21</b>. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 10.98 (s, 1H), 9.19 (m, 1H), 9.08 (m, 1H), 7.63 (d, 2H), 7.56 (m, 2H), 7.50 (m, 1H), 7.34 (s, 1H), 7.13 (dt, 1H), 6.26 (d, 1H), 5.60 (br s, 2H), 4.00 (m, 1H), 3.41 (m, 1H), 3.21 (m, 1H), 2.92 (m, 1H), 2.80 (m, 1H), 2.0 (m, 1H), 1.93 (m, 1H), 1.76 (m, 1H), 1.69 (m, 1H); LCMS (ES, M + H) = 353.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 2-(4-Fluorophenyl)-4-[(3<i>S</i>)-piperidin-3-ylamino]-1<i>H</i>-indole-7-carboxamide (<b>28</b>)</h3><div class="NLM_p last">Compound <b>28</b> was prepared using a similar procedure to <b>21.</b><sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 10.89 (s, 1H), 8.92 (m, 1H), 8.73 (m, 1H), 7.75 (d, 1H), 7.74 (d, 1H), 7.60 (d, 1H), 7.30 (t, 2H), 7.15 (d, 1H), 7.04 (br s, 1H), 6.33 (br s, 1H), 6.23 (d, 1H), 3.91 (m, 1 H), 3.41 (m, 1H), 3.25 (m, 1H), 2.89 (m, 1H), 2.75 (m, 1H), 2.03 (m, 1H), 1.94 (m, 1H), 1.74 (m, 1H), 1.66 (m, 1H); LCMS (ES, M + H) = 353.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 2-(4-Chlorophenyl)-4-[(3<i>S</i>)-piperidin-3-ylamino]-1<i>H</i>-indole-7-carboxamide (<b>29</b>)</h3><div class="NLM_p last">Compound <b>29</b> was prepared using a similar procedure to <b>21</b>. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 10.75 (s, 1H), 9.10 (m, 2H), 7.55 (d, 2H), 7.45 (d, 1H), 7.33 (d, 2H), 7.15 (d, 1H), 6.08 (d, 1H), 5.45 (br s, 3H), 3.83 (m, 1H), 3.21 (m, 1H), 3.03 (m, 1H), 2.73 (m, 1H), 2.65 (m, 1H), 1.80 (m, 2H), 1.62 (m, 1H), 1.51 (m, 1H); LCMS (ES, M + H) = 369.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 2-Phenyl-4-[(3<i>S</i>)-piperidin-3-ylamino]furo[3,2-<i>c</i>]pyridine-7-carboxamide (<b>30</b>)</h3><div class="NLM_p last">Crude <i>tert</i>-butyl (3<i>S</i>)-3-[(7-cyano-2-phenylfuro[3,2-<i>c</i>]pyridin-4-yl)amino]piperidine-1-carboxylate (178 mg) (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01490/suppl_file/jm7b01490_si_001.pdf" class="ext-link">Supporting Information</a>) was treated with 12 N HCl (5 mL), and the mixture was stirred at rt overnight. After removal of the solvent, the residue was purified by Gilson PrepLC to give the title compound as a trifluoroacetate salt. The salt was dissolved in MeOH (1 mL) and then charged with 4 N HCl/dioxane (2 mL). After stirring overnight, the white solid was filtered and dried in the air to afford the title compound (53 mg). <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 9.14 (br s, 1H), 8.89 (brs, 1H), 8.34 (s, 1H), 7.91 (d, 2H), 7.85 (s, 1H), 7.67 (s, 2H), 7.55 (t, 2H), 7.45 (t, 1H), 4.47 (m, 1H), 3.19 (m, 2H), 2.96 (m, 2H), 2.03 (m, 2H), 1.72 (m, 2H). LCMS (ES, M + H) = 337.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 2-Phenyl-4-[(3<i>S</i>)-piperidin-3-yloxy]thieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>31</b>)</h3><div class="NLM_p last">A solution of <i>tert</i>-butyl (3<i>S</i>)-3-[(7-cyano-2-phenylthieno[3,2-<i>c</i>]pyridin-4-yl)oxy]piperidine-1-carboxylate (1.0 g, 2.3 mmol) and 12 N HCl (conc, 15 mL) was stirred for 12 h. Water (100 mL) was added, and the solution was concentrated to dryness in vacuo. The white solid obtained was dissolved in 100 mL of MeOH and concentrated in vacuo to give the product (0.86 g, 96%) after drying under high vacuum. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 9.56 (d, 1 H), 9.10 (s, 1 H), 8.67 (s, 1 H), 8.32 (s, 1 H), 8.28 (s, 1 H), 7.87 (d, 2 H), 7.66 (s, 1 H), 7.49 (t, 2 H), 7.40 (t, 1 H), 5.64 (s, 1 H), 3.41 (s, 2 H), 3.17–3.28 (m, 1 H), 3.03 (d, 1 H), 1.91–2.06 (m, 3 H), 1.65–1.79 (m, 1 H). LCMS (ES, M + H) = 354.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 2-Phenyl-4-(piperidin-3-ylthio)thieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>32</b>)</h3><div class="NLM_p last">Prepared using a similar procedure to <b>5</b> with benzyl 3-mercaptopiperidine-1-carboxylate (synthesis in <a href="/doi/suppl/10.1021/acs.jmedchem.7b01490/suppl_file/jm7b01490_si_001.pdf" class="ext-link">Supporting Information</a>) as the corresponding reagent. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 9.23 (br, 2H), 8.91 (s, 1H), 8.45 (s, 1H), 7.88 (d, 2H), 7.83 (br, 1H), 7.82 (s, 1H), 7.50 (t, 2H), 7.43 (t, 1H), 4.41 (m, 1H), 3.63 (m, 1H), 3.23 (m, 1H), 3.09 (m, 1H), 2.94 (m, 1H), 2.22–2.13 (m, 1H), 1.96–1.72 (m, 3H); LCMS (ES, M + H) = 370.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 4-{Methyl[(3<i>S</i>)-piperidin-3-yl]amino}-2-phenylthieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>33</b>)</h3><div class="NLM_p last">Compound <b>33</b> was prepared using a similar procedure to 5 but using <i>tert</i>-butyl (3<i>S</i>)-3-(methylamino)piperidine-1-carboxylate (synthesis in <a href="/doi/suppl/10.1021/acs.jmedchem.7b01490/suppl_file/jm7b01490_si_001.pdf" class="ext-link">Supporting Information</a>) as the starting material. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 9.26 (br s, 1H), 8.92 (br s, 1H), 8.59 (s, 1H), 8.18 (br s, 1H), 7.94 (s, 1H), 7.85 (m, 2H), 7.46 (m, 2H), 7.40 (m, 1H), 4.83 (m, 1H), 3.42 (m, 1H), 3.29 (s, 3H), 3.22 (m, 2H), 2.89 (m, 1H), 2.00–1.79 (m, 4H). LCMS (ES, M + H) = 367.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 4-{Ethyl[(3<i>S</i>)-piperidin-3-yl]amino}-2-phenylthieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>34</b>)</h3><div class="NLM_p last">Compound <b>34</b> was prepared using a similar procedure to <b>5</b> but using <i>tert</i>-butyl (3<i>S</i>)-3-(ethylamino)piperidine-1-carboxylate as the corresponding reagent. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 9.26 (b, 1H), 8.95 (b, 1H), 8.63 (s, 1H), 8.19 (b, 1H),7.86 (m, 2H), 8.77 (s, 1H), 7.49 (m, 3H), 7.40 (m,2H), 4.75 (m, 1H), 3.77 (m, 2H), 3.40 (m, 1H), 3.23 (m, 2H), 2.87 (m, 1H), 1.96 (m, 3H), 1.74 (m, 1H), 1.17 (t, 3H); LCMS (ES, M + H) = 381.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 4-{(2-Hydroxyethyl)[(3<i>S</i>)-piperidin-3-yl]amino}-2-phenylthieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>35</b>)</h3><div class="NLM_p last">Compound <b>35</b> was prepared using a similar procedure to <b>5</b> but using (<i>S</i>)-<i>tert</i>-butyl 3-(2-hydroxyethylamino)piperidine-1-carboxylate as the corresponding reagent. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub> + D<sub>2</sub>O; δ ppm) 8.57 (s, 1H), 7.80 (s, 1H), 7.77 (m, 2H), 7.49 (m, 2H), 7.39 (m, 1H), 4.59 (m, 1H), 3.77 (m, 1H), 3.69 (m, 1H), 3.54 (m, 2H), 3.39 (m, 1H), 3.20 (m, 2H), 2.82 (m, 1H), 1.89 (m, 3H), 1.70 (m, 1H); LCMS (ES, M + H) = 397.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 2-Phenyl-4-{(2-phenylethyl)[(3<i>S</i>)-piperidin-3-yl]amino}thieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>36</b>)</h3><div class="NLM_p last">Compound <b>36</b> was prepared using a similar procedure to <b>5</b> but using (<i>S</i>)-<i>tert</i>-butyl 3-(phenethylamino)piperidine-1-carboxylate as the corresponding reagent. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub> + D<sub>2</sub>O; δ ppm) 8.63 (s, 1H), 767 (m, 2H), 7.53 (s, 1H), 7.44 (m, 3H), 7.14–7.23 (m, 5H), 4.50 (m, 1H), 3.85 (m, 2H), 3.15 (m, 3H), 2.80 (m, 3H), 1.80–1.87 (m, 3H), 1.66 (m, 1H); LCMS (ES, M + H) = 457.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>tert</i>-Butyl ((1<i>S</i>)-1-Acetyl-4-{[(benzyloxy)carbonyl]amino}butyl)carbamate (<b>38</b>)</h3><div class="NLM_p last">To a three-necked flask containing <i>N</i><sup>5</sup>-[(benzyloxy)carbonyl]-<i>N</i><sup>2</sup>-(<i>tert</i>-butoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-ornithine (<b>37</b>) (36.6 g, 100 mmol) equipped with a magnetic stir bar and an addition funnel was added dry THF (100 mL). The addition funnel was charged with MeLi (1.6 M in ether; 275 mL; 440 mmol), which was subsequently added slowly (over 20 min) to the reaction mixture cooled to 0 °C. This solution was then warmed to rt. After stirring for an additional 5 h, the reaction was quenched by pouring onto a stirred ice/water mixture. The aqueous mixture was extracted with EtOAc (3 × 100 mL). The combined organic layers were then washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to yield a yellow oil (6.0 g, 98%). After purification using MPLC (SiO<sub>2</sub>; 25–60% EtOAc/hexanes), the product was isolated as a clear oil (5.2 g, 14%). <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 7.35 (m, 5H), 7.25 (m, 2H), 5.00 (s, 2H), 3.85 (m, 1H), 2.98 (dd, 2H), 2.05 (s, 3H), 1.63 (m, 1H), 1.39 (s, 9H), 1.34 (m, 3H). LCMS (ES, M + H) = 365.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>tert</i>-Butyl 2-methylpiperidin-3-ylcarbamate (<b>39</b>)</h3><div class="NLM_p last">To a stirred solution of <i>tert</i>-butyl ((1<i>S</i>)-1-acetyl-4-{[(benzyloxy)carbonyl]amino}butyl)carbamate (<b>38</b>) (3.9 g, 10.7 mmol) in MeOH (200 mL) was added 10% Pd/C (0.1 mmol). The heterogeneous mixture was hydrogenated at atmospheric pressure for 3 days (or 40 psi overnight). The product as the mixture of four diastereomers was isolated as clear oil after filtration through diatomaceous earth and evaporation of the filtrate to give the product without further purification (2.3 g; 100%). LCMS (ES, M + H) = 215.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> (<i>trans</i>)-Benzyl 3-(<i>tert</i>-Butoxycarbonylamino)-2-methylpiperidine-1-carboxylate (<b>40</b>)</h3><div class="NLM_p last">To a stirred solution of <i>tert</i>-butyl [<i>trans</i>-2-methylpiperidin-3-yl]carbamate (<b>39</b>) (2.3 g, 10.7 mmol) and diisopropylethylamine (2.1 mL, 12 mmol) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (40 mL) cooled to 0 °C was added benzyl chloroformate (1.7 mL, 12 mmol). The reaction mixture was then warmed to rt and stirred for an additional 1 h. The mixture was then diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with 1 N HCl and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to yield a yellow oil. After purification using MPLC (SiO<sub>2</sub>; 10–40% EtOAc/hexanes), the product (trans diastereomer) was isolated as a crystalline solid (1.8 g, 49% yield). <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 7.34 (m, 5H), 6.99 (d, 1H), 5.04 (s, 2H), 4.28 (dd, 1H), 3.83 (m, 1H), 3.37 (m, 1H), 2.86 (m, 1H), 1.77 (m, 2H), 1.46 (m, 1H), 1.36 (s, 9H), 1.33 (m, 1H), 1.11 (d, 3H). LCMS (ES, M + H = 349). The cis diastereomer, (<i>cis</i>)-benzyl 3-(<i>tert</i>-butoxycarbonylamino)-2-methylpiperidine-1-carboxylate was also isolated pure (1.3 g, 35% yield). <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 7.35 (m, 5H), 6.97 (d, 1H), 5.07 (s, 2H), 4.44 (m, 1H), 3.80 (m, 1H), 3.40 (m, 1H), 2.78 (m, 1H), 1.63 (m, 1H), 1.49 (m, 2H), 1.39 (s, 9H), 1.36 (m, 1H), 0.96 (d, 3H). LCMS (ES, M + H) = 349.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> (<i>trans</i>)-Benzyl 3-Amino-2-methylpiperidine-1-carboxylate (<b>41</b>)</h3><div class="NLM_p last">To a solution of benzyl <i>tran</i>s-3-[(<i>tert</i>-butoxycarbonyl)amino]-2-methylpiperidine-1-carboxylate (1.8 g, 5.2 mmol) dissolved in MeOH (10 mL) was added HCl (4 N in dioxane; 20 mL). After stirring for 1 h at rt, the reaction was concentrated in vacuo, redissolved in MeOH, and then concentrated in vacuo to yield the hydrochloride salt of the title compound as a clear crystalline solid (1.46 g, 100%). <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 8.27 (br s, 3H), 7.39 (m, 3H), 7.35 (m, 1H), 7.32 (m, 1H), 5.09 (s, 2H), 4.36 (dd, 1H), 3.88 (m, 1H), 3.26 (m, 1H), 2.92 (m, 1H), 1.79 (m, 3H), 1.48 (m, 1H), 1.16 (d, 3H). LCMS (ES, M + H) = 249.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> (<i>cis</i>)-Benzyl 3-Amino-2-methylpiperidine-1-carboxylate (<b>42</b>)</h3><div class="NLM_p last">To a solution of benzyl <i>cis</i>-3-[(<i>tert</i>-butoxycarbonyl)amino]-2-methylpiperidine-1-carboxylate (1.2 g, 3.4 mmol) dissolved in MeOH (10 mL) was added HCl (4 N in dioxane; 20 mL). After stirring for 1 h at rt, the reaction was concentrated in vacuo, redissolved in MeOH, and then concentrated in vacuo to yield the hydrochloride salt of the title compound as a clear crystalline solid (0.97 g, 100%). <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 8.39 (br s, 3H), 7.36 (m, 3H), 7.33 (m, 2H), 5.09 (s, 2H), 4.61 (dd, 1H), 3.83 (m, 1H), 3.26 (m, 1H), 2.86 (m, 1H), 1.72 (m, 3H), 1.41 (m, 1H), 1.10 (d, 3H). LCMS (ES, M + H) = 249.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 4-((2<i>R</i>,3<i>S</i>)-2-Methylpiperidin-3-ylamino)-2-phenylthieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>44</b>)</h3><div class="NLM_p last">Prepared in a similar route to compound <b>5</b> but using benzyl <i>trans</i>-3-amino-2-methylpiperidine-1-carboxylate (<b>41</b>) as the starting material (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, step g), followed by chiral preparatory HPLC separation (column: Chiralcel OD, 250 mm × 20 mm, 10 μm) and eluted with 85% hexane and 15% 1:1 ethanol/methanol, 0.1% diethylamine at a flow rate of 20 mL/min. The second to elute was collected and concentrated to afford the title compound (<i>t</i><sub>R</sub> = 14.2 min, 98.7% ee). <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 9.47 (m, 1 H), 9.04 (m, 1 H), 8.59 (m, 1 H), 8.45 (s, 1 H), 8.25 (m, 1 H), 7.71 (d, 2 H), 7.56 (m, 1 H), 7.45 (m, 2 H), 7.35 (m, 1 H), 4.34 (m, 1 H), 3.42 (m, 1 H), 3.22 (m, 1 H), 2.82 (m, 1 H), 2.07 (m, 1 H), 1.83 (m, 2 H), 1.59 (m, 1 H), 1.26 (d, 3 H). LCMS (ES, M + H) = 367.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 4-((2<i>S</i>,3<i>S</i>)-2-Methylpiperidin-3-ylamino)-2-phenylthieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>45</b>)</h3><div class="NLM_p last">Prepared in a similar route to compound <b>44</b> but using benzyl (<i>cis</i>)-benzyl 3-amino-2-methylpiperidine-1-carboxylate as the starting material in step g, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, followed by chiral preparatory HPLC separation (column: Chiralpak OD, 250 mm × 21 mm, 10 μm) and eluted with 85% hexane and 15% 1:1 ethanol/methanol, 0.1% diethylamine at a flow rate of 20 mL/min. The second to elute was collected and concentrated to afford the title compound (<i>t</i><sub>R</sub> = 12.3 min, 98% ee). <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 9.79 (m, 1H), 8.95 (m, 2H, 8.51 (s, 1H), 8.15 (m, 1H), 7.78 (d, 2H), 7.49 (m, 3H), 7.38 (m, 1H), 4.73 (m, 1H), 3.71 (m, 1H), 3.28 (m, 1H), 3.00 (m, 1H), 1.95 (m, 2H), 1.82 (m, 1H), 1.69 (m, 1H), 1.30 (d, 3H); LCMS (ES, M + H) = 367.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> <i>trans</i>-4-[(4-Hydroxypiperidin-3-yl)amino]-2-phenylthieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>46</b>)</h3><div class="NLM_p last">Prepared in a similar route to compound <b>5</b> but using benzyl <i>trans</i>-3-amino-4-hydroxypiperidine-1-carboxylate<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> as the starting material in step g, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 9.29 (m, 1H), 8.85 (m, 1H), 8.60 (m, 1H), 8.51 (s, 1H), 8.19 (m, 1H), 7.77 (d, 2H), 7.56 (m, 1H), 7.50 (dd, 2H), 7.40 (dd, 1H), 4.42 (m, 1H), 4.0–4.3 (br s, 1H), 3.88 (m, 1H), 3.51 (m, 1H), 3.27 (m, 1H), 3.05 (m, 2H), 2.16 (m, 1H), 1.73 (m, 1H); LCMS (ES, M + H) = 369.</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 4-{[<i>trans</i>-2-(2-Hydroxyethyl)piperidin-3-yl]amino}-2-phenylthieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>47</b>)</h3><div class="NLM_p last">Prepared in a similar route to compound <b>5</b> but using benzyl <i>trans</i>-3-amino-2-(2-hydroxyethyl)piperidine-1-carboxylate (synthesis in <a href="/doi/suppl/10.1021/acs.jmedchem.7b01490/suppl_file/jm7b01490_si_001.pdf" class="ext-link">Supporting Information</a>) as the starting material in step g, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 9.57 (m, 1H), 8.92 (m, 1H), 8.61 (s, 1H), 8.14 (br s, 1H), 7.97 (s, 1H), 7.87 (d, 2H), 7.50 (m, 3H), 7.40 (m, 1H), 4.82 (m, 1H), 3.55 (m, 1H), 3.29 (s, 3H), 3.23 (m, 1H), 2.94 (m, 1H), 1.97 (m, 4H), 1.21 (d, 3H). LCMS (ES, M + H) = 381.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 4-[(<i>cis</i>-2,6-Dimethylpiperidin-3-yl)amino]-2-phenylthieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>48</b>)</h3><div class="NLM_p last">To a flask containing 4-[(<i>cis</i>-2,6-dimethylpiperidin-3-yl)amino]-2-phenylthieno[3,2-<i>c</i>]pyridine-7-carbonitrile was added 5.00 mL of 12 N HCl. The reaction mixture was stirred at rt. Additional 12 N HCl was added over 12 h to afford complete conversion to the desired product. Upon completion, the reaction mixture was diluted with MeOH and concentrated under reduced pressure to yield the product, which was purified by preparatory HPLC (5%–95% H<sub>2</sub>O/MeCN/0.1% TFA) to afford the title compound as a mixture of isomers. Analytical data provided for major isomer present in mixture: <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 9.96 (m, 1H), 9.19 (m, 1H), 9.02 (m, 1H), 8.50 (s, 1H), 8.21 (m, 1H), 7.79 (m, 2H), 7.49 (m, 2H), 7.35 (m, 2H), 4.74 (m, 1H), 3.67 (m, 1H), 3.27 (m, 1H), 1.84 (m, 4H), 1.36 (m, 6H). LCMS (ES, M + H) = 381.</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 4-(<i>cis</i>-6-Methylpiperidin-3-ylamino)-2-phenylthieno[3,2-<i>c</i>]pyridine-7-carboxamide (<b>49</b>)</h3><div class="NLM_p last">Prepared in a similar route to compound <b>48</b> but using benzyl <i>trans</i>-2-methyl-5-(methylamino)piperidine-1-carboxylate (synthesized similarly to <b>48</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01490/suppl_file/jm7b01490_si_001.pdf" class="ext-link">Supporting Information</a>) as the starting material in step g, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>; δ ppm) 9.84 (m, 1H), 9.41 (m, 1H), 9.18 (m, 1H), 8.53 (s, 1H), 8.40 (m, 1H), 7.72 (m, 3H), 7.51 (m, 3H), 4.72 (m, 1H), 3.21 (m, 3H), 1.89 (m, 4H), 1.34 (m, 3H); LCMS (ES, M + H) = 367.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-6"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i64"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01490">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77464" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77464" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01490" class="ext-link">10.1021/acs.jmedchem.7b01490</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Complete experimental for the syntheses of compounds <b>5</b>, <b>19</b>, <b>20</b>, <b>31</b>, <b>32</b>, <b>33</b>, <b>43</b>, <b>47</b>, and <b>48</b>; assays protocols on solubility, log <i>D</i>, rat microsome CL<sub>int</sub>, and hERG inhibition; experimental details on crystallographic information (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01490/suppl_file/jm7b01490_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01490/suppl_file/jm7b01490_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01490/suppl_file/jm7b01490_si_001.pdf">jm7b01490_si_001.pdf (401.73 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01490/suppl_file/jm7b01490_si_002.csv">jm7b01490_si_002.csv (2.37 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are the following: <b>13</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FC8">6FC8</a>; <b>21</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FCK">6FCK</a>; <b>44</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FCF">6FCF</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b01490" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43374" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43374" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bin Yang</span> - <span class="hlFld-Affiliation affiliation">Oncology
Chemistry, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1499-5569" title="Orcid link">http://orcid.org/0000-0002-1499-5569</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#197b7077376078777e59786a6d6b78637c777c7a78377a7674"><span class="__cf_email__" data-cfemail="94f6fdfabaedf5faf3d4f5e7e0e6f5eef1faf1f7f5baf7fbf9">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melissa M. Vasbinder</span> - <span class="hlFld-Affiliation affiliation">Oncology
Chemistry, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander W. Hird</span> - <span class="hlFld-Affiliation affiliation">Oncology
Chemistry, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qibin Su</span> - <span class="hlFld-Affiliation affiliation">Oncology
Chemistry, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haixia Wang</span> - <span class="hlFld-Affiliation affiliation">Oncology
Chemistry, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yan Yu</span> - <span class="hlFld-Affiliation affiliation">Oncology
Chemistry, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dorin Toader</span> - <span class="hlFld-Affiliation affiliation">Oncology
Chemistry, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul D. Lyne</span> - <span class="hlFld-Affiliation affiliation">Oncology
Chemistry, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jon A. Read</span> - <span class="hlFld-Affiliation affiliation">Discovery
Sciences, IMED Biotech Unit, AstraZeneca, Building 310, Cambridge Science
Park, Milton Road, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Breed</span> - <span class="hlFld-Affiliation affiliation">Discovery
Sciences, IMED Biotech Unit, AstraZeneca, Building 310, Cambridge Science
Park, Milton Road, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephanos Ioannidis</span> - <span class="hlFld-Affiliation affiliation">Oncology
Chemistry, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chun Deng</span> - <span class="hlFld-Affiliation affiliation">Oncology
Chemistry, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Grondine</span> - <span class="hlFld-Affiliation affiliation">Oncology
Chemistry, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nancy DeGrace</span> - <span class="hlFld-Affiliation affiliation">Oncology
Chemistry, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Whitston</span> - <span class="hlFld-Affiliation affiliation">Oncology
Chemistry, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick Brassil</span> - <span class="hlFld-Affiliation affiliation">Oncology
Chemistry, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James W. Janetka</span> - <span class="hlFld-Affiliation affiliation">Oncology
Chemistry, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i70" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i70"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i71" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i71"> Abbreviations Used</h2><tr><td class="NLM_term">APCI</td><td class="NLM_def"><p class="first last">atmospheric pressure chemical ionization</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine 5-triphosphate</p></td></tr><tr><td class="NLM_term">CDCl<sub>3</sub></td><td class="NLM_def"><p class="first last">deuterated chloroform</p></td></tr><tr><td class="NLM_term">CI</td><td class="NLM_def"><p class="first last">chemical ionization</p></td></tr><tr><td class="NLM_term">EI</td><td class="NLM_def"><p class="first last">electron impact</p></td></tr><tr><td class="NLM_term">ESP</td><td class="NLM_def"><p class="first last">electrospray</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">LCMS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">TCU</td><td class="NLM_def"><p class="first last">thiophenecarboxamide urea</p></td></tr><tr><td class="NLM_term">4-CTP</td><td class="NLM_def"><p class="first last">thieno[2,3-<i>c</i>]pyridine-4-carboxamide</p></td></tr><tr><td class="NLM_term">7-CTP</td><td class="NLM_def"><p class="first last">thieno[3,2-<i>c</i>]pyridine-7-carboxamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethylsulfoxide</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynomics</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">MgSO<sub>4</sub></td><td class="NLM_def"><p class="first last">magnesium sulfate</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyloxycarbonyl</p></td></tr><tr><td class="NLM_term">Cbz</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyloxycarbonyl</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i72">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17113" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17113" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 23 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Helleday, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petermann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R. A.</span><span> </span><span class="NLM_article-title">DNA repair pathways as targets for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span><span class="refDoi"> DOI: 10.1038/nrc2342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1038%2Fnrc2342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=18256616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitlOisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=193-204&author=T.+Helledayauthor=E.+Petermannauthor=C.+Lundinauthor=B.+Hodgsonauthor=R.+A.+Sharma&title=DNA+repair+pathways+as+targets+for+cancer+therapy&doi=10.1038%2Fnrc2342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">DNA repair pathways as targets for cancer therapy</span></div><div class="casAuthors">Helleday, Thomas; Petermann, Eva; Lundin, Cecilia; Hodgson, Ben; Sharma, Ricky A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">193-204</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  DNA repair pathways can enable tumor cells to survive DNA damage that is induced by chemotherapeutic treatments; therefore, inhibitors of specific DNA repair pathways might prove efficacious when used in combination with DNA-damaging chemotherapeutic drugs.  In addn., alterations in DNA repair pathways that arise during tumor development can make some cancer cells reliant on a reduced set of DNA repair pathways for survival.  There is evidence that drugs that inhibit one of these pathways in such tumors could prove useful as single-agent therapies, with the potential advantage that this approach could be selective for tumor cells and have fewer side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3W53LJmdCPrVg90H21EOLACvtfcHk0lhDOdpy-5NnZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitlOisr8%253D&md5=8592af6d815e5ca9c80ee256791bafb7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2342%26sid%3Dliteratum%253Aachs%26aulast%3DHelleday%26aufirst%3DT.%26aulast%3DPetermann%26aufirst%3DE.%26aulast%3DLundin%26aufirst%3DC.%26aulast%3DHodgson%26aufirst%3DB.%26aulast%3DSharma%26aufirst%3DR.%2BA.%26atitle%3DDNA%2520repair%2520pathways%2520as%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D193%26epage%3D204%26doi%3D10.1038%2Fnrc2342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Kastan, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartek, J.</span><span> </span><span class="NLM_article-title">Cell-cycle checkpoints and cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">432</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">323</span><span class="refDoi"> DOI: 10.1038/nature03097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1038%2Fnature03097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=15549093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpvVCjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=432&publication_year=2004&pages=316-323&author=M.+B.+Kastanauthor=J.+Bartek&title=Cell-cycle+checkpoints+and+cancer&doi=10.1038%2Fnature03097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-cycle checkpoints and cancer</span></div><div class="casAuthors">Kastan, Michael B.; Bartek, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">432</span>
        (<span class="NLM_cas:issue">7015</span>),
    <span class="NLM_cas:pages">316-323</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  All life on earth must cope with const. exposure to DNA-damaging agents such as the Sun's radiation.  Highly conserved DNA-repair and cell-cycle checkpoint pathways allow cells to deal with both endogenous and exogenous sources of DNA damage.  How much an individual is exposed to these agents and how their cells respond to DNA damage are crit. determinants of whether that individual will develop cancer.  These cellular responses are also important for detg. toxicities and responses to current cancer therapies, most of which target the DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpONns98smbebVg90H21EOLACvtfcHk0lhDOdpy-5NnZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpvVCjtLo%253D&md5=23577cd35313a3a11afee151281c3fd4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnature03097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03097%26sid%3Dliteratum%253Aachs%26aulast%3DKastan%26aufirst%3DM.%2BB.%26aulast%3DBartek%26aufirst%3DJ.%26atitle%3DCell-cycle%2520checkpoints%2520and%2520cancer%26jtitle%3DNature%26date%3D2004%26volume%3D432%26spage%3D316%26epage%3D323%26doi%3D10.1038%2Fnature03097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Bunch, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eastman, A.</span><span> </span><span class="NLM_article-title">Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor</span> <span class="citation_source-journal">Clin. Can. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">791</span><span class="NLM_x">–</span> <span class="NLM_lpage">797</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=791-797&author=R.+T.+Bunchauthor=A.+Eastman&title=Enhancement+of+cisplatin-induced+cytotoxicity+by+7-hydroxystaurosporine+%28UCN-01%29%2C+a+new+G2-checkpoint+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBunch%26aufirst%3DR.%2BT.%26aulast%3DEastman%26aufirst%3DA.%26atitle%3DEnhancement%2520of%2520cisplatin-induced%2520cytotoxicity%2520by%25207-hydroxystaurosporine%2520%2528UCN-01%2529%252C%2520a%2520new%2520G2-checkpoint%2520inhibitor%26jtitle%3DClin.%2520Can.%2520Res.%26date%3D1996%26volume%3D2%26spage%3D791%26epage%3D797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Bucher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britten, C. D.</span><span> </span><span class="NLM_article-title">G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">528</span><span class="refDoi"> DOI: 10.1038/sj.bjc.6604208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1038%2Fsj.bjc.6604208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=18231106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhs1KrsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2008&pages=523-528&author=N.+Bucherauthor=C.+D.+Britten&title=G2+checkpoint+abrogation+and+checkpoint+kinase-1+targeting+in+the+treatment+of+cancer&doi=10.1038%2Fsj.bjc.6604208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer</span></div><div class="casAuthors">Bucher, N.; Britten, C. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">523-528</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Rigorous quality control steps, termed checkpoints, tightly regulate progression through the cell cycle.  DNA-damaging chemotherapy and radiation activate functional cellular checkpoints.  These checkpoints can facilitate DNA repair and promote cell death in unrepaired cells.  There are at least three DNA damage checkpoints - at G1/S, S, and G2/M - as well as a mitotic spindle checkpoint.  Most cancer cells harbor mutations in tumor suppressors and/or oncogenes, which impair certain cell checkpoints.  Inhibiting the remaining cell checkpoints - particularly after exposure of cancer cells to chemotherapy and/or radiation - allows cell death, a strategy now being employed in cancer therapeutics.  With our increasing knowledge of cell cycle regulation, many compds. have been developed to inhibit specific checkpoint components, particularly at the G2/M transition.  One such target is checkpoint kinase-1 (Chk1).  We review here the mol. framework of the cell cycle, the rationale for targeting Chk1, the preclin. concepts related to the development of Chk1 inhibitors, and the efficacy and safety results from Chk1 inhibitors now in phase I/II trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKqRg9PDH1B7Vg90H21EOLACvtfcHk0lhDOdpy-5NnZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhs1KrsLc%253D&md5=607123f2a15cbe76fbd2aba55da7d289</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6604208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6604208%26sid%3Dliteratum%253Aachs%26aulast%3DBucher%26aufirst%3DN.%26aulast%3DBritten%26aufirst%3DC.%2BD.%26atitle%3DG2%2520checkpoint%2520abrogation%2520and%2520checkpoint%2520kinase-1%2520targeting%2520in%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2008%26volume%3D98%26spage%3D523%26epage%3D528%26doi%3D10.1038%2Fsj.bjc.6604208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Ma, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piwnica-Worms, H.</span><span> </span><span class="NLM_article-title">Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span><span class="refDoi"> DOI: 10.1016/j.molmed.2010.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1016%2Fj.molmed.2010.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=21087899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFWgsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=88-96&author=C.+X.+Maauthor=J.+W.+Janetkaauthor=H.+Piwnica-Worms&title=Death+by+releasing+the+breaks%3A+CHK1+inhibitors+as+cancer+therapeutics&doi=10.1016%2Fj.molmed.2010.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics</span></div><div class="casAuthors">Ma, Cynthia X.; Janetka, James W.; Piwnica-Worms, Helen</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">88-96</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Defects in p53 function, which occur frequently in human cancers due to mutations in TP53 or disruptions in the p53 regulatory pathway, render cells dependent on CHK1 (Checkpoint Kinase 1) to activate cell cycle checkpoints.  In the presence of DNA damage or replication stress, inhibition of CHK1 leads to "mitotic catastrophe" and cell death in p53-deficient tumors while sparing p53-proficient cells.  CHK1 inhibitors sensitize tumors to a variety of DNA-damaging agents or antimetabolites in preclin. models and are being evaluated in early phase clin. trials.  In this review, we summarize recent advances and controversies in the development and application of CHK1 inhibitors as cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAxtqrXv9ZqbVg90H21EOLACvtfcHk0lgFDlB_XDj6Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFWgsro%253D&md5=e53c01cf0016d5be069913a041d67a08</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2010.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2010.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DC.%2BX.%26aulast%3DJanetka%26aufirst%3DJ.%2BW.%26aulast%3DPiwnica-Worms%26aufirst%3DH.%26atitle%3DDeath%2520by%2520releasing%2520the%2520breaks%253A%2520CHK1%2520inhibitors%2520as%2520cancer%2520therapeutics%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2011%26volume%3D17%26spage%3D88%26epage%3D96%26doi%3D10.1016%2Fj.molmed.2010.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Reader, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klair, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scanlon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proisy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Addison, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwood, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eve, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8328</span><span class="NLM_x">–</span> <span class="NLM_lpage">8342</span><span class="refDoi"> DOI: 10.1021/jm2007326</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007326" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFSlurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8328-8342&author=J.+C.+Readerauthor=T.+P.+Matthewsauthor=S.+Klairauthor=K.+M.+Cheungauthor=J.+Scanlonauthor=N.+Proisyauthor=G.+Addisonauthor=J.+Ellardauthor=N.+Pitonauthor=S.+Taylorauthor=M.+Cherryauthor=M.+Fisherauthor=K.+Boxallauthor=S.+Burnsauthor=M.+I.+Waltonauthor=I.+M.+Westwoodauthor=A.+Hayesauthor=P.+Eveauthor=M.+Valentiauthor=A.+de+Haven+Brandonauthor=G.+Boxauthor=R.+L.+van+Montfortauthor=D.+H.+Williamsauthor=G.+W.+Aherneauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=M.+D.+Garrettauthor=I.+Collins&title=Structure-guided+evolution+of+potent+and+selective+CHK1+inhibitors+through+scaffold+morphing&doi=10.1021%2Fjm2007326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing</span></div><div class="casAuthors">Reader, John C.; Matthews, Thomas P.; Klair, Suki; Cheung, Kwai-Ming J.; Scanlon, Jane; Proisy, Nicolas; Addison, Glynn; Ellard, John; Piton, Nelly; Taylor, Suzanne; Cherry, Michael; Fisher, Martin; Boxall, Kathy; Burns, Samantha; Walton, Michael I.; Westwood, Isaac M.; Hayes, Angela; Eve, Paul; Valenti, Melanie; de Haven Brandon, Alexis; Box, Gary; van Montfort, Rob L. M.; Williams, David H.; Aherne, G. Wynne; Raynaud, Florence I.; Eccles, Suzanne A.; Garrett, Michelle D.; Collins, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8328-8342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pyrazolopyridine lead inhibitors with micromolar affinities for the checkpoint kinase CHK1 and selective for CHK1 against CHK2 were refined by fragment-growing and scaffold morphing strategies to generate the isoquinolinylaminopyrazinecarbonitrile I as a potent and selective inhibitor of CHK1 [IC50 (CHK1) = 13 nM, IC50 (CHK2) = > 100 μM] as a potential antitumor agent.  Scaffold morphing was used to improve the CHK1 potency and selectivity, synthetic accessibility, and novelty of the inhibitors; the inhibitor core was changed from pyrimido[2,3-b]azaindole to pyrazinylpyrimidinamine to imidazo[4,5-c]pyridine and isoquinoline.  The toxicities, lipophilicities, and polar surface areas of selected compds. were detd., while ligand efficiencies were detd. for the compds. prepd. and tested; the microsomal stability and oral bioavailability of I in mice were detd.  I potentiated the efficacies of irinotecan and gemcitabine in SW620 human colon carcinoma xenografts in nude mice but had no effect on its own.  The structures of six kinase inhibitors including I bound to the CHK1 kinase domain were detd. by x-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNwXjNh9xLdLVg90H21EOLACvtfcHk0lgFDlB_XDj6Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFSlurjO&md5=927c82ade2efd6df0db154e9009368f8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm2007326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007326%26sid%3Dliteratum%253Aachs%26aulast%3DReader%26aufirst%3DJ.%2BC.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DKlair%26aufirst%3DS.%26aulast%3DCheung%26aufirst%3DK.%2BM.%26aulast%3DScanlon%26aufirst%3DJ.%26aulast%3DProisy%26aufirst%3DN.%26aulast%3DAddison%26aufirst%3DG.%26aulast%3DEllard%26aufirst%3DJ.%26aulast%3DPiton%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DCherry%26aufirst%3DM.%26aulast%3DFisher%26aufirst%3DM.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DBurns%26aufirst%3DS.%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DWestwood%26aufirst%3DI.%2BM.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DEve%26aufirst%3DP.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DBox%26aufirst%3DG.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DWilliams%26aufirst%3DD.%2BH.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DStructure-guided%2520evolution%2520of%2520potent%2520and%2520selective%2520CHK1%2520inhibitors%2520through%2520scaffold%2520morphing%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8328%26epage%3D8342%26doi%3D10.1021%2Fjm2007326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Lainchbury, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHardy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eve, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haven Brandon, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reader, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10229</span><span class="NLM_x">–</span> <span class="NLM_lpage">10240</span><span class="refDoi"> DOI: 10.1021/jm3012933</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3012933" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10229-10240&author=M.+Lainchburyauthor=T.+P.+Matthewsauthor=T.+McHardyauthor=K.+J.+Boxallauthor=M.+I.+Waltonauthor=P.+D.+Eveauthor=A.+Hayesauthor=M.+R.+Valentiauthor=A.+K.+de+Haven+Brandonauthor=G.+Boxauthor=G.+W.+Aherneauthor=J.+C.+Readerauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=M.+D.+Garrettauthor=I.+Collins&title=Discovery+of+3-alkoxyamino-5-%28pyridin-2-ylamino%29pyrazine-2-carbonitriles+as+selective%2C+orally+bioavailable+CHK1+inhibitors&doi=10.1021%2Fjm3012933"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm3012933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012933%26sid%3Dliteratum%253Aachs%26aulast%3DLainchbury%26aufirst%3DM.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DMcHardy%26aufirst%3DT.%26aulast%3DBoxall%26aufirst%3DK.%2BJ.%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DEve%26aufirst%3DP.%2BD.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DValenti%26aufirst%3DM.%2BR.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%2BK.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DReader%26aufirst%3DJ.%2BC.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DDiscovery%2520of%25203-alkoxyamino-5-%2528pyridin-2-ylamino%2529pyrazine-2-carbonitriles%2520as%2520selective%252C%2520orally%2520bioavailable%2520CHK1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10229%26epage%3D10240%26doi%3D10.1021%2Fjm3012933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Dudkin, V. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreatsoulas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrington, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraley, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikuta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirdivant, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drakas, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buser, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobell, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sepp-Lorenzino, L.</span><span> </span><span class="NLM_article-title">Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2609</span><span class="NLM_x">–</span> <span class="NLM_lpage">2612</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1016%2Fj.bmcl.2012.01.110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2609-2612&author=V.+Y.+Dudkinauthor=K.+Rickertauthor=C.+Kreatsoulasauthor=C.+Wangauthor=K.+L.+Arringtonauthor=M.+E.+Fraleyauthor=G.+D.+Hartmanauthor=Y.+Yanauthor=M.+Ikutaauthor=S.+M.+Stirdivantauthor=R.+A.+Drakasauthor=E.+S.+Walshauthor=K.+Hamiltonauthor=C.+A.+Buserauthor=R.+B.+Lobellauthor=L.+Sepp-Lorenzino&title=Pyridyl+aminothiazoles+as+potent+inhibitors+of+Chk1+with+slow+dissociation+rates&doi=10.1016%2Fj.bmcl.2012.01.110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.110%26sid%3Dliteratum%253Aachs%26aulast%3DDudkin%26aufirst%3DV.%2BY.%26aulast%3DRickert%26aufirst%3DK.%26aulast%3DKreatsoulas%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DArrington%26aufirst%3DK.%2BL.%26aulast%3DFraley%26aufirst%3DM.%2BE.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DIkuta%26aufirst%3DM.%26aulast%3DStirdivant%26aufirst%3DS.%2BM.%26aulast%3DDrakas%26aufirst%3DR.%2BA.%26aulast%3DWalsh%26aufirst%3DE.%2BS.%26aulast%3DHamilton%26aufirst%3DK.%26aulast%3DBuser%26aufirst%3DC.%2BA.%26aulast%3DLobell%26aufirst%3DR.%2BB.%26aulast%3DSepp-Lorenzino%26aufirst%3DL.%26atitle%3DPyridyl%2520aminothiazoles%2520as%2520potent%2520inhibitors%2520of%2520Chk1%2520with%2520slow%2520dissociation%2520rates%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2609%26epage%3D2612%26doi%3D10.1016%2Fj.bmcl.2012.01.110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Dudkin, V. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrington, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraley, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirdivant, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drakas, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buser, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardwick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobell, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sepp-Lorenzino, L.</span><span> </span><span class="NLM_article-title">Pyridyl aminothiazoles as potent Chk1 inhibitors: optimization of cellular activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2613</span><span class="NLM_x">–</span> <span class="NLM_lpage">2619</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1016%2Fj.bmcl.2012.01.120" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2613-2619&author=V.+Y.+Dudkinauthor=C.+Wangauthor=K.+L.+Arringtonauthor=M.+E.+Fraleyauthor=G.+D.+Hartmanauthor=S.+M.+Stirdivantauthor=R.+A.+Drakasauthor=K.+Rickertauthor=E.+S.+Walshauthor=K.+Hamiltonauthor=C.+A.+Buserauthor=J.+Hardwickauthor=W.+Taoauthor=S.+C.+Beckauthor=X.+Maoauthor=R.+B.+Lobellauthor=L.+Sepp-Lorenzino&title=Pyridyl+aminothiazoles+as+potent+Chk1+inhibitors%3A+optimization+of+cellular+activity&doi=10.1016%2Fj.bmcl.2012.01.120"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.120%26sid%3Dliteratum%253Aachs%26aulast%3DDudkin%26aufirst%3DV.%2BY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DArrington%26aufirst%3DK.%2BL.%26aulast%3DFraley%26aufirst%3DM.%2BE.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DStirdivant%26aufirst%3DS.%2BM.%26aulast%3DDrakas%26aufirst%3DR.%2BA.%26aulast%3DRickert%26aufirst%3DK.%26aulast%3DWalsh%26aufirst%3DE.%2BS.%26aulast%3DHamilton%26aufirst%3DK.%26aulast%3DBuser%26aufirst%3DC.%2BA.%26aulast%3DHardwick%26aufirst%3DJ.%26aulast%3DTao%26aufirst%3DW.%26aulast%3DBeck%26aufirst%3DS.%2BC.%26aulast%3DMao%26aufirst%3DX.%26aulast%3DLobell%26aufirst%3DR.%2BB.%26aulast%3DSepp-Lorenzino%26aufirst%3DL.%26atitle%3DPyridyl%2520aminothiazoles%2520as%2520potent%2520Chk1%2520inhibitors%253A%2520optimization%2520of%2520cellular%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2613%26epage%3D2619%26doi%3D10.1016%2Fj.bmcl.2012.01.120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duca, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipps, G. W.,  Jr.</span><span> </span><span class="NLM_article-title">Discovery of a novel series of CHK1 kinase inhibitors with a distinctive hinge binding mode</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">128</span><span class="refDoi"> DOI: 10.1021/ml200249h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200249h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC38XpslGntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=123-128&author=X.+Huangauthor=C.+C.+Chengauthor=T.+O.+Fischmannauthor=J.+S.+Ducaauthor=X.+Yangauthor=M.+Richardsauthor=G.+W.+Shipps&title=Discovery+of+a+novel+series+of+CHK1+kinase+inhibitors+with+a+distinctive+hinge+binding+mode&doi=10.1021%2Fml200249h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Series of CHK1 Kinase Inhibitors with a Distinctive Hinge Binding Mode</span></div><div class="casAuthors">Huang, Xiaohua; Cheng, Cliff C.; Fischmann, Thierry O.; Duca, Jose S.; Yang, Xianshu; Richards, Matthew; Shipps, Gerald W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-128</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of CHK1 inhibitors with a distinctive hinge binding mode, exemplified by 2-aryl-N-(2-(piperazin-1-yl)phenyl)thiazole-4-carboxamide, was discovered through high-throughput screening using the affinity selection-mass spectrometry (AS-MS)-based Automated Ligand Identification System (ALIS) platform.  Structure-based ligand design and optimization led to significant improvements in potency to the single digit nanomolar range and hundred-fold selectivity against CDK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphbnP8TZLFsrVg90H21EOLACvtfcHk0liexaWWSeudRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpslGntQ%253D%253D&md5=0033fbe5837cc4c6287c4a5428665247</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fml200249h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200249h%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DC.%2BC.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DDuca%26aufirst%3DJ.%2BS.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DRichards%26aufirst%3DM.%26aulast%3DShipps%26aufirst%3DG.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520series%2520of%2520CHK1%2520kinase%2520inhibitors%2520with%2520a%2520distinctive%2520hinge%2520binding%2520mode%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D123%26epage%3D128%26doi%3D10.1021%2Fml200249h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Song, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of thienopyridinones as Chk1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4882</span><span class="NLM_x">–</span> <span class="NLM_lpage">4892</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.06.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1016%2Fj.bmc.2014.06.044" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=4882-4892&author=P.+Songauthor=P.+Pengauthor=M.+Hanauthor=X.+Caoauthor=X.+Maauthor=T.+Liuauthor=Y.+Zhouauthor=Y.+Hu&title=Design%2C+synthesis+and+biological+evaluation+of+thienopyridinones+as+Chk1+inhibitors&doi=10.1016%2Fj.bmc.2014.06.044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.06.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.06.044%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DP.%26aulast%3DPeng%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520thienopyridinones%2520as%2520Chk1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D4882%26epage%3D4892%26doi%3D10.1016%2Fj.bmc.2014.06.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Gazzard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drobnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodacre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssikatos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span> </span><span class="NLM_article-title">Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">5704</span><span class="NLM_x">–</span> <span class="NLM_lpage">5709</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.10.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1016%2Fj.bmcl.2014.10.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=25453805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVemsLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=5704-5709&author=L.+Gazzardauthor=B.+Appletonauthor=K.+Chapmanauthor=H.+Chenauthor=K.+Clarkauthor=J.+Drobnickauthor=S.+Goodacreauthor=J.+Halladayauthor=J.+Lyssikatosauthor=S.+Schmidtauthor=S.+Siderisauthor=C.+Wiesmannauthor=K.+Williamsauthor=P.+Wuauthor=I.+Yenauthor=S.+Malek&title=Discovery+of+the+1%2C7-diazacarbazole+class+of+inhibitors+of+checkpoint+kinase+1&doi=10.1016%2Fj.bmcl.2014.10.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1</span></div><div class="casAuthors">Gazzard, Lewis; Appleton, Brent; Chapman, Kerry; Chen, Huifen; Clark, Kevin; Drobnick, Joy; Goodacre, Simon; Halladay, Jason; Lyssikatos, Joseph; Schmidt, Stephen; Sideris, Steve; Wiesmann, Christian; Williams, Karen; Wu, Ping; Yen, Ivana; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5704-5709</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Checkpoint kinase 1 (ChK1) is activated in response to DNA damage, acting to temporarily block cell cycle progression and allow for DNA repair.  It is envisaged that inhibition of ChK1 will sensitize tumor cells to treatment with DNA-damaging therapies, and may enhance the therapeutic window.  High throughput screening identified carboxylate-contg. diarylpyrazines as a prominent hit series, but with limited biochem. potency and no cellular activity.  Through a series of SAR investigations and x-ray crystallog. anal. the crit. role of polar contacts with conserved waters in the kinase back pocket was established.  Structure-based design, guided by in silico modeling, transformed the series to better satisfy these contacts and the novel 1,7-diazacarbazole class of inhibitors was discovered.  Here the authors present the genesis of this novel series and the identification of GNE-783 I, a potent, selective and orally bioavailable inhibitor of ChK1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnfVjbVYw27rVg90H21EOLACvtfcHk0liexaWWSeudRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVemsLrL&md5=6a99d23ce3ebe446b57d5fe76816824b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.10.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.10.063%26sid%3Dliteratum%253Aachs%26aulast%3DGazzard%26aufirst%3DL.%26aulast%3DAppleton%26aufirst%3DB.%26aulast%3DChapman%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DClark%26aufirst%3DK.%26aulast%3DDrobnick%26aufirst%3DJ.%26aulast%3DGoodacre%26aufirst%3DS.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DLyssikatos%26aufirst%3DJ.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520the%25201%252C7-diazacarbazole%2520class%2520of%2520inhibitors%2520of%2520checkpoint%2520kinase%25201%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D5704%26epage%3D5709%26doi%3D10.1016%2Fj.bmcl.2014.10.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Janetka, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almeida, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brassil, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gero, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glynn, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ioannidis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyne, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newcombe, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oza, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pass, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toader, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasbinder, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabludoff, S. D.</span><span> </span><span class="NLM_article-title">Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4242</span><span class="NLM_x">–</span> <span class="NLM_lpage">4248</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1016%2Fj.bmcl.2008.05.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4242-4248&author=J.+W.+Janetkaauthor=L.+Almeidaauthor=S.+Ashwellauthor=P.+J.+Brassilauthor=K.+Dalyauthor=C.+Dengauthor=T.+Geroauthor=R.+E.+Glynnauthor=C.+L.+Hornauthor=S.+Ioannidisauthor=P.+Lyneauthor=N.+J.+Newcombeauthor=V.+B.+Ozaauthor=M.+Passauthor=S.+K.+Springerauthor=M.+Suauthor=D.+Toaderauthor=M.+M.+Vasbinderauthor=D.+Yuauthor=Y.+Yuauthor=S.+D.+Zabludoff&title=Discovery+of+a+novel+class+of+2-ureido+thiophene+carboxamide+checkpoint+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2008.05.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DJanetka%26aufirst%3DJ.%2BW.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DAshwell%26aufirst%3DS.%26aulast%3DBrassil%26aufirst%3DP.%2BJ.%26aulast%3DDaly%26aufirst%3DK.%26aulast%3DDeng%26aufirst%3DC.%26aulast%3DGero%26aufirst%3DT.%26aulast%3DGlynn%26aufirst%3DR.%2BE.%26aulast%3DHorn%26aufirst%3DC.%2BL.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DLyne%26aufirst%3DP.%26aulast%3DNewcombe%26aufirst%3DN.%2BJ.%26aulast%3DOza%26aufirst%3DV.%2BB.%26aulast%3DPass%26aufirst%3DM.%26aulast%3DSpringer%26aufirst%3DS.%2BK.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DToader%26aufirst%3DD.%26aulast%3DVasbinder%26aufirst%3DM.%2BM.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZabludoff%26aufirst%3DS.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520class%2520of%25202-ureido%2520thiophene%2520carboxamide%2520checkpoint%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4242%26epage%3D4248%26doi%3D10.1016%2Fj.bmcl.2008.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Oza, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almeida, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brassil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gero, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grondine, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ioannidis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyne, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newcombe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pass, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ready, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowsell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toader, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasbinder, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabludoff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J.</span><span> </span><span class="NLM_article-title">Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5130</span><span class="NLM_x">–</span> <span class="NLM_lpage">5142</span><span class="refDoi"> DOI: 10.1021/jm300025r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300025r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVWgtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5130-5142&author=V.+Ozaauthor=S.+Ashwellauthor=L.+Almeidaauthor=P.+Brassilauthor=J.+Breedauthor=C.+Dengauthor=T.+Geroauthor=M.+Grondineauthor=C.+Hornauthor=S.+Ioannidisauthor=D.+Liuauthor=P.+Lyneauthor=N.+Newcombeauthor=M.+Passauthor=J.+Readauthor=S.+Readyauthor=S.+Rowsellauthor=M.+Suauthor=D.+Toaderauthor=M.+Vasbinderauthor=D.+Yuauthor=Y.+Yuauthor=Y.+Xueauthor=S.+Zabludoffauthor=J.+Janetka&title=Discovery+of+checkpoint+kinase+inhibitor+%28S%29-5-%283-fluorophenyl%29-N-%28piperidin-3-yl%29-3-ureidothiophene-2-carboxamide+%28AZD7762%29+by+structure-based+design+and+optimization+of+thiophenecarboxamide+ureas&doi=10.1021%2Fjm300025r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Checkpoint Kinase Inhibitor (S)-5-(3-Fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by Structure-Based Design and Optimization of Thiophenecarboxamide Ureas</span></div><div class="casAuthors">Oza, Vibha; Ashwell, Susan; Almeida, Lynsie; Brassil, Patrick; Breed, Jason; Deng, Chun; Gero, Thomas; Grondine, Michael; Horn, Candice; Ioannidis, Stephanos; Liu, Dongfang; Lyne, Paul; Newcombe, Nicholas; Pass, Martin; Read, Jon; Ready, Shannon; Rowsell, Sian; Su, Mei; Toader, Dorin; Vasbinder, Melissa; Yu, Dingwei; Yu, Yan; Xue, Yafeng; Zabludoff, Sonya; Janetka, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5130-5142</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Checkpoint kinases CHK1 and CHK2 are activated in response to DNA damage that results in cell cycle arrest, allowing sufficient time for DNA repair.  Agents that lead to abrogation of such checkpoints have potential to increase the efficacy of such compds. as chemo- and radiotherapies.  Thiophenecarboxamide ureas (TCUs) were identified as inhibitors of CHK1 by high throughput screening.  A structure-based approach is described using crystal structures of JNK1 and CHK1 in complex with 1 and 2 and of the CHK1-3b complex.  The ribose binding pocket of CHK1 was targeted to generate inhibitors with excellent cellular potency and selectivity over CDK1and IKKβ, key features lacking from the initial compds.  Optimization of 3b resulted in the identification of a regioisomeric 3-TCU lead 12a.  Optimization of 12a led to the discovery of the clin. candidate 4 (AZD7762, I), which strongly potentiates the efficacy of a variety of DNA-damaging agents in preclin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra8G75JTejhbVg90H21EOLACvtfcHk0lglNFsX8dm6JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVWgtbc%253D&md5=f2880b57af6d1def8f91d3ee694e0182</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm300025r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300025r%26sid%3Dliteratum%253Aachs%26aulast%3DOza%26aufirst%3DV.%26aulast%3DAshwell%26aufirst%3DS.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DBrassil%26aufirst%3DP.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DC.%26aulast%3DGero%26aufirst%3DT.%26aulast%3DGrondine%26aufirst%3DM.%26aulast%3DHorn%26aufirst%3DC.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DLyne%26aufirst%3DP.%26aulast%3DNewcombe%26aufirst%3DN.%26aulast%3DPass%26aufirst%3DM.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DReady%26aufirst%3DS.%26aulast%3DRowsell%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DToader%26aufirst%3DD.%26aulast%3DVasbinder%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DZabludoff%26aufirst%3DS.%26aulast%3DJanetka%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520checkpoint%2520kinase%2520inhibitor%2520%2528S%2529-5-%25283-fluorophenyl%2529-N-%2528piperidin-3-yl%2529-3-ureidothiophene-2-carboxamide%2520%2528AZD7762%2529%2520by%2520structure-based%2520design%2520and%2520optimization%2520of%2520thiophenecarboxamide%2520ureas%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5130%26epage%3D5142%26doi%3D10.1021%2Fjm300025r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Oza, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brassil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ezhuthachan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyne, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newcombe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otterbien, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pass, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roswell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toader, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webborn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabludoff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span> </span><span class="NLM_article-title">Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5133</span><span class="NLM_x">–</span> <span class="NLM_lpage">5138</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1016%2Fj.bmcl.2010.07.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5133-5138&author=V.+Ozaauthor=S.+Ashwellauthor=P.+Brassilauthor=J.+Breedauthor=C.+Dengauthor=J.+Ezhuthachanauthor=H.+Hayeauthor=C.+Hornauthor=J.+Janetkaauthor=P.+Lyneauthor=N.+Newcombeauthor=L.+Otterbienauthor=M.+Passauthor=J.+Readauthor=S.+Roswellauthor=M.+Suauthor=D.+Toaderauthor=D.+Yuauthor=Y.+Yuauthor=A.+Valentineauthor=P.+Webbornauthor=A.+Whiteauthor=S.+Zabludoffauthor=X.+Zheng&title=Discovery+of+a+novel+class+of+triazolones+as+checkpoint+kinase+inhibitors%2D%2Dhit+to+lead+exploration&doi=10.1016%2Fj.bmcl.2010.07.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DOza%26aufirst%3DV.%26aulast%3DAshwell%26aufirst%3DS.%26aulast%3DBrassil%26aufirst%3DP.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DC.%26aulast%3DEzhuthachan%26aufirst%3DJ.%26aulast%3DHaye%26aufirst%3DH.%26aulast%3DHorn%26aufirst%3DC.%26aulast%3DJanetka%26aufirst%3DJ.%26aulast%3DLyne%26aufirst%3DP.%26aulast%3DNewcombe%26aufirst%3DN.%26aulast%3DOtterbien%26aufirst%3DL.%26aulast%3DPass%26aufirst%3DM.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DRoswell%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DToader%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DValentine%26aufirst%3DA.%26aulast%3DWebborn%26aufirst%3DP.%26aulast%3DWhite%26aufirst%3DA.%26aulast%3DZabludoff%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520class%2520of%2520triazolones%2520as%2520checkpoint%2520kinase%2520inhibitors--hit%2520to%2520lead%2520exploration%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5133%26epage%3D5138%26doi%3D10.1016%2Fj.bmcl.2010.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Daly, K.; Heron, N.; Hird, A.; Ioannidis, S.; Janetka, J. W.; Lyne, P.; Scott, J.; Toader, D.; Vasbinder, M.; Yu, D.; Yu, Y.</span><span> </span><span class="NLM_article-title">Substituted Heterocycles and Their Use as CHK1, PDK1 and PAK Inhibitors</span>. WO2006106326 A1, October 12,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=K.+Daly&author=N.+Heron&author=A.+Hird&author=S.+Ioannidis&author=J.+W.+Janetka&author=P.+Lyne&author=J.+Scott&author=D.+Toader&author=M.+Vasbinder&author=D.+Yu&author=Y.+Yu&title=Substituted+Heterocycles+and+Their+Use+as+CHK1%2C+PDK1+and+PAK+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDaly%26aufirst%3DK.%26atitle%3DSubstituted%2520Heterocycles%2520and%2520Their%2520Use%2520as%2520CHK1%252C%2520PDK1%2520and%2520PAK%2520Inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Beno, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartberger, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennington, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">A Survey of the role of noncovalent sulfur interactions in drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4383</span><span class="NLM_x">–</span> <span class="NLM_lpage">4438</span><span class="refDoi"> DOI: 10.1021/jm501853m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501853m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Giu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4383-4438&author=B.+R.+Benoauthor=K.+S.+Yeungauthor=M.+D.+Bartbergerauthor=L.+D.+Penningtonauthor=N.+A.+Meanwell&title=A+Survey+of+the+role+of+noncovalent+sulfur+interactions+in+drug+design&doi=10.1021%2Fjm501853m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design</span></div><div class="casAuthors">Beno, Brett R.; Yeung, Kap-Sun; Bartberger, Michael D.; Pennington, Lewis D.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4383-4438</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Electron deficient, bivalent sulfur atoms have two areas of pos. electrostatic potential, a consequence of the low-lying σ* orbitals of the C-S bond that are available for interaction with electron donors including oxygen and nitrogen atoms and, possibly, π-systems.  Intramol. interactions are by far the most common manifestation of this effect, which offers a means of modulating the conformational preferences of a mol.  Although a well-documented phenomenon, a priori applications in drug design are relatively sparse and this interaction, which is often isosteric with an intramol. hydrogen-bonding interaction, appears to be underappreciated by the medicinal chem. community.  In this Perspective, we discuss the theor. basis for sulfur σ* orbital interactions and illustrate their importance in the context of drug design and org. synthesis.  The role of sulfur interactions in protein structure and function is discussed and although relatively rare, intermol. interactions between ligand C-S σ* orbitals and proteins are illustrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYKXRsl4BQYrVg90H21EOLACvtfcHk0lit7yln_AoKFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Giu7g%253D&md5=d12f53eb3271c161cfc833fb9f7c02b3</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm501853m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501853m%26sid%3Dliteratum%253Aachs%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DYeung%26aufirst%3DK.%2BS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DA%2520Survey%2520of%2520the%2520role%2520of%2520noncovalent%2520sulfur%2520interactions%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4383%26epage%3D4438%26doi%3D10.1021%2Fjm501853m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiswell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seghezzi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddiqui, M. A.</span><span> </span><span class="NLM_article-title">Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">7216</span><span class="NLM_x">–</span> <span class="NLM_lpage">7221</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.10.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1016%2Fj.bmcl.2010.10.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=21074424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKjtLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7216-7221&author=L.+Zhaoauthor=Y.+Zhangauthor=C.+Daiauthor=T.+Guziauthor=D.+Wiswellauthor=W.+Seghezziauthor=D.+Parryauthor=T.+Fischmannauthor=M.+A.+Siddiqui&title=Design%2C+synthesis+and+SAR+of+thienopyridines+as+potent+CHK1+inhibitors&doi=10.1016%2Fj.bmcl.2010.10.105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors</span></div><div class="casAuthors">Zhao, Lianyun; Zhang, Yingxin; Dai, Chaoyang; Guzi, Timothy; Wiswell, Derek; Seghezzi, Wolfgang; Parry, David; Fischmann, Thierry; Siddiqui, M. Arshad</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7216-7221</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of CHK1 inhibitors based on a thienopyridine template were designed and synthesized.  These inhibitors maintained crit. hydrogen bonding with the hinge and conserved water in the ATP binding site.  Several compds. showed single digit nanomolar CHK1 activities.  Compd. I showed excellent enzymic activity of 1 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdQbVc-FuoTbVg90H21EOLACvtfcHk0lit7yln_AoKFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKjtLbE&md5=b9328e520c4e399e05801150f566ca5d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.10.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.10.105%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDai%26aufirst%3DC.%26aulast%3DGuzi%26aufirst%3DT.%26aulast%3DWiswell%26aufirst%3DD.%26aulast%3DSeghezzi%26aufirst%3DW.%26aulast%3DParry%26aufirst%3DD.%26aulast%3DFischmann%26aufirst%3DT.%26aulast%3DSiddiqui%26aufirst%3DM.%2BA.%26atitle%3DDesign%252C%2520synthesis%2520and%2520SAR%2520of%2520thienopyridines%2520as%2520potent%2520CHK1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7216%26epage%3D7221%26doi%3D10.1016%2Fj.bmcl.2010.10.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Cashman, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span> </span><span class="NLM_article-title">Human flavin-containing monooxygenases</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span><span class="refDoi"> DOI: 10.1146/annurev.pharmtox.46.120604.141043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1146%2Fannurev.pharmtox.46.120604.141043" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=65-100&author=J.+R.+Cashmanauthor=J.+Zhang&title=Human+flavin-containing+monooxygenases&doi=10.1146%2Fannurev.pharmtox.46.120604.141043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.46.120604.141043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.46.120604.141043%26sid%3Dliteratum%253Aachs%26aulast%3DCashman%26aufirst%3DJ.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DHuman%2520flavin-containing%2520monooxygenases%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2006%26volume%3D46%26spage%3D65%26epage%3D100%26doi%3D10.1146%2Fannurev.pharmtox.46.120604.141043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span> </span><span class="NLM_article-title">Volume of distribution in drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">5691</span><span class="NLM_x">–</span> <span class="NLM_lpage">5698</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5691-5698&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Volume+of+distribution+in+drug+design&doi=10.1021%2Facs.jmedchem.5b00201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Volume of Distribution in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5691-5698</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Vol. of distribution is one of the most important pharmacokinetic properties of a drug candidate.  It is a major determinant of half-life and dosing frequency of a drug.  For a similar log P, a basic mol. will tend to exhibit higher vol. of distribution than a neutral mol.  Acids often exhibit low vols. of distribution.  Although a design strategy against vol. of distribution can be advantageous in achieving desirable dosing regimen, it must be well-directed in order to avoid detrimental effects to other important properties.  Strategies to increase vol. of distribution include adding lipophilicity and introducing basic functional groups in a way that does not increase metabolic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP7QwgPahf4bVg90H21EOLACvtfcHk0lit7yln_AoKFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D&md5=2c7289b3602a8edef2d9ef0e6a82e483</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00201%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DVolume%2520of%2520distribution%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5691%26epage%3D5698%26doi%3D10.1021%2Facs.jmedchem.5b00201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Zabludoff, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grondine, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehy, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caleb, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haye, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mouchet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ready, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenthal, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queva, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A. M.</span><span> </span><span class="NLM_article-title">AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2955</span><span class="NLM_x">–</span> <span class="NLM_lpage">2966</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-0492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1158%2F1535-7163.MCT-08-0492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=18790776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFSmsL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=2955-2966&author=S.+D.+Zabludoffauthor=C.+Dengauthor=M.+R.+Grondineauthor=A.+M.+Sheehyauthor=S.+Ashwellauthor=B.+L.+Calebauthor=S.+Greenauthor=H.+R.+Hayeauthor=C.+L.+Hornauthor=J.+W.+Janetkaauthor=D.+Liuauthor=E.+Mouchetauthor=S.+Readyauthor=J.+L.+Rosenthalauthor=C.+Quevaauthor=G.+K.+Schwartzauthor=K.+J.+Taylorauthor=A.+N.+Tseauthor=G.+E.+Walkerauthor=A.+M.+White&title=AZD7762%2C+a+novel+checkpoint+kinase+inhibitor%2C+drives+checkpoint+abrogation+and+potentiates+DNA-targeted+therapies&doi=10.1158%2F1535-7163.MCT-08-0492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies</span></div><div class="casAuthors">Zabludoff, Sonya D.; Deng, Chun; Grondine, Michael R.; Sheehy, Adam M.; Ashwell, Susan; Caleb, Benjamin L.; Green, Stephen; Haye, Heather R.; Horn, Candice L.; Janetka, James W.; Liu, Dongfang; Mouchet, Elizabeth; Ready, Shannon; Rosenthal, Judith L.; Queva, Christophe; Schwartz, Gary K.; Taylor, Karen J.; Tse, Archie N.; Walker, Graeme E.; White, Anne M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2955-2966</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Insights from cell cycle research have led to the hypothesis that tumors may be selectively sensitized to DNA-damaging agents resulting in improved antitumor activity and a wider therapeutic margin.  The theory relies on the observation that the majority of tumors are deficient in the G1-DNA damage checkpoint pathway resulting in reliance on S and G2 checkpoints for DNA repair and cell survival.  The S and G2 checkpoints are regulated by checkpoint kinase 1, a serine/threonine kinase that is activated in response to DNA damage; thus, inhibition of checkpoint kinase 1 signaling impairs DNA repair and increases tumor cell death.  Normal tissues, however, have a functioning G1 checkpoint signaling pathway allowing for DNA repair and cell survival.  Here, we describe the preclin. profile of AZD7762, a potent ATP-competitive checkpoint kinase inhibitor in clin. trials.  AZD7762 has been profiled extensively in vitro and in vivo in combination with DNA-damaging agents and has been shown to potentiate response in several different settings where inhibition of checkpoint kinase results in the abrogation of DNA damage-induced cell cycle arrest.  Dose-dependent potentiation of antitumor activity, when AZD7762 is administered in combination with DNA-damaging agents, has been obsd. in multiple xenograft models with several DNA-damaging agents, further supporting the potential of checkpoint kinase inhibitors to enhance the efficacy of both conventional chemotherapy and radiotherapy and increase patient response rates in a variety of settings. [Mol Cancer Ther 2008;7(9):2955-66].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTXvjs3OaUFrVg90H21EOLACvtfcHk0lg17pG9jaeelw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFSmsL7O&md5=b33ff697c6592c9823e85c9bb265c02d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0492%26sid%3Dliteratum%253Aachs%26aulast%3DZabludoff%26aufirst%3DS.%2BD.%26aulast%3DDeng%26aufirst%3DC.%26aulast%3DGrondine%26aufirst%3DM.%2BR.%26aulast%3DSheehy%26aufirst%3DA.%2BM.%26aulast%3DAshwell%26aufirst%3DS.%26aulast%3DCaleb%26aufirst%3DB.%2BL.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DHaye%26aufirst%3DH.%2BR.%26aulast%3DHorn%26aufirst%3DC.%2BL.%26aulast%3DJanetka%26aufirst%3DJ.%2BW.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMouchet%26aufirst%3DE.%26aulast%3DReady%26aufirst%3DS.%26aulast%3DRosenthal%26aufirst%3DJ.%2BL.%26aulast%3DQueva%26aufirst%3DC.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DTaylor%26aufirst%3DK.%2BJ.%26aulast%3DTse%26aufirst%3DA.%2BN.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWhite%26aufirst%3DA.%2BM.%26atitle%3DAZD7762%252C%2520a%2520novel%2520checkpoint%2520kinase%2520inhibitor%252C%2520drives%2520checkpoint%2520abrogation%2520and%2520potentiates%2520DNA-targeted%2520therapies%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D2955%26epage%3D2966%26doi%3D10.1158%2F1535-7163.MCT-08-0492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nosaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makiyama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kometani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamatake, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeoka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agbo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span> </span><span class="NLM_article-title">Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">619</span><span class="NLM_x">–</span> <span class="NLM_lpage">627</span><span class="refDoi"> DOI: 10.1007/s00280-013-2234-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1007%2Fs00280-013-2234-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=23892959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlOrtbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2013&pages=619-627&author=T.+Setoauthor=T.+Esakiauthor=F.+Hiraiauthor=S.+Aritaauthor=K.+Nosakiauthor=A.+Makiyamaauthor=T.+Kometaniauthor=C.+Fujimotoauthor=M.+Hamatakeauthor=H.+Takeokaauthor=F.+Agboauthor=X.+Shi&title=Phase+I%2C+dose-escalation+study+of+AZD7762+alone+and+in+combination+with+gemcitabine+in+Japanese+patients+with+advanced+solid+tumours&doi=10.1007%2Fs00280-013-2234-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours</span></div><div class="casAuthors">Seto, Takashi; Esaki, Taito; Hirai, Fumihiko; Arita, Shuji; Nosaki, Kaname; Makiyama, Akitaka; Kometani, Takuro; Fujimoto, Chinatsu; Hamatake, Motoharu; Takeoka, Hiroaki; Agbo, Felix; Shi, Xiaojin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">619-627</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: AZD7762, a potent Chk1/Chk2 inhibitor, has shown chemosensitizing activity with gemcitabine in xenograft models.  Methods: This open-label, Phase I, dose-escalation study evaluated the safety, pharmacokinetics (PK) and preliminary efficacy (RECIST) of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors (NCT00937664).  Patients received i.v. AZD7762 alone on days 1 and 8 of a 14-day cycle (cycle 0), followed by AZD7762 plus gemcitabine 1,000 mg/m2 on days 1 and 8 of 22-day cycles, in ascending AZD7762 dose cohorts.  Results: Twenty patients received AZD7762 at doses of 6 mg (n = 3), 9 mg (n = 3), 21 mg (n = 6) and 30 mg (n = 8).  Dose-limiting toxicities occurred in 2/6 evaluable patients in the 30-mg cohort: one, CTCAE grade 3 elevated troponin T (cycle 0: AZD7762 monotherapy); one, neutropenia, thrombocytopenia, and elevated aspartate aminotransferase and alanine aminotransferase (cycle 1: combination therapy).  The 30 mg dose was therefore regarded as non-tolerable.  The most common adverse events (AEs) in cycle 0 (AZD7762 monotherapy) were bradycardia (50 %), hypertension (25 %) and fatigue (15 %).  Overall, the most common AEs were bradycardia (55 %), neutropenia (45 %) and hypertension, fatigue and rash (30 % each).  Grade ≥3 AEs were reported in 11 patients, the most common being neutropenia (45 %) and leukopenia (25 %).  AZD7762 exposure increased approx. linearly.  Gemcitabine did not appear to affect AZD7762 PK.  There were no objective responses; five patients (all lung cancer) had stable disease.  Conclusions: The max. tolerated dose of AZD7762 in combination with gemcitabine, 1,000 mg/m2 was detd. as 21 mg in Japanese patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWxvmjbQe4HbVg90H21EOLACvtfcHk0lg17pG9jaeelw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlOrtbnJ&md5=249621625eab6c9d7e0a85d4f4f47977</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs00280-013-2234-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-013-2234-6%26sid%3Dliteratum%253Aachs%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DEsaki%26aufirst%3DT.%26aulast%3DHirai%26aufirst%3DF.%26aulast%3DArita%26aufirst%3DS.%26aulast%3DNosaki%26aufirst%3DK.%26aulast%3DMakiyama%26aufirst%3DA.%26aulast%3DKometani%26aufirst%3DT.%26aulast%3DFujimoto%26aufirst%3DC.%26aulast%3DHamatake%26aufirst%3DM.%26aulast%3DTakeoka%26aufirst%3DH.%26aulast%3DAgbo%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DX.%26atitle%3DPhase%2520I%252C%2520dose-escalation%2520study%2520of%2520AZD7762%2520alone%2520and%2520in%2520combination%2520with%2520gemcitabine%2520in%2520Japanese%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2013%26volume%3D72%26spage%3D619%26epage%3D627%26doi%3D10.1007%2Fs00280-013-2234-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Sausville, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorusso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carducci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malburg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azad, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosgrove, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabludoff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agbo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oakes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senderowicz, A.</span><span> </span><span class="NLM_article-title">Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">549</span><span class="refDoi"> DOI: 10.1007/s00280-014-2380-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1007%2Fs00280-014-2380-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=24448638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2014&pages=539-549&author=E.+Sausvilleauthor=P.+Lorussoauthor=M.+Carducciauthor=J.+Carterauthor=M.+F.+Quinnauthor=L.+Malburgauthor=N.+Azadauthor=D.+Cosgroveauthor=R.+Knightauthor=P.+Barkerauthor=S.+Zabludoffauthor=F.+Agboauthor=P.+Oakesauthor=A.+Senderowicz&title=Phase+I+dose-escalation+study+of+AZD7762%2C+a+checkpoint+kinase+inhibitor%2C+in+combination+with+gemcitabine+in+US+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-014-2380-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors</span></div><div class="casAuthors">Sausville, Edward; LoRusso, Patricia; Carducci, Michael; Carter, Judith; Quinn, Mary F.; Malburg, Lisa; Azad, Nilofer; Cosgrove, David; Knight, Richard; Barker, Peter; Zabludoff, Sonya; Agbo, Felix; Oakes, Patricia; Senderowicz, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">539-549</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: AZD7762 is a Chk1 kinase inhibitor which increases sensitivity to DNA-damaging agents, including gemcitabine.  We evaluated the safety of AZD7762 monotherapy and with gemcitabine in advanced solid tumor patients.  Exptl. design: In this Phase I study, patients received i.v. AZD7762 on days 1 and 8 of a 14-day run-in cycle (cycle 0; AZD7762 monotherapy), followed by AZD7762 plus gemcitabine 750-1,000 mg/m2 on days 1 and 8, every 21 days, in ascending AZD7762 doses (cycle 1; combination therapy).  Results: Forty-two patients received AZD7762 6 mg (n = 9), 9 mg (n = 3), 14 mg (n = 6), 21 mg (n = 3), 30 mg (n = 7), 32 mg (n = 6), and 40 mg (n = 8), in combination with gemcitabine.  Common adverse events (AEs) were fatigue [41 % (17/42) patients], neutropenia/leukopenia [36 % (15/42) patients], anemia/Hb decrease [29 % (12/42) patients] and nausea, pyrexia and alanine aminotransferase/aspartate aminotransferase increase [26 % (11/42) patients each].  Grade ≥3 AEs occurred in 19 and 52 % of patients in cycles 0 and 1, resp.  Cardiac dose-limiting toxicities occurred in two patients (both AZD7762 monotherapy): grade 3 troponin I increase (32 mg) and grade 3 myocardial ischemia with chest pain, ECG changes, decreased left ventricular ejection fraction, and increased troponin I (40 mg).  AZD7762 exposure increased linearly.  Gemcitabine did not affect AZD7762 pharmacokinetics.  Two non-small-cell lung cancer patients achieved partial tumor responses (AZD7762 6 mg/gemcitabine 750 mg/m2 and AZD7762 9 mg cohort).  Conclusions: The max.-tolerated dose of AZD7762 in combination with gemcitabine 1,000 mg/m2 was 30 mg.  Although development of AZD7762 is not going forward owing to unpredictable cardiac toxicity, Chk1 remains an important therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgyFGCYJKF3rVg90H21EOLACvtfcHk0lhtnygaG0FtbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyks7s%253D&md5=6536063d427c1705dc4976826932e9ff</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs00280-014-2380-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-014-2380-5%26sid%3Dliteratum%253Aachs%26aulast%3DSausville%26aufirst%3DE.%26aulast%3DLorusso%26aufirst%3DP.%26aulast%3DCarducci%26aufirst%3DM.%26aulast%3DCarter%26aufirst%3DJ.%26aulast%3DQuinn%26aufirst%3DM.%2BF.%26aulast%3DMalburg%26aufirst%3DL.%26aulast%3DAzad%26aufirst%3DN.%26aulast%3DCosgrove%26aufirst%3DD.%26aulast%3DKnight%26aufirst%3DR.%26aulast%3DBarker%26aufirst%3DP.%26aulast%3DZabludoff%26aufirst%3DS.%26aulast%3DAgbo%26aufirst%3DF.%26aulast%3DOakes%26aufirst%3DP.%26aulast%3DSenderowicz%26aufirst%3DA.%26atitle%3DPhase%2520I%2520dose-escalation%2520study%2520of%2520AZD7762%252C%2520a%2520checkpoint%2520kinase%2520inhibitor%252C%2520in%2520combination%2520with%2520gemcitabine%2520in%2520US%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2014%26volume%3D73%26spage%3D539%26epage%3D549%26doi%3D10.1007%2Fs00280-014-2380-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 10 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Lin Wei, Wuqiang Wen, Li Rao, Yunyuan Huang, Mengting Lei, Kai Liu, Saiya Hu, Rongrong Song, Yanliang Ren, <span class="NLM_string-name hlFld-ContribAuthor">Jian Wan</span>. </span><span class="cited-content_cbyCitation_article-title">Cov_FB3D: A De Novo Covalent Drug Design Protocol Integrating the BA-SAMP Strategy and Machine-Learning-Based Synthetic Tractability Evaluation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (9)
                                     , 4388-4402. <a href="https://doi.org/10.1021/acs.jcim.9b01197" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b01197</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b01197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b01197%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DCov_FB3D%25253A%252BA%252BDe%252BNovo%252BCovalent%252BDrug%252BDesign%252BProtocol%252BIntegrating%252Bthe%252BBA-SAMP%252BStrategy%252Band%252BMachine-Learning-Based%252BSynthetic%252BTractability%252BEvaluation%26aulast%3DWei%26aufirst%3DLin%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D27122019%26date%3D09042020%26date%3D01042020%26volume%3D60%26issue%3D9%26spage%3D4388%26epage%3D4402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhongfeng Luo, Tingting Liu, Weijie Guo, Zijia Wang, Jingjun Huang, Yulin Zhu, <span class="NLM_string-name hlFld-ContribAuthor">Zhuo Zeng</span>. </span><span class="cited-content_cbyCitation_article-title">N-Acyl-5,5-dimethylhydantoin, a New Mild Acyl-Transfer Reagent in Pd Catalysis: Highly Efficient Synthesis of Functionalized Ketones. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2018,</strong> <em>22 </em>
                                    (9)
                                     , 1188-1199. <a href="https://doi.org/10.1021/acs.oprd.8b00182" title="DOI URL">https://doi.org/10.1021/acs.oprd.8b00182</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.8b00182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.8b00182%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DN-Acyl-5%25252C5-dimethylhydantoin%25252C%252Ba%252BNew%252BMild%252BAcyl-Transfer%252BReagent%252Bin%252BPd%252BCatalysis%25253A%252BHighly%252BEfficient%252BSynthesis%252Bof%252BFunctionalized%252BKetones%26aulast%3DLuo%26aufirst%3DZhongfeng%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D01062018%26date%3D13082018%26date%3D30072018%26volume%3D22%26issue%3D9%26spage%3D1188%26epage%3D1199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenwu  Liu</span>, <span class="hlFld-ContribAuthor ">Xin  Liu</span>, <span class="hlFld-ContribAuthor ">Liting  Tian</span>, <span class="hlFld-ContribAuthor ">Yaping  Gao</span>, <span class="hlFld-ContribAuthor ">Wenjie  Liu</span>, <span class="hlFld-ContribAuthor ">Huanhua  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaowen  Jiang</span>, <span class="hlFld-ContribAuthor ">Zihua  Xu</span>, <span class="hlFld-ContribAuthor ">Huaiwei  Ding</span>, <span class="hlFld-ContribAuthor ">Qingchun  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>222 </em>, 113554. <a href="https://doi.org/10.1016/j.ejmech.2021.113554" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113554</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113554%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bharmine%252Bderivatives%252Bas%252Bpotent%252BGSK-3%2525CE%2525B2%25252FDYRK1A%252Bdual%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252BAlzheimer%252527s%252Bdisease%26aulast%3DLiu%26aufirst%3DWenwu%26date%3D2021%26volume%3D222%26spage%3D113554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">The Design and Application of Bioisosteres in Drug Design. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-81. <a href="https://doi.org/10.1002/0471266949.bmc259" title="DOI URL">https://doi.org/10.1002/0471266949.bmc259</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc259%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BDesign%252Band%252BApplication%252Bof%252BBioisosteres%252Bin%252BDrug%252BDesign%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D81%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  He</span>, <span class="hlFld-ContribAuthor ">Zhi  Zheng</span>, <span class="hlFld-ContribAuthor ">Yajie  Liu</span>, <span class="hlFld-ContribAuthor ">Jiajie  Qiao</span>, <span class="hlFld-ContribAuthor ">Xinying  Zhang</span>, <span class="hlFld-ContribAuthor ">Xuesen  Fan</span>. </span><span class="cited-content_cbyCitation_article-title">Selective synthesis of β-nitrated N-heterocycles and
              N
              -nitroso-2-alkoxyamine aldehydes from inactivated cyclic amines promoted by
              t
              BuONO and oxoammonium salt. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2019,</strong> <em>55 </em>
                                    (82)
                                     , 12372-12375. <a href="https://doi.org/10.1039/C9CC05963F" title="DOI URL">https://doi.org/10.1039/C9CC05963F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CC05963F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CC05963F%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DSelective%252Bsynthesis%252Bof%252B%2525CE%2525B2-nitrated%252BN-heterocycles%252Band%252BN%252B-nitroso-2-alkoxyamine%252Baldehydes%252Bfrom%252Binactivated%252Bcyclic%252Bamines%252Bpromoted%252Bby%252Bt%252BBuONO%252Band%252Boxoammonium%252Bsalt%26aulast%3DHe%26aufirst%3DYan%26date%3D2019%26date%3D2019%26volume%3D55%26issue%3D82%26spage%3D12372%26epage%3D12375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikhil R.  Tasker</span>, <span class="hlFld-ContribAuthor ">Ettore J.  Rastelli</span>, <span class="hlFld-ContribAuthor ">James C.  Burnett</span>, <span class="hlFld-ContribAuthor ">Elizabeth R.  Sharlow</span>, <span class="hlFld-ContribAuthor ">John S.  Lazo</span>, <span class="hlFld-ContribAuthor ">Peter  Wipf</span>. </span><span class="cited-content_cbyCitation_article-title">Tapping the therapeutic potential of protein tyrosine phosphatase 4A with small molecule inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (16)
                                     , 2008-2015. <a href="https://doi.org/10.1016/j.bmcl.2019.06.048" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.06.048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.06.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.06.048%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DTapping%252Bthe%252Btherapeutic%252Bpotential%252Bof%252Bprotein%252Btyrosine%252Bphosphatase%252B4A%252Bwith%252Bsmall%252Bmolecule%252Binhibitors%26aulast%3DTasker%26aufirst%3DNikhil%2BR.%26date%3D2019%26volume%3D29%26issue%3D16%26spage%3D2008%26epage%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lexian  Tong</span>, <span class="hlFld-ContribAuthor ">Pinrao  Song</span>, <span class="hlFld-ContribAuthor ">Kailong  Jiang</span>, <span class="hlFld-ContribAuthor ">Lei  Xu</span>, <span class="hlFld-ContribAuthor ">Tingting  Jin</span>, <span class="hlFld-ContribAuthor ">Peipei  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaobei  Hu</span>, <span class="hlFld-ContribAuthor ">Sui  Fang</span>, <span class="hlFld-ContribAuthor ">Anhui  Gao</span>, <span class="hlFld-ContribAuthor ">Yubo  Zhou</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>, <span class="hlFld-ContribAuthor ">Jia  Li</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>173 </em>, 44-62. <a href="https://doi.org/10.1016/j.ejmech.2019.03.062" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.03.062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.03.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.03.062%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528R%252529-5-%252528%2525285-%2525281-methyl-1H-pyrazol-4-yl%252529-4-%252528methylamino%252529pyrimidin-2-yl%252529amino%252529-3-%252528piperidin-3-yloxy%252529picolinonitrile%25252C%252Ba%252Bnovel%252BCHK1%252Binhibitor%252Bfor%252Bhematologic%252Bmalignancies%26aulast%3DTong%26aufirst%3DLexian%26date%3D2019%26volume%3D173%26spage%3D44%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Wang</span>, <span class="hlFld-ContribAuthor ">Owen B.  Wallace</span>, <span class="hlFld-ContribAuthor ">Zhongxing  Zhang</span>, <span class="hlFld-ContribAuthor ">Haiquan  Fang</span>, <span class="hlFld-ContribAuthor ">Zhong  Yang</span>, <span class="hlFld-ContribAuthor ">Brett A.  Robinson</span>, <span class="hlFld-ContribAuthor ">Timothy P.  Spicer</span>, <span class="hlFld-ContribAuthor ">Yi-Fei  Gong</span>, <span class="hlFld-ContribAuthor ">Wade S.  Blair</span>, <span class="hlFld-ContribAuthor ">Pei-Yong  Shi</span>, <span class="hlFld-ContribAuthor ">Pin-Fang  Lin</span>, <span class="hlFld-ContribAuthor ">Milind  Deshpande</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">John F.  Kadow</span>. </span><span class="cited-content_cbyCitation_article-title">A survey of core replacements in indole-based HIV-1 attachment inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (11)
                                     , 1423-1429. <a href="https://doi.org/10.1016/j.bmcl.2019.03.018" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.03.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.03.018%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DA%252Bsurvey%252Bof%252Bcore%252Breplacements%252Bin%252Bindole-based%252BHIV-1%252Battachment%252Binhibitors%26aulast%3DWang%26aufirst%3DTao%26date%3D2019%26volume%3D29%26issue%3D11%26spage%3D1423%26epage%3D1429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikhil R.  Tasker</span>, <span class="hlFld-ContribAuthor ">Ettore J.  Rastelli</span>, <span class="hlFld-ContribAuthor ">Isabella K.  Blanco</span>, <span class="hlFld-ContribAuthor ">James C.  Burnett</span>, <span class="hlFld-ContribAuthor ">Elizabeth R.  Sharlow</span>, <span class="hlFld-ContribAuthor ">John S.  Lazo</span>, <span class="hlFld-ContribAuthor ">Peter  Wipf</span>. </span><span class="cited-content_cbyCitation_article-title">In-flow photooxygenation of aminothienopyridinones generates iminopyridinedione PTP4A3 phosphatase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (9)
                                     , 2448-2466. <a href="https://doi.org/10.1039/C9OB00025A" title="DOI URL">https://doi.org/10.1039/C9OB00025A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9OB00025A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9OB00025A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DIn-flow%252Bphotooxygenation%252Bof%252Baminothienopyridinones%252Bgenerates%252Biminopyridinedione%252BPTP4A3%252Bphosphatase%252Binhibitors%26aulast%3DTasker%26aufirst%3DNikhil%2BR.%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D9%26spage%3D2448%26epage%3D2466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Tian</span>, <span class="hlFld-ContribAuthor ">Zifei  Han</span>, <span class="hlFld-ContribAuthor ">Yuanxin  Li</span>, <span class="hlFld-ContribAuthor ">Meng  Wang</span>, <span class="hlFld-ContribAuthor ">Jiajia  Yang</span>, <span class="hlFld-ContribAuthor ">Xiaowei  Wang</span>, <span class="hlFld-ContribAuthor ">Zhili  Zhang</span>, <span class="hlFld-ContribAuthor ">Junyi  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d]pyrimidine analogues as novel CHK1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>151 </em>, 836-848. <a href="https://doi.org/10.1016/j.ejmech.2018.03.075" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.03.075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.03.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.03.075%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B2%25252C6-disubstituted-9H-purine%25252C%252B2%25252C4-disubstitued-thieno%25255B3%25252C2-d%25255Dpyrimidine%252Band%252B-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidine%252Banalogues%252Bas%252Bnovel%252BCHK1%252Binhibitors%26aulast%3DTian%26aufirst%3DChao%26date%3D2018%26volume%3D151%26spage%3D836%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0016.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. TCU and triazoloquinolone CHK1 inhibitors and their fused ring analogs using a scaffold morphing strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray crystal structure overlay of compounds <b>1</b> and <b>3</b> bound to human CHK1 kinase domain. Carbon atoms and hydrogen bonds of <b>1</b> bound to CHK1 are colored green, and carbon atoms of <b>3</b> are colored yellow (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YDJ">2YDJ</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YDK">2YDK</a>, respectively). Selected residues and inhibitors are depicted as sticks. Picture was generated in PYMOL.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 4-CTP <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) glyoxylic acid, K<sub>2</sub>CO<sub>3</sub>, MeOH, reflux, 3 h, 90% yield; (b) oxalyl chloride, DCM, rt, 63% yield; (c) NaN<sub>3</sub>, dioxane/water, rt, 1.5 h, 82% yield; (d) diphenyl ether, 230 °C, 0.5 h, 44% yield; (e) NBS, AcOH/DMF, 80 °C, 1 h, 96% yield; (f) POCl<sub>3</sub>, 110 °C, overnight, 82% yield; (g) (<i>S</i>)-3-amino-Boc-piperidine, K<sub>2</sub>CO<sub>3</sub>, NMP, 80 °C, quantitative yield; (h) Pd(Ph<sub>3</sub>P)<sub>4</sub>, <i>m</i>-F-PhB(OH)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, dioxane/water, 80 °C, 54% yield; (i) PPA, 110 °C, 12 h.</p></p></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Isosteric replacement of S–O interaction using the hydrogen bond of the indole NH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Indole Analog <b>21</b>.<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) SOCl<sub>2</sub>, MeOH, reflux, 2 days, 63% yield; (b) acetophenone, KO<i>t</i>-Bu, DMSO, −15 °C, 1 h, 90%; (c) isobutyl chloroformate, NH<sub>3</sub>, DCM, −15 °C to rt, 80% yield; (d) H<sub>2</sub>, 10% Pd/C, rt, overnight, MeOH, 80% yield; (e) 3-oxo-Boc-piperidine, Na<sub>2</sub>SO<sub>4</sub>, NaBH(OAc)<sub>3</sub>, rt, AcOH, 30% yield; (f) 4 N HCl in dioxane, MeOH, 2 h, 78% yield; (g) chiral preparative HPLC for enantiomeric separation.</p></p></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structure overlay of compounds <b>13</b> and <b>21</b> bound to human CHK1 kinase domain. Carbon atoms and hydrogen bonds of <b>13</b> bound to CHK1 are colored yellow, and carbon atoms of <b>21</b> are colored green (PDB codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FC8">6FC8</a> for <b>13</b> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FCK">6FCK</a> for <b>21</b>). <b>13</b> is modeled as a dual conformation. Selected residues and inhibitors are depicted as sticks. Picture was generated in PYMOL.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 3-Amino-2-methylpiperidines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MeLi, THF, 0 °C to rt, 5 h, 14% yield; (b) 10% Pd/C, H<sub>2</sub>. MeOH, rt, 3 days, 100% yield; (c) CbzCl, DIPEA, DCM, rt, 1 h, 49% yield; (d) silica gel column separation, EtOH/hexane, 49% yield <i>trans</i> isomer and 35% yield for <i>cis</i> isomer; (e) 4 N HCl in dioxane, MeOH, rt, 100% yield.</p></p></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray crystal structure overlay of compounds <b>44</b> and <b>3</b> bound to human CHK1 kinase domain. Carbon atoms and hydrogen bonds of <b>44</b> bound to CHK1 are colored yellow, and carbon atoms of <b>3</b> are colored green (PDB codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FCF">6FCF</a> for <b>44</b>). Selected residues and inhibitors are depicted as sticks. Pictures were generated in PYMOL.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/medium/jm-2017-014906_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Odds ratio of <b>5</b>, <b>13</b>, and <b>44</b> in hollow fiber mouse PD assay (iv administration, using HCT116 cells). The error bars represent the standard error of the mean odds ratio of multiple runs of the study. <span class="NLM_inline-formula"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/jm-2017-014906_m002.gif" alt="" /></img></span> and <span class="NLM_inline-formula"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/jm-2017-014906_m003.gif" alt="" /></img></span>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01490/20180201/images/large/jm-2017-014906_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01490&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i72">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07354" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07354" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 23 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Helleday, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petermann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R. A.</span><span> </span><span class="NLM_article-title">DNA repair pathways as targets for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span><span class="refDoi"> DOI: 10.1038/nrc2342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1038%2Fnrc2342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=18256616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitlOisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=193-204&author=T.+Helledayauthor=E.+Petermannauthor=C.+Lundinauthor=B.+Hodgsonauthor=R.+A.+Sharma&title=DNA+repair+pathways+as+targets+for+cancer+therapy&doi=10.1038%2Fnrc2342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">DNA repair pathways as targets for cancer therapy</span></div><div class="casAuthors">Helleday, Thomas; Petermann, Eva; Lundin, Cecilia; Hodgson, Ben; Sharma, Ricky A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">193-204</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  DNA repair pathways can enable tumor cells to survive DNA damage that is induced by chemotherapeutic treatments; therefore, inhibitors of specific DNA repair pathways might prove efficacious when used in combination with DNA-damaging chemotherapeutic drugs.  In addn., alterations in DNA repair pathways that arise during tumor development can make some cancer cells reliant on a reduced set of DNA repair pathways for survival.  There is evidence that drugs that inhibit one of these pathways in such tumors could prove useful as single-agent therapies, with the potential advantage that this approach could be selective for tumor cells and have fewer side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3W53LJmdCPrVg90H21EOLACvtfcHk0liuO70BH41VIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitlOisr8%253D&md5=8592af6d815e5ca9c80ee256791bafb7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2342%26sid%3Dliteratum%253Aachs%26aulast%3DHelleday%26aufirst%3DT.%26aulast%3DPetermann%26aufirst%3DE.%26aulast%3DLundin%26aufirst%3DC.%26aulast%3DHodgson%26aufirst%3DB.%26aulast%3DSharma%26aufirst%3DR.%2BA.%26atitle%3DDNA%2520repair%2520pathways%2520as%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D193%26epage%3D204%26doi%3D10.1038%2Fnrc2342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Kastan, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartek, J.</span><span> </span><span class="NLM_article-title">Cell-cycle checkpoints and cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">432</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">323</span><span class="refDoi"> DOI: 10.1038/nature03097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1038%2Fnature03097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=15549093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpvVCjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=432&publication_year=2004&pages=316-323&author=M.+B.+Kastanauthor=J.+Bartek&title=Cell-cycle+checkpoints+and+cancer&doi=10.1038%2Fnature03097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-cycle checkpoints and cancer</span></div><div class="casAuthors">Kastan, Michael B.; Bartek, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">432</span>
        (<span class="NLM_cas:issue">7015</span>),
    <span class="NLM_cas:pages">316-323</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  All life on earth must cope with const. exposure to DNA-damaging agents such as the Sun's radiation.  Highly conserved DNA-repair and cell-cycle checkpoint pathways allow cells to deal with both endogenous and exogenous sources of DNA damage.  How much an individual is exposed to these agents and how their cells respond to DNA damage are crit. determinants of whether that individual will develop cancer.  These cellular responses are also important for detg. toxicities and responses to current cancer therapies, most of which target the DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpONns98smbebVg90H21EOLACvtfcHk0liroHCd6BhYpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpvVCjtLo%253D&md5=23577cd35313a3a11afee151281c3fd4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnature03097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03097%26sid%3Dliteratum%253Aachs%26aulast%3DKastan%26aufirst%3DM.%2BB.%26aulast%3DBartek%26aufirst%3DJ.%26atitle%3DCell-cycle%2520checkpoints%2520and%2520cancer%26jtitle%3DNature%26date%3D2004%26volume%3D432%26spage%3D316%26epage%3D323%26doi%3D10.1038%2Fnature03097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Bunch, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eastman, A.</span><span> </span><span class="NLM_article-title">Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor</span> <span class="citation_source-journal">Clin. Can. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">791</span><span class="NLM_x">–</span> <span class="NLM_lpage">797</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=791-797&author=R.+T.+Bunchauthor=A.+Eastman&title=Enhancement+of+cisplatin-induced+cytotoxicity+by+7-hydroxystaurosporine+%28UCN-01%29%2C+a+new+G2-checkpoint+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBunch%26aufirst%3DR.%2BT.%26aulast%3DEastman%26aufirst%3DA.%26atitle%3DEnhancement%2520of%2520cisplatin-induced%2520cytotoxicity%2520by%25207-hydroxystaurosporine%2520%2528UCN-01%2529%252C%2520a%2520new%2520G2-checkpoint%2520inhibitor%26jtitle%3DClin.%2520Can.%2520Res.%26date%3D1996%26volume%3D2%26spage%3D791%26epage%3D797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Bucher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britten, C. D.</span><span> </span><span class="NLM_article-title">G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">528</span><span class="refDoi"> DOI: 10.1038/sj.bjc.6604208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1038%2Fsj.bjc.6604208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=18231106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhs1KrsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2008&pages=523-528&author=N.+Bucherauthor=C.+D.+Britten&title=G2+checkpoint+abrogation+and+checkpoint+kinase-1+targeting+in+the+treatment+of+cancer&doi=10.1038%2Fsj.bjc.6604208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer</span></div><div class="casAuthors">Bucher, N.; Britten, C. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">523-528</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Rigorous quality control steps, termed checkpoints, tightly regulate progression through the cell cycle.  DNA-damaging chemotherapy and radiation activate functional cellular checkpoints.  These checkpoints can facilitate DNA repair and promote cell death in unrepaired cells.  There are at least three DNA damage checkpoints - at G1/S, S, and G2/M - as well as a mitotic spindle checkpoint.  Most cancer cells harbor mutations in tumor suppressors and/or oncogenes, which impair certain cell checkpoints.  Inhibiting the remaining cell checkpoints - particularly after exposure of cancer cells to chemotherapy and/or radiation - allows cell death, a strategy now being employed in cancer therapeutics.  With our increasing knowledge of cell cycle regulation, many compds. have been developed to inhibit specific checkpoint components, particularly at the G2/M transition.  One such target is checkpoint kinase-1 (Chk1).  We review here the mol. framework of the cell cycle, the rationale for targeting Chk1, the preclin. concepts related to the development of Chk1 inhibitors, and the efficacy and safety results from Chk1 inhibitors now in phase I/II trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKqRg9PDH1B7Vg90H21EOLACvtfcHk0liroHCd6BhYpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhs1KrsLc%253D&md5=607123f2a15cbe76fbd2aba55da7d289</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6604208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6604208%26sid%3Dliteratum%253Aachs%26aulast%3DBucher%26aufirst%3DN.%26aulast%3DBritten%26aufirst%3DC.%2BD.%26atitle%3DG2%2520checkpoint%2520abrogation%2520and%2520checkpoint%2520kinase-1%2520targeting%2520in%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2008%26volume%3D98%26spage%3D523%26epage%3D528%26doi%3D10.1038%2Fsj.bjc.6604208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Ma, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piwnica-Worms, H.</span><span> </span><span class="NLM_article-title">Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span><span class="refDoi"> DOI: 10.1016/j.molmed.2010.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1016%2Fj.molmed.2010.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=21087899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFWgsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=88-96&author=C.+X.+Maauthor=J.+W.+Janetkaauthor=H.+Piwnica-Worms&title=Death+by+releasing+the+breaks%3A+CHK1+inhibitors+as+cancer+therapeutics&doi=10.1016%2Fj.molmed.2010.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics</span></div><div class="casAuthors">Ma, Cynthia X.; Janetka, James W.; Piwnica-Worms, Helen</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">88-96</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Defects in p53 function, which occur frequently in human cancers due to mutations in TP53 or disruptions in the p53 regulatory pathway, render cells dependent on CHK1 (Checkpoint Kinase 1) to activate cell cycle checkpoints.  In the presence of DNA damage or replication stress, inhibition of CHK1 leads to "mitotic catastrophe" and cell death in p53-deficient tumors while sparing p53-proficient cells.  CHK1 inhibitors sensitize tumors to a variety of DNA-damaging agents or antimetabolites in preclin. models and are being evaluated in early phase clin. trials.  In this review, we summarize recent advances and controversies in the development and application of CHK1 inhibitors as cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAxtqrXv9ZqbVg90H21EOLACvtfcHk0liroHCd6BhYpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFWgsro%253D&md5=e53c01cf0016d5be069913a041d67a08</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2010.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2010.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DC.%2BX.%26aulast%3DJanetka%26aufirst%3DJ.%2BW.%26aulast%3DPiwnica-Worms%26aufirst%3DH.%26atitle%3DDeath%2520by%2520releasing%2520the%2520breaks%253A%2520CHK1%2520inhibitors%2520as%2520cancer%2520therapeutics%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2011%26volume%3D17%26spage%3D88%26epage%3D96%26doi%3D10.1016%2Fj.molmed.2010.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Reader, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klair, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scanlon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proisy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Addison, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwood, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eve, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8328</span><span class="NLM_x">–</span> <span class="NLM_lpage">8342</span><span class="refDoi"> DOI: 10.1021/jm2007326</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007326" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFSlurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8328-8342&author=J.+C.+Readerauthor=T.+P.+Matthewsauthor=S.+Klairauthor=K.+M.+Cheungauthor=J.+Scanlonauthor=N.+Proisyauthor=G.+Addisonauthor=J.+Ellardauthor=N.+Pitonauthor=S.+Taylorauthor=M.+Cherryauthor=M.+Fisherauthor=K.+Boxallauthor=S.+Burnsauthor=M.+I.+Waltonauthor=I.+M.+Westwoodauthor=A.+Hayesauthor=P.+Eveauthor=M.+Valentiauthor=A.+de+Haven+Brandonauthor=G.+Boxauthor=R.+L.+van+Montfortauthor=D.+H.+Williamsauthor=G.+W.+Aherneauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=M.+D.+Garrettauthor=I.+Collins&title=Structure-guided+evolution+of+potent+and+selective+CHK1+inhibitors+through+scaffold+morphing&doi=10.1021%2Fjm2007326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing</span></div><div class="casAuthors">Reader, John C.; Matthews, Thomas P.; Klair, Suki; Cheung, Kwai-Ming J.; Scanlon, Jane; Proisy, Nicolas; Addison, Glynn; Ellard, John; Piton, Nelly; Taylor, Suzanne; Cherry, Michael; Fisher, Martin; Boxall, Kathy; Burns, Samantha; Walton, Michael I.; Westwood, Isaac M.; Hayes, Angela; Eve, Paul; Valenti, Melanie; de Haven Brandon, Alexis; Box, Gary; van Montfort, Rob L. M.; Williams, David H.; Aherne, G. Wynne; Raynaud, Florence I.; Eccles, Suzanne A.; Garrett, Michelle D.; Collins, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8328-8342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pyrazolopyridine lead inhibitors with micromolar affinities for the checkpoint kinase CHK1 and selective for CHK1 against CHK2 were refined by fragment-growing and scaffold morphing strategies to generate the isoquinolinylaminopyrazinecarbonitrile I as a potent and selective inhibitor of CHK1 [IC50 (CHK1) = 13 nM, IC50 (CHK2) = > 100 μM] as a potential antitumor agent.  Scaffold morphing was used to improve the CHK1 potency and selectivity, synthetic accessibility, and novelty of the inhibitors; the inhibitor core was changed from pyrimido[2,3-b]azaindole to pyrazinylpyrimidinamine to imidazo[4,5-c]pyridine and isoquinoline.  The toxicities, lipophilicities, and polar surface areas of selected compds. were detd., while ligand efficiencies were detd. for the compds. prepd. and tested; the microsomal stability and oral bioavailability of I in mice were detd.  I potentiated the efficacies of irinotecan and gemcitabine in SW620 human colon carcinoma xenografts in nude mice but had no effect on its own.  The structures of six kinase inhibitors including I bound to the CHK1 kinase domain were detd. by x-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNwXjNh9xLdLVg90H21EOLACvtfcHk0ljO_c05zB2qaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFSlurjO&md5=927c82ade2efd6df0db154e9009368f8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm2007326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007326%26sid%3Dliteratum%253Aachs%26aulast%3DReader%26aufirst%3DJ.%2BC.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DKlair%26aufirst%3DS.%26aulast%3DCheung%26aufirst%3DK.%2BM.%26aulast%3DScanlon%26aufirst%3DJ.%26aulast%3DProisy%26aufirst%3DN.%26aulast%3DAddison%26aufirst%3DG.%26aulast%3DEllard%26aufirst%3DJ.%26aulast%3DPiton%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DCherry%26aufirst%3DM.%26aulast%3DFisher%26aufirst%3DM.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DBurns%26aufirst%3DS.%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DWestwood%26aufirst%3DI.%2BM.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DEve%26aufirst%3DP.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DBox%26aufirst%3DG.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DWilliams%26aufirst%3DD.%2BH.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DStructure-guided%2520evolution%2520of%2520potent%2520and%2520selective%2520CHK1%2520inhibitors%2520through%2520scaffold%2520morphing%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8328%26epage%3D8342%26doi%3D10.1021%2Fjm2007326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Lainchbury, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHardy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eve, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haven Brandon, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reader, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10229</span><span class="NLM_x">–</span> <span class="NLM_lpage">10240</span><span class="refDoi"> DOI: 10.1021/jm3012933</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3012933" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10229-10240&author=M.+Lainchburyauthor=T.+P.+Matthewsauthor=T.+McHardyauthor=K.+J.+Boxallauthor=M.+I.+Waltonauthor=P.+D.+Eveauthor=A.+Hayesauthor=M.+R.+Valentiauthor=A.+K.+de+Haven+Brandonauthor=G.+Boxauthor=G.+W.+Aherneauthor=J.+C.+Readerauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=M.+D.+Garrettauthor=I.+Collins&title=Discovery+of+3-alkoxyamino-5-%28pyridin-2-ylamino%29pyrazine-2-carbonitriles+as+selective%2C+orally+bioavailable+CHK1+inhibitors&doi=10.1021%2Fjm3012933"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm3012933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012933%26sid%3Dliteratum%253Aachs%26aulast%3DLainchbury%26aufirst%3DM.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DMcHardy%26aufirst%3DT.%26aulast%3DBoxall%26aufirst%3DK.%2BJ.%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DEve%26aufirst%3DP.%2BD.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DValenti%26aufirst%3DM.%2BR.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%2BK.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DReader%26aufirst%3DJ.%2BC.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DDiscovery%2520of%25203-alkoxyamino-5-%2528pyridin-2-ylamino%2529pyrazine-2-carbonitriles%2520as%2520selective%252C%2520orally%2520bioavailable%2520CHK1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10229%26epage%3D10240%26doi%3D10.1021%2Fjm3012933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Dudkin, V. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreatsoulas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrington, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraley, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikuta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirdivant, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drakas, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buser, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobell, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sepp-Lorenzino, L.</span><span> </span><span class="NLM_article-title">Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2609</span><span class="NLM_x">–</span> <span class="NLM_lpage">2612</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1016%2Fj.bmcl.2012.01.110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2609-2612&author=V.+Y.+Dudkinauthor=K.+Rickertauthor=C.+Kreatsoulasauthor=C.+Wangauthor=K.+L.+Arringtonauthor=M.+E.+Fraleyauthor=G.+D.+Hartmanauthor=Y.+Yanauthor=M.+Ikutaauthor=S.+M.+Stirdivantauthor=R.+A.+Drakasauthor=E.+S.+Walshauthor=K.+Hamiltonauthor=C.+A.+Buserauthor=R.+B.+Lobellauthor=L.+Sepp-Lorenzino&title=Pyridyl+aminothiazoles+as+potent+inhibitors+of+Chk1+with+slow+dissociation+rates&doi=10.1016%2Fj.bmcl.2012.01.110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.110%26sid%3Dliteratum%253Aachs%26aulast%3DDudkin%26aufirst%3DV.%2BY.%26aulast%3DRickert%26aufirst%3DK.%26aulast%3DKreatsoulas%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DArrington%26aufirst%3DK.%2BL.%26aulast%3DFraley%26aufirst%3DM.%2BE.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DIkuta%26aufirst%3DM.%26aulast%3DStirdivant%26aufirst%3DS.%2BM.%26aulast%3DDrakas%26aufirst%3DR.%2BA.%26aulast%3DWalsh%26aufirst%3DE.%2BS.%26aulast%3DHamilton%26aufirst%3DK.%26aulast%3DBuser%26aufirst%3DC.%2BA.%26aulast%3DLobell%26aufirst%3DR.%2BB.%26aulast%3DSepp-Lorenzino%26aufirst%3DL.%26atitle%3DPyridyl%2520aminothiazoles%2520as%2520potent%2520inhibitors%2520of%2520Chk1%2520with%2520slow%2520dissociation%2520rates%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2609%26epage%3D2612%26doi%3D10.1016%2Fj.bmcl.2012.01.110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Dudkin, V. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrington, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraley, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirdivant, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drakas, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buser, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardwick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobell, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sepp-Lorenzino, L.</span><span> </span><span class="NLM_article-title">Pyridyl aminothiazoles as potent Chk1 inhibitors: optimization of cellular activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2613</span><span class="NLM_x">–</span> <span class="NLM_lpage">2619</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1016%2Fj.bmcl.2012.01.120" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2613-2619&author=V.+Y.+Dudkinauthor=C.+Wangauthor=K.+L.+Arringtonauthor=M.+E.+Fraleyauthor=G.+D.+Hartmanauthor=S.+M.+Stirdivantauthor=R.+A.+Drakasauthor=K.+Rickertauthor=E.+S.+Walshauthor=K.+Hamiltonauthor=C.+A.+Buserauthor=J.+Hardwickauthor=W.+Taoauthor=S.+C.+Beckauthor=X.+Maoauthor=R.+B.+Lobellauthor=L.+Sepp-Lorenzino&title=Pyridyl+aminothiazoles+as+potent+Chk1+inhibitors%3A+optimization+of+cellular+activity&doi=10.1016%2Fj.bmcl.2012.01.120"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.120%26sid%3Dliteratum%253Aachs%26aulast%3DDudkin%26aufirst%3DV.%2BY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DArrington%26aufirst%3DK.%2BL.%26aulast%3DFraley%26aufirst%3DM.%2BE.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DStirdivant%26aufirst%3DS.%2BM.%26aulast%3DDrakas%26aufirst%3DR.%2BA.%26aulast%3DRickert%26aufirst%3DK.%26aulast%3DWalsh%26aufirst%3DE.%2BS.%26aulast%3DHamilton%26aufirst%3DK.%26aulast%3DBuser%26aufirst%3DC.%2BA.%26aulast%3DHardwick%26aufirst%3DJ.%26aulast%3DTao%26aufirst%3DW.%26aulast%3DBeck%26aufirst%3DS.%2BC.%26aulast%3DMao%26aufirst%3DX.%26aulast%3DLobell%26aufirst%3DR.%2BB.%26aulast%3DSepp-Lorenzino%26aufirst%3DL.%26atitle%3DPyridyl%2520aminothiazoles%2520as%2520potent%2520Chk1%2520inhibitors%253A%2520optimization%2520of%2520cellular%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2613%26epage%3D2619%26doi%3D10.1016%2Fj.bmcl.2012.01.120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duca, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipps, G. W.,  Jr.</span><span> </span><span class="NLM_article-title">Discovery of a novel series of CHK1 kinase inhibitors with a distinctive hinge binding mode</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">128</span><span class="refDoi"> DOI: 10.1021/ml200249h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200249h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC38XpslGntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=123-128&author=X.+Huangauthor=C.+C.+Chengauthor=T.+O.+Fischmannauthor=J.+S.+Ducaauthor=X.+Yangauthor=M.+Richardsauthor=G.+W.+Shipps&title=Discovery+of+a+novel+series+of+CHK1+kinase+inhibitors+with+a+distinctive+hinge+binding+mode&doi=10.1021%2Fml200249h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Series of CHK1 Kinase Inhibitors with a Distinctive Hinge Binding Mode</span></div><div class="casAuthors">Huang, Xiaohua; Cheng, Cliff C.; Fischmann, Thierry O.; Duca, Jose S.; Yang, Xianshu; Richards, Matthew; Shipps, Gerald W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-128</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of CHK1 inhibitors with a distinctive hinge binding mode, exemplified by 2-aryl-N-(2-(piperazin-1-yl)phenyl)thiazole-4-carboxamide, was discovered through high-throughput screening using the affinity selection-mass spectrometry (AS-MS)-based Automated Ligand Identification System (ALIS) platform.  Structure-based ligand design and optimization led to significant improvements in potency to the single digit nanomolar range and hundred-fold selectivity against CDK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphbnP8TZLFsrVg90H21EOLACvtfcHk0ljO_c05zB2qaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpslGntQ%253D%253D&md5=0033fbe5837cc4c6287c4a5428665247</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fml200249h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200249h%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DC.%2BC.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DDuca%26aufirst%3DJ.%2BS.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DRichards%26aufirst%3DM.%26aulast%3DShipps%26aufirst%3DG.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520series%2520of%2520CHK1%2520kinase%2520inhibitors%2520with%2520a%2520distinctive%2520hinge%2520binding%2520mode%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D123%26epage%3D128%26doi%3D10.1021%2Fml200249h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Song, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of thienopyridinones as Chk1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4882</span><span class="NLM_x">–</span> <span class="NLM_lpage">4892</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.06.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1016%2Fj.bmc.2014.06.044" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=4882-4892&author=P.+Songauthor=P.+Pengauthor=M.+Hanauthor=X.+Caoauthor=X.+Maauthor=T.+Liuauthor=Y.+Zhouauthor=Y.+Hu&title=Design%2C+synthesis+and+biological+evaluation+of+thienopyridinones+as+Chk1+inhibitors&doi=10.1016%2Fj.bmc.2014.06.044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.06.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.06.044%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DP.%26aulast%3DPeng%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520thienopyridinones%2520as%2520Chk1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D4882%26epage%3D4892%26doi%3D10.1016%2Fj.bmc.2014.06.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Gazzard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drobnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodacre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssikatos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span> </span><span class="NLM_article-title">Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">5704</span><span class="NLM_x">–</span> <span class="NLM_lpage">5709</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.10.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1016%2Fj.bmcl.2014.10.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=25453805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVemsLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=5704-5709&author=L.+Gazzardauthor=B.+Appletonauthor=K.+Chapmanauthor=H.+Chenauthor=K.+Clarkauthor=J.+Drobnickauthor=S.+Goodacreauthor=J.+Halladayauthor=J.+Lyssikatosauthor=S.+Schmidtauthor=S.+Siderisauthor=C.+Wiesmannauthor=K.+Williamsauthor=P.+Wuauthor=I.+Yenauthor=S.+Malek&title=Discovery+of+the+1%2C7-diazacarbazole+class+of+inhibitors+of+checkpoint+kinase+1&doi=10.1016%2Fj.bmcl.2014.10.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1</span></div><div class="casAuthors">Gazzard, Lewis; Appleton, Brent; Chapman, Kerry; Chen, Huifen; Clark, Kevin; Drobnick, Joy; Goodacre, Simon; Halladay, Jason; Lyssikatos, Joseph; Schmidt, Stephen; Sideris, Steve; Wiesmann, Christian; Williams, Karen; Wu, Ping; Yen, Ivana; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5704-5709</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Checkpoint kinase 1 (ChK1) is activated in response to DNA damage, acting to temporarily block cell cycle progression and allow for DNA repair.  It is envisaged that inhibition of ChK1 will sensitize tumor cells to treatment with DNA-damaging therapies, and may enhance the therapeutic window.  High throughput screening identified carboxylate-contg. diarylpyrazines as a prominent hit series, but with limited biochem. potency and no cellular activity.  Through a series of SAR investigations and x-ray crystallog. anal. the crit. role of polar contacts with conserved waters in the kinase back pocket was established.  Structure-based design, guided by in silico modeling, transformed the series to better satisfy these contacts and the novel 1,7-diazacarbazole class of inhibitors was discovered.  Here the authors present the genesis of this novel series and the identification of GNE-783 I, a potent, selective and orally bioavailable inhibitor of ChK1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnfVjbVYw27rVg90H21EOLACvtfcHk0lilMEMp5o-crQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVemsLrL&md5=6a99d23ce3ebe446b57d5fe76816824b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.10.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.10.063%26sid%3Dliteratum%253Aachs%26aulast%3DGazzard%26aufirst%3DL.%26aulast%3DAppleton%26aufirst%3DB.%26aulast%3DChapman%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DClark%26aufirst%3DK.%26aulast%3DDrobnick%26aufirst%3DJ.%26aulast%3DGoodacre%26aufirst%3DS.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DLyssikatos%26aufirst%3DJ.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520the%25201%252C7-diazacarbazole%2520class%2520of%2520inhibitors%2520of%2520checkpoint%2520kinase%25201%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D5704%26epage%3D5709%26doi%3D10.1016%2Fj.bmcl.2014.10.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Janetka, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almeida, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brassil, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gero, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glynn, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ioannidis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyne, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newcombe, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oza, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pass, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toader, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasbinder, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabludoff, S. D.</span><span> </span><span class="NLM_article-title">Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4242</span><span class="NLM_x">–</span> <span class="NLM_lpage">4248</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1016%2Fj.bmcl.2008.05.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4242-4248&author=J.+W.+Janetkaauthor=L.+Almeidaauthor=S.+Ashwellauthor=P.+J.+Brassilauthor=K.+Dalyauthor=C.+Dengauthor=T.+Geroauthor=R.+E.+Glynnauthor=C.+L.+Hornauthor=S.+Ioannidisauthor=P.+Lyneauthor=N.+J.+Newcombeauthor=V.+B.+Ozaauthor=M.+Passauthor=S.+K.+Springerauthor=M.+Suauthor=D.+Toaderauthor=M.+M.+Vasbinderauthor=D.+Yuauthor=Y.+Yuauthor=S.+D.+Zabludoff&title=Discovery+of+a+novel+class+of+2-ureido+thiophene+carboxamide+checkpoint+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2008.05.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DJanetka%26aufirst%3DJ.%2BW.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DAshwell%26aufirst%3DS.%26aulast%3DBrassil%26aufirst%3DP.%2BJ.%26aulast%3DDaly%26aufirst%3DK.%26aulast%3DDeng%26aufirst%3DC.%26aulast%3DGero%26aufirst%3DT.%26aulast%3DGlynn%26aufirst%3DR.%2BE.%26aulast%3DHorn%26aufirst%3DC.%2BL.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DLyne%26aufirst%3DP.%26aulast%3DNewcombe%26aufirst%3DN.%2BJ.%26aulast%3DOza%26aufirst%3DV.%2BB.%26aulast%3DPass%26aufirst%3DM.%26aulast%3DSpringer%26aufirst%3DS.%2BK.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DToader%26aufirst%3DD.%26aulast%3DVasbinder%26aufirst%3DM.%2BM.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZabludoff%26aufirst%3DS.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520class%2520of%25202-ureido%2520thiophene%2520carboxamide%2520checkpoint%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4242%26epage%3D4248%26doi%3D10.1016%2Fj.bmcl.2008.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Oza, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almeida, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brassil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gero, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grondine, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ioannidis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyne, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newcombe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pass, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ready, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowsell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toader, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasbinder, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabludoff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J.</span><span> </span><span class="NLM_article-title">Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5130</span><span class="NLM_x">–</span> <span class="NLM_lpage">5142</span><span class="refDoi"> DOI: 10.1021/jm300025r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300025r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVWgtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5130-5142&author=V.+Ozaauthor=S.+Ashwellauthor=L.+Almeidaauthor=P.+Brassilauthor=J.+Breedauthor=C.+Dengauthor=T.+Geroauthor=M.+Grondineauthor=C.+Hornauthor=S.+Ioannidisauthor=D.+Liuauthor=P.+Lyneauthor=N.+Newcombeauthor=M.+Passauthor=J.+Readauthor=S.+Readyauthor=S.+Rowsellauthor=M.+Suauthor=D.+Toaderauthor=M.+Vasbinderauthor=D.+Yuauthor=Y.+Yuauthor=Y.+Xueauthor=S.+Zabludoffauthor=J.+Janetka&title=Discovery+of+checkpoint+kinase+inhibitor+%28S%29-5-%283-fluorophenyl%29-N-%28piperidin-3-yl%29-3-ureidothiophene-2-carboxamide+%28AZD7762%29+by+structure-based+design+and+optimization+of+thiophenecarboxamide+ureas&doi=10.1021%2Fjm300025r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Checkpoint Kinase Inhibitor (S)-5-(3-Fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by Structure-Based Design and Optimization of Thiophenecarboxamide Ureas</span></div><div class="casAuthors">Oza, Vibha; Ashwell, Susan; Almeida, Lynsie; Brassil, Patrick; Breed, Jason; Deng, Chun; Gero, Thomas; Grondine, Michael; Horn, Candice; Ioannidis, Stephanos; Liu, Dongfang; Lyne, Paul; Newcombe, Nicholas; Pass, Martin; Read, Jon; Ready, Shannon; Rowsell, Sian; Su, Mei; Toader, Dorin; Vasbinder, Melissa; Yu, Dingwei; Yu, Yan; Xue, Yafeng; Zabludoff, Sonya; Janetka, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5130-5142</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Checkpoint kinases CHK1 and CHK2 are activated in response to DNA damage that results in cell cycle arrest, allowing sufficient time for DNA repair.  Agents that lead to abrogation of such checkpoints have potential to increase the efficacy of such compds. as chemo- and radiotherapies.  Thiophenecarboxamide ureas (TCUs) were identified as inhibitors of CHK1 by high throughput screening.  A structure-based approach is described using crystal structures of JNK1 and CHK1 in complex with 1 and 2 and of the CHK1-3b complex.  The ribose binding pocket of CHK1 was targeted to generate inhibitors with excellent cellular potency and selectivity over CDK1and IKKβ, key features lacking from the initial compds.  Optimization of 3b resulted in the identification of a regioisomeric 3-TCU lead 12a.  Optimization of 12a led to the discovery of the clin. candidate 4 (AZD7762, I), which strongly potentiates the efficacy of a variety of DNA-damaging agents in preclin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra8G75JTejhbVg90H21EOLACvtfcHk0lilMEMp5o-crQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVWgtbc%253D&md5=f2880b57af6d1def8f91d3ee694e0182</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm300025r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300025r%26sid%3Dliteratum%253Aachs%26aulast%3DOza%26aufirst%3DV.%26aulast%3DAshwell%26aufirst%3DS.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DBrassil%26aufirst%3DP.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DC.%26aulast%3DGero%26aufirst%3DT.%26aulast%3DGrondine%26aufirst%3DM.%26aulast%3DHorn%26aufirst%3DC.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DLyne%26aufirst%3DP.%26aulast%3DNewcombe%26aufirst%3DN.%26aulast%3DPass%26aufirst%3DM.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DReady%26aufirst%3DS.%26aulast%3DRowsell%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DToader%26aufirst%3DD.%26aulast%3DVasbinder%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DZabludoff%26aufirst%3DS.%26aulast%3DJanetka%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520checkpoint%2520kinase%2520inhibitor%2520%2528S%2529-5-%25283-fluorophenyl%2529-N-%2528piperidin-3-yl%2529-3-ureidothiophene-2-carboxamide%2520%2528AZD7762%2529%2520by%2520structure-based%2520design%2520and%2520optimization%2520of%2520thiophenecarboxamide%2520ureas%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5130%26epage%3D5142%26doi%3D10.1021%2Fjm300025r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Oza, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brassil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ezhuthachan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyne, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newcombe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otterbien, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pass, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roswell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toader, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webborn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabludoff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span> </span><span class="NLM_article-title">Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5133</span><span class="NLM_x">–</span> <span class="NLM_lpage">5138</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1016%2Fj.bmcl.2010.07.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5133-5138&author=V.+Ozaauthor=S.+Ashwellauthor=P.+Brassilauthor=J.+Breedauthor=C.+Dengauthor=J.+Ezhuthachanauthor=H.+Hayeauthor=C.+Hornauthor=J.+Janetkaauthor=P.+Lyneauthor=N.+Newcombeauthor=L.+Otterbienauthor=M.+Passauthor=J.+Readauthor=S.+Roswellauthor=M.+Suauthor=D.+Toaderauthor=D.+Yuauthor=Y.+Yuauthor=A.+Valentineauthor=P.+Webbornauthor=A.+Whiteauthor=S.+Zabludoffauthor=X.+Zheng&title=Discovery+of+a+novel+class+of+triazolones+as+checkpoint+kinase+inhibitors%2D%2Dhit+to+lead+exploration&doi=10.1016%2Fj.bmcl.2010.07.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DOza%26aufirst%3DV.%26aulast%3DAshwell%26aufirst%3DS.%26aulast%3DBrassil%26aufirst%3DP.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DC.%26aulast%3DEzhuthachan%26aufirst%3DJ.%26aulast%3DHaye%26aufirst%3DH.%26aulast%3DHorn%26aufirst%3DC.%26aulast%3DJanetka%26aufirst%3DJ.%26aulast%3DLyne%26aufirst%3DP.%26aulast%3DNewcombe%26aufirst%3DN.%26aulast%3DOtterbien%26aufirst%3DL.%26aulast%3DPass%26aufirst%3DM.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DRoswell%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DToader%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DValentine%26aufirst%3DA.%26aulast%3DWebborn%26aufirst%3DP.%26aulast%3DWhite%26aufirst%3DA.%26aulast%3DZabludoff%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520class%2520of%2520triazolones%2520as%2520checkpoint%2520kinase%2520inhibitors--hit%2520to%2520lead%2520exploration%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5133%26epage%3D5138%26doi%3D10.1016%2Fj.bmcl.2010.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Daly, K.; Heron, N.; Hird, A.; Ioannidis, S.; Janetka, J. W.; Lyne, P.; Scott, J.; Toader, D.; Vasbinder, M.; Yu, D.; Yu, Y.</span><span> </span><span class="NLM_article-title">Substituted Heterocycles and Their Use as CHK1, PDK1 and PAK Inhibitors</span>. WO2006106326 A1, October 12,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=K.+Daly&author=N.+Heron&author=A.+Hird&author=S.+Ioannidis&author=J.+W.+Janetka&author=P.+Lyne&author=J.+Scott&author=D.+Toader&author=M.+Vasbinder&author=D.+Yu&author=Y.+Yu&title=Substituted+Heterocycles+and+Their+Use+as+CHK1%2C+PDK1+and+PAK+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDaly%26aufirst%3DK.%26atitle%3DSubstituted%2520Heterocycles%2520and%2520Their%2520Use%2520as%2520CHK1%252C%2520PDK1%2520and%2520PAK%2520Inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Beno, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartberger, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennington, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">A Survey of the role of noncovalent sulfur interactions in drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4383</span><span class="NLM_x">–</span> <span class="NLM_lpage">4438</span><span class="refDoi"> DOI: 10.1021/jm501853m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501853m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Giu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4383-4438&author=B.+R.+Benoauthor=K.+S.+Yeungauthor=M.+D.+Bartbergerauthor=L.+D.+Penningtonauthor=N.+A.+Meanwell&title=A+Survey+of+the+role+of+noncovalent+sulfur+interactions+in+drug+design&doi=10.1021%2Fjm501853m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design</span></div><div class="casAuthors">Beno, Brett R.; Yeung, Kap-Sun; Bartberger, Michael D.; Pennington, Lewis D.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4383-4438</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Electron deficient, bivalent sulfur atoms have two areas of pos. electrostatic potential, a consequence of the low-lying σ* orbitals of the C-S bond that are available for interaction with electron donors including oxygen and nitrogen atoms and, possibly, π-systems.  Intramol. interactions are by far the most common manifestation of this effect, which offers a means of modulating the conformational preferences of a mol.  Although a well-documented phenomenon, a priori applications in drug design are relatively sparse and this interaction, which is often isosteric with an intramol. hydrogen-bonding interaction, appears to be underappreciated by the medicinal chem. community.  In this Perspective, we discuss the theor. basis for sulfur σ* orbital interactions and illustrate their importance in the context of drug design and org. synthesis.  The role of sulfur interactions in protein structure and function is discussed and although relatively rare, intermol. interactions between ligand C-S σ* orbitals and proteins are illustrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYKXRsl4BQYrVg90H21EOLACvtfcHk0lhR75p2PhGNfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Giu7g%253D&md5=d12f53eb3271c161cfc833fb9f7c02b3</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm501853m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501853m%26sid%3Dliteratum%253Aachs%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DYeung%26aufirst%3DK.%2BS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DA%2520Survey%2520of%2520the%2520role%2520of%2520noncovalent%2520sulfur%2520interactions%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4383%26epage%3D4438%26doi%3D10.1021%2Fjm501853m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiswell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seghezzi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddiqui, M. A.</span><span> </span><span class="NLM_article-title">Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">7216</span><span class="NLM_x">–</span> <span class="NLM_lpage">7221</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.10.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1016%2Fj.bmcl.2010.10.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=21074424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKjtLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7216-7221&author=L.+Zhaoauthor=Y.+Zhangauthor=C.+Daiauthor=T.+Guziauthor=D.+Wiswellauthor=W.+Seghezziauthor=D.+Parryauthor=T.+Fischmannauthor=M.+A.+Siddiqui&title=Design%2C+synthesis+and+SAR+of+thienopyridines+as+potent+CHK1+inhibitors&doi=10.1016%2Fj.bmcl.2010.10.105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors</span></div><div class="casAuthors">Zhao, Lianyun; Zhang, Yingxin; Dai, Chaoyang; Guzi, Timothy; Wiswell, Derek; Seghezzi, Wolfgang; Parry, David; Fischmann, Thierry; Siddiqui, M. Arshad</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7216-7221</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of CHK1 inhibitors based on a thienopyridine template were designed and synthesized.  These inhibitors maintained crit. hydrogen bonding with the hinge and conserved water in the ATP binding site.  Several compds. showed single digit nanomolar CHK1 activities.  Compd. I showed excellent enzymic activity of 1 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdQbVc-FuoTbVg90H21EOLACvtfcHk0lhR75p2PhGNfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKjtLbE&md5=b9328e520c4e399e05801150f566ca5d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.10.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.10.105%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDai%26aufirst%3DC.%26aulast%3DGuzi%26aufirst%3DT.%26aulast%3DWiswell%26aufirst%3DD.%26aulast%3DSeghezzi%26aufirst%3DW.%26aulast%3DParry%26aufirst%3DD.%26aulast%3DFischmann%26aufirst%3DT.%26aulast%3DSiddiqui%26aufirst%3DM.%2BA.%26atitle%3DDesign%252C%2520synthesis%2520and%2520SAR%2520of%2520thienopyridines%2520as%2520potent%2520CHK1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7216%26epage%3D7221%26doi%3D10.1016%2Fj.bmcl.2010.10.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Cashman, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span> </span><span class="NLM_article-title">Human flavin-containing monooxygenases</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span><span class="refDoi"> DOI: 10.1146/annurev.pharmtox.46.120604.141043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1146%2Fannurev.pharmtox.46.120604.141043" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=65-100&author=J.+R.+Cashmanauthor=J.+Zhang&title=Human+flavin-containing+monooxygenases&doi=10.1146%2Fannurev.pharmtox.46.120604.141043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.46.120604.141043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.46.120604.141043%26sid%3Dliteratum%253Aachs%26aulast%3DCashman%26aufirst%3DJ.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DHuman%2520flavin-containing%2520monooxygenases%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2006%26volume%3D46%26spage%3D65%26epage%3D100%26doi%3D10.1146%2Fannurev.pharmtox.46.120604.141043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span> </span><span class="NLM_article-title">Volume of distribution in drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">5691</span><span class="NLM_x">–</span> <span class="NLM_lpage">5698</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5691-5698&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Volume+of+distribution+in+drug+design&doi=10.1021%2Facs.jmedchem.5b00201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Volume of Distribution in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5691-5698</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Vol. of distribution is one of the most important pharmacokinetic properties of a drug candidate.  It is a major determinant of half-life and dosing frequency of a drug.  For a similar log P, a basic mol. will tend to exhibit higher vol. of distribution than a neutral mol.  Acids often exhibit low vols. of distribution.  Although a design strategy against vol. of distribution can be advantageous in achieving desirable dosing regimen, it must be well-directed in order to avoid detrimental effects to other important properties.  Strategies to increase vol. of distribution include adding lipophilicity and introducing basic functional groups in a way that does not increase metabolic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP7QwgPahf4bVg90H21EOLACvtfcHk0li6GvpHGrxJjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D&md5=2c7289b3602a8edef2d9ef0e6a82e483</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00201%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DVolume%2520of%2520distribution%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5691%26epage%3D5698%26doi%3D10.1021%2Facs.jmedchem.5b00201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Zabludoff, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grondine, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehy, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caleb, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haye, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mouchet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ready, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenthal, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queva, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A. M.</span><span> </span><span class="NLM_article-title">AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2955</span><span class="NLM_x">–</span> <span class="NLM_lpage">2966</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-0492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1158%2F1535-7163.MCT-08-0492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=18790776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFSmsL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=2955-2966&author=S.+D.+Zabludoffauthor=C.+Dengauthor=M.+R.+Grondineauthor=A.+M.+Sheehyauthor=S.+Ashwellauthor=B.+L.+Calebauthor=S.+Greenauthor=H.+R.+Hayeauthor=C.+L.+Hornauthor=J.+W.+Janetkaauthor=D.+Liuauthor=E.+Mouchetauthor=S.+Readyauthor=J.+L.+Rosenthalauthor=C.+Quevaauthor=G.+K.+Schwartzauthor=K.+J.+Taylorauthor=A.+N.+Tseauthor=G.+E.+Walkerauthor=A.+M.+White&title=AZD7762%2C+a+novel+checkpoint+kinase+inhibitor%2C+drives+checkpoint+abrogation+and+potentiates+DNA-targeted+therapies&doi=10.1158%2F1535-7163.MCT-08-0492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies</span></div><div class="casAuthors">Zabludoff, Sonya D.; Deng, Chun; Grondine, Michael R.; Sheehy, Adam M.; Ashwell, Susan; Caleb, Benjamin L.; Green, Stephen; Haye, Heather R.; Horn, Candice L.; Janetka, James W.; Liu, Dongfang; Mouchet, Elizabeth; Ready, Shannon; Rosenthal, Judith L.; Queva, Christophe; Schwartz, Gary K.; Taylor, Karen J.; Tse, Archie N.; Walker, Graeme E.; White, Anne M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2955-2966</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Insights from cell cycle research have led to the hypothesis that tumors may be selectively sensitized to DNA-damaging agents resulting in improved antitumor activity and a wider therapeutic margin.  The theory relies on the observation that the majority of tumors are deficient in the G1-DNA damage checkpoint pathway resulting in reliance on S and G2 checkpoints for DNA repair and cell survival.  The S and G2 checkpoints are regulated by checkpoint kinase 1, a serine/threonine kinase that is activated in response to DNA damage; thus, inhibition of checkpoint kinase 1 signaling impairs DNA repair and increases tumor cell death.  Normal tissues, however, have a functioning G1 checkpoint signaling pathway allowing for DNA repair and cell survival.  Here, we describe the preclin. profile of AZD7762, a potent ATP-competitive checkpoint kinase inhibitor in clin. trials.  AZD7762 has been profiled extensively in vitro and in vivo in combination with DNA-damaging agents and has been shown to potentiate response in several different settings where inhibition of checkpoint kinase results in the abrogation of DNA damage-induced cell cycle arrest.  Dose-dependent potentiation of antitumor activity, when AZD7762 is administered in combination with DNA-damaging agents, has been obsd. in multiple xenograft models with several DNA-damaging agents, further supporting the potential of checkpoint kinase inhibitors to enhance the efficacy of both conventional chemotherapy and radiotherapy and increase patient response rates in a variety of settings. [Mol Cancer Ther 2008;7(9):2955-66].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTXvjs3OaUFrVg90H21EOLACvtfcHk0li6GvpHGrxJjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFSmsL7O&md5=b33ff697c6592c9823e85c9bb265c02d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0492%26sid%3Dliteratum%253Aachs%26aulast%3DZabludoff%26aufirst%3DS.%2BD.%26aulast%3DDeng%26aufirst%3DC.%26aulast%3DGrondine%26aufirst%3DM.%2BR.%26aulast%3DSheehy%26aufirst%3DA.%2BM.%26aulast%3DAshwell%26aufirst%3DS.%26aulast%3DCaleb%26aufirst%3DB.%2BL.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DHaye%26aufirst%3DH.%2BR.%26aulast%3DHorn%26aufirst%3DC.%2BL.%26aulast%3DJanetka%26aufirst%3DJ.%2BW.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMouchet%26aufirst%3DE.%26aulast%3DReady%26aufirst%3DS.%26aulast%3DRosenthal%26aufirst%3DJ.%2BL.%26aulast%3DQueva%26aufirst%3DC.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DTaylor%26aufirst%3DK.%2BJ.%26aulast%3DTse%26aufirst%3DA.%2BN.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWhite%26aufirst%3DA.%2BM.%26atitle%3DAZD7762%252C%2520a%2520novel%2520checkpoint%2520kinase%2520inhibitor%252C%2520drives%2520checkpoint%2520abrogation%2520and%2520potentiates%2520DNA-targeted%2520therapies%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D2955%26epage%3D2966%26doi%3D10.1158%2F1535-7163.MCT-08-0492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nosaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makiyama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kometani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamatake, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeoka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agbo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span> </span><span class="NLM_article-title">Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">619</span><span class="NLM_x">–</span> <span class="NLM_lpage">627</span><span class="refDoi"> DOI: 10.1007/s00280-013-2234-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1007%2Fs00280-013-2234-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=23892959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlOrtbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2013&pages=619-627&author=T.+Setoauthor=T.+Esakiauthor=F.+Hiraiauthor=S.+Aritaauthor=K.+Nosakiauthor=A.+Makiyamaauthor=T.+Kometaniauthor=C.+Fujimotoauthor=M.+Hamatakeauthor=H.+Takeokaauthor=F.+Agboauthor=X.+Shi&title=Phase+I%2C+dose-escalation+study+of+AZD7762+alone+and+in+combination+with+gemcitabine+in+Japanese+patients+with+advanced+solid+tumours&doi=10.1007%2Fs00280-013-2234-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours</span></div><div class="casAuthors">Seto, Takashi; Esaki, Taito; Hirai, Fumihiko; Arita, Shuji; Nosaki, Kaname; Makiyama, Akitaka; Kometani, Takuro; Fujimoto, Chinatsu; Hamatake, Motoharu; Takeoka, Hiroaki; Agbo, Felix; Shi, Xiaojin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">619-627</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: AZD7762, a potent Chk1/Chk2 inhibitor, has shown chemosensitizing activity with gemcitabine in xenograft models.  Methods: This open-label, Phase I, dose-escalation study evaluated the safety, pharmacokinetics (PK) and preliminary efficacy (RECIST) of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors (NCT00937664).  Patients received i.v. AZD7762 alone on days 1 and 8 of a 14-day cycle (cycle 0), followed by AZD7762 plus gemcitabine 1,000 mg/m2 on days 1 and 8 of 22-day cycles, in ascending AZD7762 dose cohorts.  Results: Twenty patients received AZD7762 at doses of 6 mg (n = 3), 9 mg (n = 3), 21 mg (n = 6) and 30 mg (n = 8).  Dose-limiting toxicities occurred in 2/6 evaluable patients in the 30-mg cohort: one, CTCAE grade 3 elevated troponin T (cycle 0: AZD7762 monotherapy); one, neutropenia, thrombocytopenia, and elevated aspartate aminotransferase and alanine aminotransferase (cycle 1: combination therapy).  The 30 mg dose was therefore regarded as non-tolerable.  The most common adverse events (AEs) in cycle 0 (AZD7762 monotherapy) were bradycardia (50 %), hypertension (25 %) and fatigue (15 %).  Overall, the most common AEs were bradycardia (55 %), neutropenia (45 %) and hypertension, fatigue and rash (30 % each).  Grade ≥3 AEs were reported in 11 patients, the most common being neutropenia (45 %) and leukopenia (25 %).  AZD7762 exposure increased approx. linearly.  Gemcitabine did not appear to affect AZD7762 PK.  There were no objective responses; five patients (all lung cancer) had stable disease.  Conclusions: The max. tolerated dose of AZD7762 in combination with gemcitabine, 1,000 mg/m2 was detd. as 21 mg in Japanese patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWxvmjbQe4HbVg90H21EOLACvtfcHk0lhH05YGw5RS3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlOrtbnJ&md5=249621625eab6c9d7e0a85d4f4f47977</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs00280-013-2234-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-013-2234-6%26sid%3Dliteratum%253Aachs%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DEsaki%26aufirst%3DT.%26aulast%3DHirai%26aufirst%3DF.%26aulast%3DArita%26aufirst%3DS.%26aulast%3DNosaki%26aufirst%3DK.%26aulast%3DMakiyama%26aufirst%3DA.%26aulast%3DKometani%26aufirst%3DT.%26aulast%3DFujimoto%26aufirst%3DC.%26aulast%3DHamatake%26aufirst%3DM.%26aulast%3DTakeoka%26aufirst%3DH.%26aulast%3DAgbo%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DX.%26atitle%3DPhase%2520I%252C%2520dose-escalation%2520study%2520of%2520AZD7762%2520alone%2520and%2520in%2520combination%2520with%2520gemcitabine%2520in%2520Japanese%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2013%26volume%3D72%26spage%3D619%26epage%3D627%26doi%3D10.1007%2Fs00280-013-2234-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Sausville, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorusso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carducci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malburg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azad, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosgrove, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabludoff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agbo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oakes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senderowicz, A.</span><span> </span><span class="NLM_article-title">Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">549</span><span class="refDoi"> DOI: 10.1007/s00280-014-2380-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=10.1007%2Fs00280-014-2380-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=24448638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2014&pages=539-549&author=E.+Sausvilleauthor=P.+Lorussoauthor=M.+Carducciauthor=J.+Carterauthor=M.+F.+Quinnauthor=L.+Malburgauthor=N.+Azadauthor=D.+Cosgroveauthor=R.+Knightauthor=P.+Barkerauthor=S.+Zabludoffauthor=F.+Agboauthor=P.+Oakesauthor=A.+Senderowicz&title=Phase+I+dose-escalation+study+of+AZD7762%2C+a+checkpoint+kinase+inhibitor%2C+in+combination+with+gemcitabine+in+US+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-014-2380-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors</span></div><div class="casAuthors">Sausville, Edward; LoRusso, Patricia; Carducci, Michael; Carter, Judith; Quinn, Mary F.; Malburg, Lisa; Azad, Nilofer; Cosgrove, David; Knight, Richard; Barker, Peter; Zabludoff, Sonya; Agbo, Felix; Oakes, Patricia; Senderowicz, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">539-549</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: AZD7762 is a Chk1 kinase inhibitor which increases sensitivity to DNA-damaging agents, including gemcitabine.  We evaluated the safety of AZD7762 monotherapy and with gemcitabine in advanced solid tumor patients.  Exptl. design: In this Phase I study, patients received i.v. AZD7762 on days 1 and 8 of a 14-day run-in cycle (cycle 0; AZD7762 monotherapy), followed by AZD7762 plus gemcitabine 750-1,000 mg/m2 on days 1 and 8, every 21 days, in ascending AZD7762 doses (cycle 1; combination therapy).  Results: Forty-two patients received AZD7762 6 mg (n = 9), 9 mg (n = 3), 14 mg (n = 6), 21 mg (n = 3), 30 mg (n = 7), 32 mg (n = 6), and 40 mg (n = 8), in combination with gemcitabine.  Common adverse events (AEs) were fatigue [41 % (17/42) patients], neutropenia/leukopenia [36 % (15/42) patients], anemia/Hb decrease [29 % (12/42) patients] and nausea, pyrexia and alanine aminotransferase/aspartate aminotransferase increase [26 % (11/42) patients each].  Grade ≥3 AEs occurred in 19 and 52 % of patients in cycles 0 and 1, resp.  Cardiac dose-limiting toxicities occurred in two patients (both AZD7762 monotherapy): grade 3 troponin I increase (32 mg) and grade 3 myocardial ischemia with chest pain, ECG changes, decreased left ventricular ejection fraction, and increased troponin I (40 mg).  AZD7762 exposure increased linearly.  Gemcitabine did not affect AZD7762 pharmacokinetics.  Two non-small-cell lung cancer patients achieved partial tumor responses (AZD7762 6 mg/gemcitabine 750 mg/m2 and AZD7762 9 mg cohort).  Conclusions: The max.-tolerated dose of AZD7762 in combination with gemcitabine 1,000 mg/m2 was 30 mg.  Although development of AZD7762 is not going forward owing to unpredictable cardiac toxicity, Chk1 remains an important therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgyFGCYJKF3rVg90H21EOLACvtfcHk0lhH05YGw5RS3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyks7s%253D&md5=6536063d427c1705dc4976826932e9ff</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs00280-014-2380-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-014-2380-5%26sid%3Dliteratum%253Aachs%26aulast%3DSausville%26aufirst%3DE.%26aulast%3DLorusso%26aufirst%3DP.%26aulast%3DCarducci%26aufirst%3DM.%26aulast%3DCarter%26aufirst%3DJ.%26aulast%3DQuinn%26aufirst%3DM.%2BF.%26aulast%3DMalburg%26aufirst%3DL.%26aulast%3DAzad%26aufirst%3DN.%26aulast%3DCosgrove%26aufirst%3DD.%26aulast%3DKnight%26aufirst%3DR.%26aulast%3DBarker%26aufirst%3DP.%26aulast%3DZabludoff%26aufirst%3DS.%26aulast%3DAgbo%26aufirst%3DF.%26aulast%3DOakes%26aufirst%3DP.%26aulast%3DSenderowicz%26aufirst%3DA.%26atitle%3DPhase%2520I%2520dose-escalation%2520study%2520of%2520AZD7762%252C%2520a%2520checkpoint%2520kinase%2520inhibitor%252C%2520in%2520combination%2520with%2520gemcitabine%2520in%2520US%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2014%26volume%3D73%26spage%3D539%26epage%3D549%26doi%3D10.1007%2Fs00280-014-2380-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YDK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YDK','PDB','2YDK'); return false;">PDB: 2YDK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X8E" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X8E','PDB','2X8E'); return false;">PDB: 2X8E</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YDJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YDJ','PDB','2YDJ'); return false;">PDB: 2YDJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FC8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FC8','PDB','6FC8'); return false;">PDB: 6FC8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FCK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FCK','PDB','6FCK'); return false;">PDB: 6FCK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FCF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FCF','PDB','6FCF'); return false;">PDB: 6FCF</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-6"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i64"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01490">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_27128"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01490">10.1021/acs.jmedchem.7b01490</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Complete experimental for the syntheses of compounds <b>5</b>, <b>19</b>, <b>20</b>, <b>31</b>, <b>32</b>, <b>33</b>, <b>43</b>, <b>47</b>, and <b>48</b>; assays protocols on solubility, log <i>D</i>, rat microsome CL<sub>int</sub>, and hERG inhibition; experimental details on crystallographic information (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01490/suppl_file/jm7b01490_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01490/suppl_file/jm7b01490_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01490/suppl_file/jm7b01490_si_001.pdf">jm7b01490_si_001.pdf (401.73 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01490/suppl_file/jm7b01490_si_002.csv">jm7b01490_si_002.csv (2.37 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are the following: <b>13</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FC8">6FC8</a>; <b>21</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FCK">6FCK</a>; <b>44</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FCF">6FCF</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01490&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-3%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01490%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01490" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a2b76dcd51969","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
